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The H+ and Cu2+ equilibria of four glycine peptides (glycyl-glycine, glycyl-L-leucine, 
glycyl-L-phenylalanine and glycyl-L-histidine) and four sarcosine peptides (sarcosyl-
glycine, sarcosyl-L-leucine, sarcosyl-L-phenylalanine and sarcosyl-L-histidine) have 
been studied using glass electrode potentiometry and isothermal titration calorimetry at 
25 0C and an ionic strength 0.15 M  (NaCl).   The terminal amine of the sarcosine 
peptides is more basic than the glycine analogues.  The methyl group on the terminal 
amine (for sarcosine peptides) does not affect the stability constants of the ML species, 
significantly.    Log K for ML species for all the Cu(II)/peptides complexes ranged 
between 5.79 and 6.54, except for glycyl-L-histidine that showed log KML = 9.16.   Heat 
accompanying the formation of ML for all the species ranged between -5.1 kcal mol-1 and 
-6.6 kcal mol-1, except for glycyl-L-histidine that showed ΔHML = -3.6 kcal.mol-1.     
 
Structures for the different species in solution were postulated based on nuclear magnetic 
resonance and ultraviolet-visible spectrophotometry data.   Molecular mechanics was 
used to investigate the possible structures.   The minimum energy of the trans form of 
most the complexes was less than the cis form of the complexes.    
 
Octanol/water partition coefficients (log Pow) were determined as a measure of the tissue 
permeability of the complexes.   All the log Pow values were negative indicating that the 
complexes would be poorly absorbed through the skin.   A computer model of blood 
plasma (ECCLES) was used to assess the speciation in vivo of the copper complexes. 
Glycyl-L-phenylalanine had the highest mobilization of Cu(II), with a log (p.m.i) of 4.44 
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LIST OF FIGURES 
Figure 1.1: Examples of NSAID’s (structural representation) 
Figure 1.2: Examples of DMARD’s (structural representation) 
Figure 1.3: An examples of corticosteroids (structural representation) 
Figure 2.1: Structure of Cu(II)-human serum albumin  
Figure 2.2: Structures of proposed glycine and sarcosine dipeptides 
Figure 3.0: Typical ZH-bar, ZM-bar and QM-bar curves 
Figure 3.1: ZH-bar as a function of pH for the protonation of glycine 
Figure 3.2: Speciation for the protonation of glycine 
Figure 3.3: ZH-bar as a function of pH for the protonation of sarcosine 
Figure 3.4: Speciation for the protonation of sarcosine 
Figure 3.5: ZH-bar as a function of pH for the protonation of GLY-GLY 
Figure 3.6: Speciation for the protonation of GLY-GLY 
Figure 3.7: ZH-bar as a function of pH for the protonation of SAR-GLY 
Figure 3.8: Speciation for the protonation of SAR-GLY 
Figure 3.9: ZH-bar as a function of pH for the protonation of GLY-LEU 
Figure 3.10: Speciation for the protonation of GLY-LEU 
Figure 3.11: ZH-bar as a function of pH for the protonation of SAR-LEU 
Figure 3.12: Speciation for the protonation of SAR-LEU 
Figure 3.13: ZH-bar  as a function of pH for the protonation of GLY-PHE 
Figure 3.14: Speciation for the protonation of GLY-PHE 
Figure 3.15: ZH-bar  as a function of pH for the protonation of SAR-PHE 
Figure 3.16: Speciation for the protonation of SAR-PHE 
Figure 3.17: ZM-bar as a function of pL for the Cu(II)/GLY titrations 
Figure 3.18: QM-bar as a function of pH for the Cu(II)/GLY titrations.   Pink curve is n- 
                      bar, blue curve is experimental Q-bar and the solid line is the theoretical  
                      plot. 
Figure 3.19: Speciation for complex formation titrations of Cu(II)/GLY, 1:2 ratio 
Figure 3.20: ZM-bar as a function of pL for the Cu(II)/SAR titrations 













                      bar, blue curve is experimental Q-bar and the solid line is the theoretical 
                      plot. 
Figure 3.22: Speciation for complex formation titrations of Cu(II)/SAR, 1:2 ratio 
Figure 3.23: ZM-bar as a function of pL for the Cu(II)/GLY-GLY titrations 
Figure 3.24: QM-bar as a function of pH for the Cu(II)/GLY-GLY titrations.   Pink curve  
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  
                      theoretical plot. 
Figure 3.25: Speciation for complex formation titrations of Cu(II)/GLY-GLY, 1:2 ratio. 
Figure 3.26: ZM-bar as a function of pL for the Ni(II)/GLY-GLY titrations 
Figure 3.27: QM-bar as a function of pH for the Ni(II)/GLY-GLY titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.28: Speciation for complex formation titrations of Ni(II)/GLY-GLY, 1:2 ratio. 
Figure 3.29: ZM-bar as a function of pL for the Zn (II)/GLY-GLY titrations 
Figure 3.30: QM-bar as a function of pH for the Zn (II)/GLY-GLY titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  
                      theoretical plot. 
Figure 3.31: Speciation for complex formation titrations of Zn (II)/GLY-GLY, 1:2 ratio. 
Figure 3.32: ZM-bar as a function of pL for the Cu(II)/SAR-GLY titrations 
Figure 3.33: QM-bar as a function of pH for the Cu(II)/SAR-GLY titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  
                      theoretical plot. 
Figure 3.34: Speciation for complex formation titrations of Cu(II)/SAR-GLY, 1:2 ratio. 
Figure 3.35: ZM-bar as a function of pL for the Ni(II)/SAR-GLY titrations 
Figure 3.36: QM-bar as a function of pH for the Ni(II)/SAR-GLY titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  
                      theoretical plot. 
Figure 3.37: Speciation for complex formation titrations of Ni(II)/SAR-GLY, 1:2 ratio 
Figure 3.38: ZM-bar as a function of pL for the Zn (II)/SAR-GLY titrations 
Figure 3.39: QM-bar as a function of pH for the Zn (II)/SAR-GLY titrations.   Pink curve 













                      theoretical plot. 
Figure 3.40: Speciation for complex formation titrations of Zn (II)/SAR-GLY, 1:2 ratio 
Figure 3.41: ZM-bar as a function of pL for the Cu(II)/GLY-LEU titrations 
Figure 3.42: QM-bar as a function of pH for the Cu(II)/GLY-LEU titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.43: Speciation for complex formation titrations of Cu(II)/GLY-LEU, 1:2 ratio. 
Figure 3.44: ZM-bar as a function of pL for the Ni(II)/GLY-LEU titrations 
Figure 3.45: QM-bar as a function of pH for the Zn (II)/GLY-LEU titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.46: Speciation for complex formation titrations of Ni(II)/GLY-LEU, 1:2 ratio. 
Figure 3.47: ZM-bar as a function of pL for the Zn (II)/GLY-LEU titrations 
Figure 3.48: QM-bar as a function of pH for the Zn (II)/GLY-LEU titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.49: Speciation for complex formation titrations of Zn (II)/GLY-LEU, 1:2 ratio 
Figure 3.50: ZM-bar as a function of pL for the Cu(II)/SAR-LEU titrations 
Figure 3.51: QM-bar as a function of pH for the Cu(II)/SAR-LEU titrations.   Pink curve  
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.52: Speciation for complex formation titrations of Cu(II)/SAR-LEU, 1:2 ratio. 
Figure 3.53: ZM-bar as a function of pL for the Ni(II)/SAR-LEU titrations 
Figure 3.54: QM-bar as a function of pH for the Ni(II)/SAR-LEU titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                      theoretical plot. 
Figure 3.55: Speciation for complex formation titrations of Ni(II)/SAR-LEU, 1:2 ratio. 
Figure 3.56: ZM-bar as a function of pL for the Zn (II)/SAR-LEU titrations 
Figure 3.57: QM-bar as a function of pH for the Zn (II)/SAR-LEU titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  













Figure 3.58: Speciation for complex formation titrations of Zn (II)/SAR-LEU, 1:2 ratio. 
Figure 3.59: ZM-bar as a function of pL for the Cu(II)/GLY-PHE titrations 
Figure 3.60: QM-bar as a function of pH for the Cu(II)/GLY-PHE titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the  
                      theoretical plot. 
Figure 3.61: Speciation for complex formation titrations of Cu(II)/GLY-PHE, 1:2 ratio. 
Figure 3.62: ZM-bar as a function of pL for the Ni(II)/GLY-PHE titrations 
Figure 3.63: QM-bar as a function of pH for the Ni(II)/GLY-PHE titrations.   Pink curve 
                       is n-bar, blue curve is experimental Q-bar and the solid line is the 
                        theoretical plot. 
Figure 3.64: Speciation for complex formation titrations of Ni(II)/GLY-PHE, 1:2 ratio. 
Figure 3.65: ZM-bar as a function of pL for the Zn (II)/GLY-PHE titrations 
Figure 3.66: QM-bar as a function of pH for the Zn (II)/GLY-PHE titrations.   Pink curve 
                      is n-bar, blue curve is experimental Q-bar and the solid line is the 
                       theoretical plot. 
Figure 3.67: Speciation for complex formation titrations of Zn (II)/GLY-PHE, 1:2 ratio 
Figure 3.68: ZM-bar as a function of pL for the Cu(II)/SAR-PHE titrations 
Figure 3.69: QM-bar as a function of pH for the Cu(II)/SAR-PHE titrations.   Pink curve 
                     is n-bar, blue curve is experimental Q-bar and the solid line is the theoretical  
                     plot. 
Figure 3.70: Speciation for complex formation titrations of Cu(II)/SAR-PHE, 1:2 ratio 
Figure 3.71: ZM-bar as a function of pL for the Ni(II)/SAR-PHE titrations 
Figure 3.72: QM-bar as a function of pH for the Ni(II)/SAR-PHE titrations.   Pink curve 
                     is n-bar, blue curve is experimental Q-bar and the solid line is the theoretical 
                     plot. 
Figure 3.73: Speciation for complex formation titrations of Ni(II)/SAR-PHE, 1:2 ratio 
Figure 3.74: ZM-bar as a function of pL for the Zn (II)/SAR-PHE titrations 
Figure 3.75: QM-bar as a function of pH for the Zn (II)/SAR-PHE titrations.   Pink curve  
                       is n-bar, blue curve is experimental Q-bar and the solid line is the  
                       theoretical plot. 













Figure 4.1: Isotherm for water titrated against water. 
Figure 4.2: Isotherms for acid/base titrations. 
Figure 4.3: Isotherms for the protonation for the protonation of glycine. 
Figure 4.4: Isotherms for the protonation for the protonation of sarcosine. 
Figure 4.5: Isotherms for the protonation for the protonation of glycyl-glycine. 
Figure 4.6: Isotherms for the protonation for the protonation of sarcosyl-glycine. 
Figure 4.7: Isotherms for the protonation for the protonation of glycyl-L-leucine. 
Figure 4.8: Isotherms for the protonation for the protonation of sarcosyl-L-leucine. 
Figure 4.9: Isotherms for the protonation for the protonation of glycyl-L-phenylalanine. 
Figure 4.10: Isotherms for the protonation for the protonation of sarcosyl-L- 
                       phenylalanine. 
Figure 4.11: Isotherms for the protonation for the protonation of glycyl-L-histidine. 
Figure 4.12: Isotherms for competitive protonation titrations of SAR and SAR-LEU 
Figure 4.13: Isotherms for the GLY/ Cu(II) titrations. 
Figure 4.14: Isotherms for the SAR/ Cu(II) titrations. 
Figure 4.15: Isotherms for the GLY-GLY/ Cu(II) titrations. 
Figure 4.16: Isotherms for the SAR-GLY/ Cu(II) titrations. 
Figure 4.17: Isotherms for the GLY-LEU/ Cu(II) titrations. 
Figure 4.18: Isotherms for the SAR-LEU/ Cu(II) titrations. 
Figure 4.19: Isotherms for the GLY-PHE/ Cu(II) titrations. 
Figure 4.20: Isotherms for the SAR-PHE/ Cu(II) titrations. 
Figure 4.21: Isotherms for the GLY-HIS/ Cu(II) titrations. 
Figure 5.1: 1H NMR results for the protonation of glycyl-L-leucine. 
Figure 5.2: 1H NMR results for the protonation of sarcosyl-L-leucine. 
Figure 5.3: 1H NMR results for the protonation of glycyl-L-phenylalanine. 
Figure 5.4: 1H NMR results for the protonation of glycyl-L-phenylalanine. 
Figure 5.5: 1H NMR results for GLY-LEU / Cu(II) 
Figure 5.6: 1H NMR results for SAR-LEU / Cu(II) 
Figure 5.7: 1H NMR results for GLY-PHE / Cu(II) 
Figure 5.8: 1H NMR results for SAR-PHE / Cu(II) 













                      GLY complexes. 
Figure 5.10: Structures of complexes formed between Cu(II) and GLY-GLY. 
Figure 5.11: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR- 
                      GLY complexes. 
Figure 5.12: Structures of complexes formed between Cu(II) and SAR-GLY. 
Figure 5.13: Molar extinction coefficients as a function of wavelength for Cu(II)/GLY- 
                      LEU complexes. 
Figure 5.14: Structures of complexes formed between Cu(II) and GLY-LEU. 
Figure 5.15: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR- 
                      LEU complexes. 
Figure 5.16: Structures of complexes formed between Cu(II) and SAR-LEU. 
Figure 5.17: Molar extinction coefficients as a function of wavelength for Cu(II)/GLY- 
                      PHE complexes. 
Figure 5.18: Structures of complexes formed between Cu(II) and GLY-PHE. 
Figure 5.19: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR- 
                      PHE complexes 
Figure 5.20: Structures of complexes formed between Cu(II) and SAR-PHE. 
Figure 6.1: Log (Dow) as a function of pH for Cu(II)/GLY-GLY titrations. 
Figure 6.2: Log (Dow) as a function of pH for Cu(II)/SAR-GLY titrations. 
Figure 6.3: Log (Dow) as a function of pH for Cu(II)/GLY-LEU titrations. 
Figure 6.4: Log (Dow) as a function of pH for Cu(II)/SAR-LEU titrations. 
Figure 6.5: Log (Dow)  as a function of pH for Cu(II)/GLY-PHE titrations. 
Figure 6.6: Log (Dow) as a function of pH for Cu(II)/SAR-PHE titrations. 
Figure 6.7: Log (Dow) as a function of pH for Cu(II)/GLY-HIS titrations. 
Figure 6.8: p.m.i as a function of log10 [L] for complexes of GLY-GLY and Cu(II), Ni  
                    (II) and Zn (II). 
Figure 6.9: p.m.i as a function of log10 [L] for complexes of SAR-GLY GLY and Cu(II), 
                    Ni(II) and Zn (II). 
Figure 6.10: p.m.i as a function of log10 [L] for complexes of GLY-LEU GLY and Cu                        
                     (II), Ni(II) and Zn (II). 













                     (II), Ni(II) and Zn (II). 
Figure 6.12: p.m.i as a function of log10 [L] for complexes of GLY-PHE GLY and Cu  
                      (II), Ni(II) and Zn (II). 
Figure 6.13: p.m.i as a function of log10 [L] for complexes of SAR-PHE GLY and Cu  
                     (II), Ni(II) and Zn (II). 
Figure 6.14: p.m.i as a function of log10 [L] for complexes of Cu(II) and GLY-GLY,  
                     SAR-GLY, GLY-LEU, SAR-LEU, GLY-PHE, SAR-PHE and GLY-HIS. 
Figure 7.1:   p.m.i as a function of log10 [L] for complexes of Cu(II) and GLY-GLY, 
                      SAR-GLY, GLY-LEU, SAR-LEU, GLY-PHE, SAR-PHE and GLY-HIS 
























LIST OF TABLES 
Table 3.1: Calculated protonation constants of glycine and the standard deviations. 
Table 3.2: Calculated protonation constants of sarcosine and the standard deviations. 
Table 3.3: Calculated protonation constants of GLY-GLY and the standard deviations. 
Table 3.4: Calculated protonation constants of SAR-GLY and the standard deviations. 
Table 3.5: Calculated protonation constants of GLY-LEU and the standard deviations. 
Table 3.6: Calculated protonation constants of SAR-LEU and the standard deviations. 
Table 3.7: Calculated protonation constants of GLY-PHE and the standard deviations. 
Table 3.8: Calculated protonation constants of SAR-PHE and the standard deviations 
Table 3.9: Calculated equilibrium constants for Cu(II)/GLY complexes. 
Table 3.10: Calculated equilibrium constants for Cu(II)/SAR complexes. 
Table 3.11: Calculated equilibrium constants for Cu(II)/GLY-GLY complexes. 
Table 3.12: Calculated equilibrium constants for Ni(II)/GLY-GLY complexes.  
Table 3.13: Calculated equilibrium constants for Zn (II)/GLY-GLY complexes. 
Table 3.14: Calculated equilibrium constants for Cu(II)/SAR-GLY complexes.  
Table 3.15: Calculated equilibrium constants for Ni(II)/SAR-GLY complexes.  
Table 3.16: Calculated equilibrium constants for Zn (II)/SAR-GLY complexes.  
Table 3.17: Calculated equilibrium constants for Cu(II)/GLY-LEU complexes. 
Table 3.18: Calculated equilibrium constants for Ni(II)/GLY-LEU complexes. 
Table 3.19: Calculated equilibrium constants for Zn (II)/GLY-LEU complexes. 













Table 3.21: Calculated equilibrium constants for Ni(II)/SAR-LEU complexes. 
Table 3.22: Calculated equilibrium constants for Zn (II)/SAR-LEU complexes. 
Table 3.23: Calculated equilibrium constants for Cu(II)/GLY-PHE complexes. 
Table 3.24: Calculated equilibrium constants for Ni(II)/GLY-PHE complexes. 
Table 3.25: Calculated equilibrium constants for Zn (II)/GLY-PHE complexes. 
Table 3.26: Calculated equilibrium constants for Cu(II)/SAR-PHE complexes. 
Table 3.27: Calculated equilibrium constants for Ni(II)/SAR-PHE complexes. 
Table 3.28: Calculated equilibrium constants for Zn (II)/SAR-PHE complexes. 
Table 3.29: A summary table for protonation constants. 
Table 3.30: A summary table of equilibrium constants. 
Table 4.1: Thermodynamic parameters NaOH vs HCl titrations. 
Table 4.2: Calculated enthalpy changes and entropy changes for the formation of water. 
Table 4.3: Calculated enthalpy changes and entropy changes for protonation of glycine.  
Table 4.4: Calculated heats of protonation of sarcosine and the standard deviations. 
Table 4.5: Calculated heats of protonation of glycyl-glycine and the standard deviations. 
Table 4.6: Calculated heats of protonation of sarcosyl-glycine and the standard 
                  deviations. 
Table 4.7: Calculated heats of protonation of glycyl-L-leucine and the standard 
                 deviations. 
Table 4.8: Calculated heats of protonation of sarcosyl-L-leucine and the standard 













Table 4.9: Calculated heats of protonation of glycyl-L-phenylalanine and the standard 
                  deviations.      
Table 4.10: Calculated heats of protonation of sarcosyl-L-phenylalanine and the standard  
                  deviations. 
Table 4.11: Calculated heats of protonation of glycyl-L-histidine and the standard 
                   deviations. 
Table 4.12: Calculated heats for complexation of Cu(II) with GLY and the standard  
                  deviations.  
Table 4.13: Calculated heats for complexation of Cu(II) with SAR and the standard 
                   deviations. 
Table 4.14: Calculated heats for complexation of Cu(II) with GLY-GLY and the 
                    standard deviations.      
Table 4.15: Calculated heats for complexation of Cu(II) with SAR-GLY and the standard  
                     deviations.      
Table 4.16: Calculated heats for complexation of Cu(II) with GLY-LEU and the standard 
                     deviations.      
Table 4.17: Calculated heats for complexation of Cu(II) with SAR-LEU and the standard 
                     deviations.      
Table 4.18: Calculated heats for complexation of Cu(II) with GLY-PHE and the standard 
                     deviations.      













                    deviations.      
Table 4.20: Calculated heats for complexation of Cu(II) with GLY-HIS and the standard  
                     deviations.  
Table 4.21: Gibbs’s free energy, enthalpy change and entropy change for the complex 
                      formation titrations of Cu(II) with GLY ligands and SAR ligands. 
Table 4.22: Gibbs’s free energy, enthalpy change and entropy change for the protonation  
                     of GLY ligands and SAR ligands.      
Table 5.0: Electron donor groups and corresponding ligand field. 
Table 5.1: Proposed electron donor groups and corresponding calculated λmax’s for  
                 Cu(II)/dipeptide complexes. 
Table 5.2: Observed and calculated λmax’s for Cu(II)/GLY-GLY complexes. 
Table 5.3: Observed and calculated λmax’s for Cu(II)/SAR-GLY complexes. 
Table 5.4: Observed and calculated λmax’s for Cu(II)/GLY-LEU complexes. 
Table 5.5: Observed and calculated λmax’s for Cu(II)/SAR-LEU complexes. 
Table 5.6: Observed and calculated λmax’s for Cu(II)/GLY-PHE complexes. 
Table 5.7: Observed and calculated λmax’s for Cu(II)/SAR-PHE complexes. 
Table 5.8: Total minimum strain energies of structures (a) to (q). 
Table 6.1: Log Dow’s for Cu(II) complexes with different ligands at pH 7.4. 













TABLE OF CONTENTS 
1. RHEUMATOID ARTHRITIS………………………………………………………1 
1.1   INTRODUCTION………………………………………………………………….1 
1.2   THERAPY FOR RHEUMATOID ARTHRITIS………………………………..…2 
1.2.1   Non-steroidal anti-inflammatory drugs…………………………………..3 
1.2.2   Disease modifying anti-rheumatic drugs……………………………....…3 
1.2.3   Corticosteroids (Glucocorticoids)……………………………………...…4 
1.3   COPPER AND RHEUMATOID ARTHRITIS…………………………………....5 
1.4   AIM……………………………………………………………………………...…5 
1.5   OBJECTIVES…………………………………………………………………...…6 
REFERENCES……………………………………………………………….…………7 
2.   LIGAND DESIGN……………………………………………………………..…10 
2.1 INTRODUCTION,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10 
2.2 LIGAND SELECTION…………………………………………………………....11 
REFERENCES……………………………………………………………...…………13 
3. POTENTIOMETRY………………………………………………………………14 
3.1   INTRODUCTION……………………………………………………………….14 
3.2   THEORY…………………………………………………………………...……16 
3.3   EXPERIMENTAL………………………………………………………….……20 
   3.3.1    Sample preparation…………………………………………………….….…20 
   3.3.2    Potentiometric measurements………………………………………….….....20 
   3.3.3    Data handling………………………………………………………….…..…21 
3.4   RESULTS…………………………………………………………………..….…25 
   3.4.1    Protonation titrations………………………………………………………..…..…..25 
       3.4.1.1     Protonation of glycine…………………………………….....….25 
       3.4.1.2     Protonation of sarcosine……………………………….………..27 













                   3.4.1.4     Protonation of sarcosyl-glycine……………………..…………..30 
                   3.4.1.5     Protonation of glycyl-L-leucine………………………………....31 
                   3.4.1.6     Protonation of sarcosyl-L-leucine……………………..……...…33 
                   3.4.1.7     Protonation of glycyl-L-phenylalanine…………………….……34 
                   3.4.1.8     Protonation of sarcosyl-L-phenylalanine……………….....….…35 
                   3.4.1.9     Protonation of glycyl-L-histidine……………………...………..37 
                   3.4.1.10   Protonation of sarcosyl-L-histidine…………………...…...……37 
  3.4.2    Complex formation titrations……………………………………..…….……38 
      3.4.2.1     Glycine complexes………………………………..……….……38 
                  3.4.2.1.1     GLY / Cu(II)……………………………..………...…38 
      3.4.2.2     Sarcosine complexes…………………………….……….……..40 
                  3.4.2.2.1     SAR / Cu(II)…………………………….…......……..40 
      3.4.2.3    Glycyl-glycine complexes………………………………………42 
                  3.4.2.3.1     GLY-GLY / Cu(II)……………..……………………42 
                  3.4.2.3.2     GLY-GLY / Ni(II)……………………..….…………44 
                  3.4.2.3.3     GLY-GLY / Zn(II)…………………..………….……46 
      3.4.2.4    Sarcosyl-glycine complexes……………………………….....…48 
                  3.4.2.4.1     SAR-GLY / Cu(II)…………………...…………..…..48 
                  3.4.2.4.2     SARGLY / Ni(II)………………………….……..…..50 
                  3.4.2.4.3     SAR-GLY / Zn(II)…………………...…………....…52 
      3.4.2.5    Glycyl-L-leucine complexes……………………………….……54 
                  3.4.2.5.1     GLY-LEU / Cu(II)…...……………………………….54 
                  3.4.2.5.2     GLY-LEU / Ni(II)……..…………….………….……56 
                  3.4.2.5.3     GLY-LEU / Zn(II)……………………………………58 
      3.4.2.6    Sarcosyl-L-leucine complexes………….………………………..60 
                  3.4.2.6.1     SAR-LEU / Cu(II)………………………………….…60 
                  3.4.2.6.2     SAR-LEU / Ni(II)…………....………………….…….62 
                  3.4.2.6.3     SAR-LEU / Zn(II)…………………………….………64 
      3.4.2.7    Glycyl-L-phenylalanine complexes….………………………..…66 
                  3.4.2.7.1     GLY-PHE / Cu(II)………………………………….…66 













                  3.4.2.7.3     GLY-PHE / Zn (II)……………………………………70 
      3.4.2.8    Sarcosyl-L-phenylalanine complexes……………………………72 
                  3.4.2.8.1     GLY-PHE / Cu(II)……………..……….………….…72 
                  3.4.2.8.2     GLY-PHE / Ni(II)……………………………….....…74 
                  3.4.2.8.3     GLY-PHE / Zn(II)……………………………..…...…75 
3.5    DISCUSSION……………………………………………………………….…..77 
3.6    CONCLUSION……………………………………………………………….…80 
RERERENCES ……………………………………………………………………..…81 
4. ISOTHERMAL TITRATION CALORIMETRY………………………….……84 
4.1   INTRODUCTION………………………………………………………..………84 
4.2   THEORY………………………………………………………….........…………86 
4.3   EXPERIMENTAL……………………………………………………..…………91 
          4.3.1    Sample preparation and calorimetric measurements………….….………91 
          4.3.2    Data handling…………………………………………………………….92 
4.4   RESULTS…………………………………………………………………………93  
         4.4.1 Method validation………………………………………………………..…93 
       4.4.1.1     Water/water titrations……………………………………………93 
       4.4.1.2     Acid/base titrations………………………………………………94 
         4.4.2    Protonation titrations………………………………………………...……97 
       4.4.2.1     Protonation of glycine……………………………………………97 
     4.4.2.2     Protonation of sarcosine…………………………………...……100 
       4.4.2.3     Protonation of glycyl-glycine………….……………………..…101 
       4.4.2.4     Protonation of sarcosyl-glycine…………………………………103 
       4.4.2.5     Protonation of glycyl-L-leucine…………………………………104 
       4.4.2.6     Protonation of sarcosyl-L-leucine…………………………….…106 
       4.4.2.7     Protonation of glycyl-L-phenylalanine………………………….107 
       4.4.2.8     Protonation of sarcosyl-L-phenylalanine……………..…………108 
       4.4.2.9     Protonation of glycyl-L-histidine…………….…………………110 
       4.4.3    Complex formation titrations…………………………………..………….112 
       4.4.3.1     GLY / Cu(II)……………………………………………………113 













       4.4.3.3     GLY-GLY / Cu(II)……………………………………….…….117 
       4.4.3.4     SAR-GLY / Cu(II)………………………………………...……118 
       4.4.3.5     GLY-LEU / Cu(II)……………………………………...………119 
       4.4.3.6     SAR-LEU / Cu(II)……………………………………...….……121 
       4.4.3.7     GLY-PHE / Cu(II)…………………………………....……...….122 
       4.4.3.8     SAR-PHE / Cu(II)……………………………………….......…..124 
       4.4.3.9     GLY-HIS / Cu(II)…………………………………………....… 125 
4.5    DISCUSSION…………………………………………………………................128 
4.6    CONCLUSIONS…………………………………………………………....……132 
RERERENCES…………………………………………………………………..……..133 
5. STRUCTURAL STUDIES……………………………………………………...….135 
5.1   1H NMR SPECTROSCOPY………………………………………………..……..135 
5.1.1   INTRODUCTION………………………………………………………135 
5.1.2   EXPERIMENTAL…………………………………………………..…..135 
5.1.3   RESULTS…………………………………………………………….…136 
   5.1.3.1    Protonation titrations…………………………………….....136 
       5.1.3.1.1     Protonation of glycyl-L-leucine…………………….…136 
       5.1.3.1.2     Protonation of sarcosyl-L-leucine……………………..137 
       5.1.3.1.3     Protonation of glycyl-L-phenylalanine………………..139 
       5.1.3.1.4     Protonation of sarcosyl-L-phenylalanine…………..….140 
    5.1.3.2    Complex formation titrations…………………………..….141 
        5.1.3.2.1     GLY-LEU / Cu(II)……………………………….…..141 
        5.1.3.2.2     SAR-LEU / Cu(II)……………………………………142 
        5.1.3.2.3     GLY-PHE / Cu(II)……………………………..…….143 
        5.1.3.2.4     SAR-PHE / Cu(II)……………………………………144 
   5.1.3.3    Discussion……………………………………………….…145 
5.2   UV-VIS SPECTROPHOTOMETRY…………………………………………….148 
5.2.1   INTRODUCTION………………………………………………………148 
5.2.2   EXPERIMENTAL………………………………………………………149 
5.2.3   RESULTS……………………………………………………………….150 













    5.2.3.2     SAR-GLY / Cu(II)……………………………………...…155 
    5.2.3.3     GLY-LEU / Cu(II)……………………………………..….157 
    5.2.3.4     SAR-LEU / Cu(II)………………………………………...160 
    5.2.3.5     GLY-PHE / Cu(II)………………………………………...162 
    5.2.3.6     SAR-PHE / Cu(II)…………………………………..…….164 
5.2.4    Discussions……………………………………………………………..165 
5.3   MOLECULAR MECHANICS……………………………………………...……166 
5.3.1   INTRODUCTION………………………………………………….…..166 
5.3.2   EXPERIMENTAL…………………………………………….……..…168 
5.3.3   RESULTS……………………………………………………………….168 
5.4   GENERAL CONCLUSIONS…………………………………………….………170 
RERERENCES…………………………………………………………………………174 
6. TISSUE PERMEABILITY AND BIO-DISTRIBUTION STUDIES…………....176 
6.1 OCTANOL / WATER PARTITION COEFFICIENTS……………………………176 
6.1.1   INTRODUCTION………………………………………………………176 
6.1.2   EXPERIMENTAL………………………………………………………178 
6.1.3   RESULTS………………………………………….....…………………178 
       6.1.3.1     GLY-GLY / Cu(II) ………………………………...……178 
6.1.3.2     SAR-GLY /Cu(II)………………………………….……179 
6.1.3.3     GLY-LEU /Cu(II)………………………………….……180 
6.1.3.4     SAR-LEU /Cu(II)……………………………………..…180 
6.1.3.5     GLY-PHE /Cu(II)………………………………….……181 
6.1.3.6     SAR-PHE /Cu(II)……………………….………….……181 
6.1.3.7     GLY-HIS /Cu(II)……………………….……………….182 
6.1.4      DISCUSSION……………………………….………….……..182 
6.2   BLOOD PLASMA MODEL…………………………………….………………..184 
6.2.1   INTRODUCTION………………………………………………………184 
6.2.2   DATA HANDLING……………………………………….……………184 
6.2.3   RESULTS……………………………….....……………........…………185 
       6.2.3.1     GLY-GLY / Cu(II)……………………...………………185 













       6.2.3.3     GLY-LEU / Cu(II)............................................................186 
       6.2.3.4     SAR-LEU / Cu(II).............................................................186 
       6.2.3.5     GLY-PHE / Cu(II)……………………………....………187 
       6.2.3.6     SAR-PHE / Cu(II)…………………………….......……..187 
       6.2.3.7     GLY-HIS / Cu(II)……………………………...………..188 
6.2.4    DISCUSSION………………………………………….....…………….188 
6.2   CONCLUSIONS………………………………………………………………….189 
REFERENCES……………………………………………………………………...….190 
7.     GENERAL DISCUSSIONS AND RECOMMENDATIONS…………………192 
7.1   DISCUSSIONS………………………………………………………………...….192 












1.  RHEUMATOID ARTHRITIS 
1.1   INTRODUCTION 
Rheumatoid arthritis (RA) is an autoimmune disease that causes systematic and chronic 
inflammation of the joints and other parts of the body [1, 9, 14-16].   RA is progressive 
disease.   At an early stage, the body produces an antibody that attacks healthy body 
tissues resulting in excessive production of cytokines [14-18].   These cytokines cause 
changes in the synovial membrane, as a result the body produces excessive amounts of 
synovium fluid.   Excessive amounts of synovial fluid around the joints can lead to mild 
loss of functioning and mobility of the joints [14-18].   If this condition is not treated the 
synovial membrane might swell off and cause the cartilage to wear off.   This may cause 
the synonium fluid to thicken.   The thickening of the synovium fluid leads to growth and 
division of pannus (second stage).   This can lead to cartilage and bones being eroded 
which may cause severe loss of mobility (final stage) [14-18]. 
 
Rheumatoid arthritis affects 1 to 3 % of the world population [1].   Early symptoms are 
common in persons between 30 and 50 years of age [1].   RA affects more women than 
men, with a ratio of 3:1 women to men reported in 2008 [1]. 
 
Morning stiffness, joint pain, swelling and tenderness around the joints, and loss of 
functioning and mobility of joints are the symptoms of RA [11-13]. 
 
The exact cause of rheumatoid arthritis is not yet known.   It is however believed that a 
combination of factors may cause this condition.   These include; 
1. Genetic susceptibility:   human leukocyte antigen (HLA) is believed to increase 
the progression of RA.  Most individuals with HLA-DR1 and HLA-DR4 genes 
have been reported to be at risk of developing RA [1-3]. 
2. Hormonal factors:   scientists think certain hormones may cause RA.   This is due 












3.  Environmental factors:   some authors believe certain bacteria and virus may 
cause RA.   Other authors [32, 33] believe smoking may trigger rheumatoid 
arthritis. 
 
The direct connection between these factors and RA has not been completely established.   
Patients with rheumatoid arthritis have been reported to have elevated amounts serum 
copper and synovium fluid copper than people who do not have RA [5-8].   It is believed 
that this is a result of homeostasis.   A precise correlation has not been established. 
    
1.2   THERAPY FOR RHEUMATOID ARTHRITIS 
There is no cure for RA, however symptoms and progression can be treated.   The 
traditional method is by wearing copper bracelets [4, 19-21].   It is believed that the 
copper in the bracelets and sweat form chelates that permeate through the skin into the 
bloodstream where they will be transported to the affected areas [4].   Copper-sweat 
chelates are less toxic than drugs which, in most cases are associated with side effects.   
There are limitations.   The efficiency of the chelates depends on amount of copper in the 
bracelet and the rate at with these chelates permeates through the skin [4, 19-21].   
Another traditional treatment, but less common, is by wearing stainless steel bracelets 
with neodymium magnets encapsulated in them.   These bracelets do not provide with 
useful chelates (for treatment of RA) but the magnetic field accelerates the circulation of 
blood to all parts of the body [22, 23], and thus distributing copper evenly throughout the 
body. 
 
A copper enriched diet has also been reported to be useful in alleviating RA symptoms.   
This includes a diet that consists of animal liver, cereals, legumes, crustacean, shell fish, 
dried fruits, nuts and chocolate [24-26]. 
 
Pharmaceutical treatment includes the use of non-steroidal anti-inflammatory drugs 
(NSAID’s), disease modifying anti-rheumatic drugs (DMARD’s) and glucocorticoids.   












1.2.1   Non-steroidal anti-inflammatory drugs 
NSAID’s are used to alleviate inflammation and to treat mild to moderate pain.   
Examples of these are aspirin, ibuprofen and naproxen (chemical structures are given in 
Figure 1.1).   Non-steroidal anti-inflammatory drugs alleviate inflammation and pain by 
blocking cyclooxygenase (COX) which is an enzyme that is responsible for the 
production of prostaglandins [34, 35].   Prostaglandins activate inflammation, pain and 
fever.   NSAID’s are effective but they are associated with side effects: nausea, loss of 
appetite, vomiting, diarrhea, constipation, rash, dizziness, drowsiness and headache.   
They can also cause ulcers, renal impairment, gastrointestinal irritation and sometimes 
bleeding if used for a long period of time.   NSAIDS’s do not reduce/stop the progression 
















Figure 1.1:   Examples of NSAID’s (structural representation) 
 
1.2.2   Disease modifying anti-rheumatic drugs 
DMARD’s reduce the progression of RA and prevent bone damage. [36]   
Hydroxychloroquinone, methotreane and auranofin are examples of disease modifying 
anti-rheumatic drugs.   The structures of these are given in Figure 1.2.   The mechanism 
through which these drugs work has not been fully established.   The use of DMARD’s is 
also associated with some side effects.    These include upset stomach, sore and dry 
mouth, nausea, skin rash.   Prolonged usage may lead to gastrointestinal irritation, renal 











































Figure 1.2:   Examples of DMARD’s (structural representation) 
 
1.2.3   Corticosteroids (Glucocorticoids) 
These can be taken during the final stage of RA.   These drugs suppress inflammation and 
they have a high potency compared to NSAID’s and DMARD’s but they can make the 
immune system to be less resistant to infections [38, 39].   An example of corticosteroids 
is prednisone.    Side effects include a puffy face, a sharp appetite, weight gain, mood 
























1.3   COPPER AND RHEUMATOID ARTHRITIS  
Copper salts and organic salts have been reported to play an important role in reducing 
inflammation [29-31].   The most common copper salts are copper salicylate and copper 
aspirinate, A precise mechanism on how this is achieved has not been established 
however, it is believed that copper may; 
 
1. reduce the production or activity of prostaglandins which stimulate pain and 
inflammation [9], 
2. increase the production or activity of lysyl oxidase.   Lysyl oxidase is a copper-
containing enzyme that is responsible for the protection of connective in tissues 
[7]. 
3. boost the production of histidine which regulates the response of inflammation, 
4. increase the production or the activity of superoxide dismutase (SD) which is an 
enzyme responsible for repairing cells [10], 
5. reduce the production or the activity of lysosomes [17-18].  
  
1.4   AIM 
The main aim of this study is to alleviate the inflammation associated with RA by 
developing a dermally absorbable, copper complex that will elevate the bioavailable pool 
of copper in vivo.    These ligands should; 
1. be more selective for Cu (II) than for other cations found in high concentrations in 
blood plasma, 
2. form thermodynamically stable complexes with Cu (II).   These complexes should 
however be kinetically labile so that the copper is at the biological sites where it is 
needed, 
3. promote dermal absorption as this is the preferred route of administration.   Anti-
inflammatory drugs that are administered orally are accompanied by side effect.   
Side effects like ulcers, renal impairment, and gastrointestinal irritation may be 













1.5   OBJECTIVES 
1. Design new ligands (drugs) that fulfill the aims. 
2. Determine the thermodynamic properties of these ligands and their complexes 
with Cu (II) using; 
a) Glass electrode potentiometry, and 
b) Isothermal titration calorimetry 
3. Predict the structures of the complex species using; 
a) UV-Vis spectrophotometry,  
b) 1H NMR, and 
c) Molecular mechanics 
4. Determine the lipophilicity/hydrophilicity of the complexes using octanol/water 
distribution coefficients, and evaluate the ligand in silica (via computer 
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2.   LIGAND DESIGN 
2.1 INTRODUCTION 
The aim of this study was to develop ligands which are able to increase the bio-available pool 
of copper in vivo.   The hypothesis being that an increase in this pool of copper would have 
an anti-inflammatory effect in diseases like rheumatoid arthritis.  The design of a drug/ligand 
depends on a number of factors.   It depends on; 
 
1. Knowledge of the biological sites (active sites) of ligands:   if the active sites of the 
ligands are known it is easy to predict whether the ligands and the target molecule (or 
metal ion) will actually bind.   The species that will form when the ligands bind to the 
target molecule or metal ion, and their stabilities can be predicted based on previous 
studies. 
 
2. Prediction of stability of drugs (affinity and selectivity to the metal ion of interest):   
this is necessary in predicting whether the ligands will be effective in transporting the 
metal ion of interest and whether the ligands are selective for a specific ion or not.   It 
is also important in predicting the dosage.   High affinity/highly selective ligands can 
be effective even with small doses.   Selective ligands will not chelate and remove 
essential metal ions from the blood plasma [5-6] 
 
3. Prediction of the potency /efficacy of the drugs:   this factor is important in predicting 
whether the ligands are capable of producing a biological response once they have 
binded with the target molecule (or metal ion).   This is also important in predicting 
whether the ligands will transport and deliver the molecules or metal ions of interest 
to the parts of the body where they are needed. 
 
4. Prediction of the aqueous solubility of drugs:   this factor affects the bioavailability of 
the drug [1].   This is therefore necessary in predicting the route of administration, 
orally or trans-dermally. 
 
5. Knowledge of the toxicity of drugs and target metabolites.   This factor is important 












2.2 LIGAND SELECTION 
In blood plasma, copper is transported by proteins; human serum albumin (HSA) being the 
most effective protein [10-12].   Cu(II) binding sites of HSA are shown in Figure 2.1.   
Amine and amide N-donors of HSA are the main transport binding sites for Cu(II).   N-
donors have been reported to be more selective for Cu(II) than other metal ions found in high 
concentrations in blood plasma [11-14].   This however, makes complexes of Cu(II) and HSA 
very stable and thus less bioavailable.   A chelate sequence 5, 5, 6 (Cu-NH2-CH-CO-N;      
Cu-N-CH-CO-N; Cu-N-CH-CH2-CH rings) is observed for Cu(II)-HSA (Figure 2.1). 
 
 
Figure 2.1:   Structure of Cu(II)-human serum albumin [18]. 
 
The design of the ligands was based on the structure of HSA.   The designed ligands each 
have three active Cu(II) binding sites: an amine N-donor, an amide N-donor and a 
carboxylate O-donor.   Glycyl-L-histidine and sarcosyl-L-histidine each has two additional 
N-donor atoms on the imidazole ring.   The structures of these are given in Figure 2.2.   The 
amine and the amide N-donor groups will make the ligands to be more selective for Cu(II) 
than for Ca (II), Ni (II) and Zn (II) which are found in high concentrations in blood plasma.   
Cu(II) complexes of these ligands should be less stable than Cu(II)-HSA complexes and so 
release the their copper in plasma.   Cu-O bond is not as strong as Cu-N [2, 17] and thus 
complexes formed between these ligands and Cu(II) will not be as strong as the Cu(II)-HSA 
complexes which has Cu(II) coordinating on four N-donors.   This may improve the 
liability/bioavailability of the complexes of Cu(II) with these ligands. 
 
Two series of ligands have been chosen; glycine dipeptides and sarcosine dipeptides.   This 












non-methylated analogues [15, 16].   N-methylated peptides are also less susceptible to 
metabolism [19].   Drugs that will be administered trans-dermally are preferred over drugs 
that will be administered orally therefore the ligands have to be slightly lipophilic.   This 
however, has to be achieved without compromising the stability of the Cu(II) complexes.   
Thermodynamic, permeation and solubility properties of complexes of Cu(II) with these two 
series of ligands are therefore compared.   The length of the peptides between the C-terminal 
and the N-terminal is the same for all the ligands because the length of the chain may also 
affect the solubility of organic compounds.  The group on the α-carbon of the C-terminal may 
also have an effect not only on the stability of the complexes but also on the solubility of 





























































Figure 2.2:   Structures of proposed glycine and sarcosine dipeptides 
 
Even though a trans-dermal route of administration is preferred over oral, all experiments are 
run in water therefore all the ligands have to be soluble in water.   Proposed ligands all have 
two amino acid residues therefore they are generally soluble in water [4, 7-9] and generally 
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3. GLASS ELECTRODE POTENTIOMETRY  
3.1   INTRODUCTION 
Potentiometry is a technique used to study chemical interactions of substances in solution   
[2].   The titration vessel is filled with analyte solutions of known concentration and volume.   
Standard solutions of the titrant are injected into the titration vessel, and the potential 
difference between the glass electrode and the reference electrode is measured.   These are 
direct measurements since indicators are not used.   The output is therefore not corrected. 
 
Data is reported in millivolts per unit volume of injection.   The output basically depends on 
the concentrations of the analyte solution and the titrant solution.   From the output, 
equilibrium constants of species are calculated.   The effect of temperature and ionic strength 
on equilibrium constants have been reported [4-6].   The titrations are therefore run at a fixed 
temperature and a fixed ionic strength. 
    
In pH glass electrode potentiometry, the sensor (pH electrode) consists of a reference 
electrode, a glass electrode and a salt bridge.   Each of these components has its own 
potential.   A reference electrode potential (Eref) is the potential of the internal reference 
solution.   It has fixed value and is not affected by the concentration of the analyte solution.   
This is however affected by temperature and thus has to be determined before running the 
titrations [36].   The potential of the glass electrode (Eg) depends on the concentration of the 
analyte solution.   The liquid junction potential (Ej) is the difference between the potential of 
the internal reference solution and the potential of the analyte solution.   These components 
are arranged in this fashion:  
reference electrode ‖ salt bridge ‖ analyte solution ‖ glass electrode 
 
The observed potential (Ecell) is the sum of all three; 
 
                 
(3.1) 
 
Eg depends on the activity of H+ ions ({H+}).   Eg can be expressed in terms of the standard 












     
  





R is the universal gas constant, T is the temperature and F is Faraday’s constant.   
Substituting Equation 3.2 into 3.1 yields; 
 
              (  
  





Eg depends on the pH of the analyte solution therefore it depends on the activity of H+ {H} 
ions can be expressed as; 
           
(3.4) 
 
Where  H is the activity coefficient and [H] is the concentration of H+ ions.   The charge has 
been omitted for simplicity. 
 





∑      
  
(3.5) 
Where Ci is the concentration of species i and Zi is the charge of species i. 
 
If I is constant then Equation 3.3 can be written as; 
 
                


















R and F are constants.   If T is also constant, the slope (s) of the electrode can be expressed 
as; 
  




The dependence of potentials on pH (or –log [H]) yields a linear curve.   Putting Equation 3.7 
into 3.6 yields; 
                         
(3.8) 
Calibration of the electrode requires the determination of Econstant and s. 
 
3.2   THEORY 
From the self ionisation of water;  H2O     OH +  H 
 
The charges have been omitted for simplicity,  





Where OH is the initial concentration of the hydroxide ions, H is the initial concentration of 
H+ ions and Kw is the dissociation constant of water. 
 
 For a ligand L being protonated into LH by the reaction; L + H   LH 
 
The thermodynamic protonation constant for LH, TKLH can be expressed as; 
 
        
    
      
 
(3.10) 
Where {LH} is the activity of LH, {L} is the activity of L and {H} is the activity of H.   The 
activity of a species X can be expressed in terms of its concentration [12] and the activity 
coefficient  X as given in Equation 3.11; 
 














        
          
                  
 
(3.12) 
Equation 3.12 can be rearranged;  
 
        (
    
       
) (
    




At constant ionic strength (     
       
) is constant therefore the concentration binding affinity KLH 
can be expressed as;  
      
    
      
 
(3.14) 
 For a ligand that has two dissociable protons;  
LH+ H   LH2 
 
KLH2 can be expressed as; 
       
      
       
 
(3.15) 
For a ligand that has multiple dissociable protons; 
 
LHn-1+ H   LHn 
 
KLHn can be expressed as;  
       
      


















Cumulative protonation/deprotonation constants (β’s) can be expressed as; 
 
L + H   LH                                      
    




LH + H   LH2                                      
      




LH2 + H   LH3                                         
      




LHn-1 + H   LHn                                            
      





For a metal M and a ligand L forming a complex ML by; 
M + L  ML 
The concentration equilibrium constant for ML can be expressed as  
      
     
      
 
(3.21) 
And for;  
MLn-1 + L  MLn 
The concentration equilibrium constant can be expressed as; 
       
      
          
 
(3.22) 
Log K’s for other species MLH-1, MLH-2 do not have a definite meaning.   For a reaction;  
ML  MLH-1 + H 
         
           














Log K for more complicated species ML2H-1, ML2H-2 depend of the pathway of the reaction.   
There are two (or more) possible routes for the formation of these species.   ML2H-1 can be 
formed by; 
ML2  ML2H-1 + H 
          
           




MLH-1 + L  ML2H-1 
          
        
           
 
(3.25) 
Similarly, log KML2H-2 from different routes;  
ML2  ML2H-2 + 2H 
MLH-2 + L  ML2H-2 
ML2H-1  ML2H-2 + H 
 
The stability of these species is therefore better described by the cumulative stability 
constants, log β’s. 
 
Cumulative equilibrium constants can be calculated; 
 M + L   ML                                      
    
      
 
(3.26) 
ML + L   ML2                                      
      
       
 
(3.27) 
ML2 + L   ML3                                         
      
       
 
(3.28) 
MLn-1 + L   MLn                                             
      
















For the reaction;  
pM + qL + rH   MpLqHr 
 
Where p, q and r are stoichiometric coefficients,  
         
          
            
 
(3.30) 
3.3   EXPERIMENTAL 
   3.3.1    Sample preparation 
Sodium chloride granules, potassium hydrogen phthalate, and sodium hydroxide and 
hydrochloric acid ampoules were purchased from Merck.   They were of analytical grade and 
were used without further purification.   Glycine, glycyl-glycine, glycyl-L-leucine, glycyl-L-
phenylalanine, glycyl-L-histidine and sarcosine were purchased from Sigma-Aldrich.   
Sarcosyl-glycine, sarcosyl-L-leucine, sarcosyl-L-phenylalanine and sarcosyl-L-histidine were 
purchased from GL Biochem (Shanghai).  
 
NaOH ampoules were diluted with distilled/de-ionized water as described on the ampoule 
box.   All weighing was done to 5 decimal places on an A&D GH-202 analytical scale 
balance.  NaOH was standardized against standard potassium hydrogen phthalate [28, 29].   
HCl ampoules were also diluted with distilled deionised water as described on the ampoule 
box.   HCl solutions were standardized by titration against NaOH and borax, and the end 
point was determined with the Gran method [3, 18].    
 
Ligand solutions were prepared in standard HCl solutions.   Metal ion solutions were 
prepared and standardized as described [20, 21].    
 
   3.3.2    Potentiometric measurements 
Ω Metrohm glass electrodes were used to measure the electrode potentials.   These potentials 
were monitored with 848 Titrino plus autotitrator from Ω Metrohm.   A double walled 
titration vessel (with water at 25 0C circulating between the walls) was used.   All titrations 
were run at 25 0C and 0.15 M ionic strength (NaCl) in an inert atmosphere of nitrogen.   The 
slope of the glass electrode was calibrated using three pH buffer solutions of different pH’s 












standard electrode potential (E0) and pKw were calculated from NaOH/HCl titrations.   E0 
ranged between 402.97 and 416.03 milivolts, pKw ranged between 13.76 and 13.79.   Metal 
titrations were performed using 1:2 metal/ligand concentrations 
 
   3.3.3    Data handling 
Potentiometric data is reported in potential difference (in millivolts) per unit volume of 
injection.   Stability constants are calculated from this data.   In this study the computer 
program, Equilibrium Simulations for Titration Analysis (ESTA) was used to analyse the raw 
potentiometric data.   ESTA has a number of tasks.   In this study ZBAR, QBAR and OBJE 
tasks were used. 
 
ZBAR task is a simulation unit that uses mass balance equations to characterise the system on 
point by point basis [1].   This task plots curves, ZH-bar curve for ligand protonation and ZM-
bar curve for complex formation titrations.   The protonation/deprotonation formation 
function (ZH-bar) is expressed as; 
       
       
     
 
(3.31) 
Where TH is the total concentration of hydronium ions, Tlig is the total concentration of the 
ligand and OH. 
A typical ZH-bar curve is given in Figure 3.0A.   If a ligand has two dissociable protons, ZH-
bar levels off at two and at on .   The pka values can also be estimated from ZH-bar curves.   
The pka’s are given by the pH that makes the mid-point of the steepest slope; log KLH =  7.8 
and log KLH2 = 3.4. 
 
Complex formation function (ZM-bar) depends on the cumulative protonation/deprotonation 
constants of the ligand to which the metal ion is binding to.   This can be expressed as; 
       
       ∑      
   
   
 
(3.32) 
Where TM is the total metal concentration, and; 
  
       














ESTA calculates the residual; 
               
 
      
 
     
(3.34) 
Where Z0-bar is the observed and ZC-bar is the calculated Z-bar.   A good agreement is 
observed if the observed and calculated Z-bar curves are superimposable. 
 
ZM-bar works for ML, ML2, ML3…MLn species.   A typical ZM curve is given in Figure 
3.0B.   If ML is the most predominant species in solution, ZM-bar levels off at 1.   Log KML 
can be estimated from the pL that makes the mid-point of the steepest slope; log KML = 8.9.   
If MLn (n = 1, 2, 3…) is not the most predominant species in solution, the ZM-bar fails.   
Typical graphs are given in Figure 3.0C.   The curling of the plots indicates the formation of 
hydroxo species.   From ZM-bar graphs, the model of Cu(II)/ligand species can be predicted.   
Looking at the black plot (Figure 3.0C),  the graph levels off at 1 indicating formation of ML, 
then curls back at low pL’s indicating the formation of MLH-1.   The pink plot of Figure 3.0 
indicates that hydroxo species begin to form at very low pH’s. 
 
It is also important to know how many protons have been lost upon complexation with a 
metal ion.   A deprotonation function (QM-bar) is calculated; 
 
        
  




Where T*H is total concentration or H+ ions in solution at the observed pH.   The mass 
balance equations for T*H and TL can be expressed as; 
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(3.36) 
Once QM-bar has been calculated, it can be plotted as a function of pH.   ESTA plots QM-bar 













       
  




A typical QM-bar graph is given in Figure 3.0D.   The pink plot is the n-bar.   The blue plot is 
QM-bar.   N-bar levels off at 1 indicating there is one dissociable proton on the ligand.   At pH 
3.9 there is an intersection between n-bar and QM-bar.   This indicates that the proton on the 
ligand has been displaced due to complexation; therefore the species formed is ML.   At pH 
6.4, the ligand has lost two protons due to complexation (QM-bar = 2), the complex species 
forming here is the MLH-1.   Between pH 6.4 and pH 8.9, n-bar and QM-bar parallel 
indicating that there are no more protons being displaced by the metal ion.   At pH 8.9, the 



























































Once the models have been chosen (for both the protonation titrations and the complex 
formation titrations and log K’s have been estimated, cumulative equilibrium constants (log 
β’s) can be put into OBJE task.   OBJE task of ESTA optimises titration parameters using the 
weighted or unweighted least squares.   The optimisation is based on the residuals of the 
electrode potential and the objective function (Uobj).   Uobj is expressed as; 
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(3.38) 
Where N is the number of experimental titration points, np is the total number of points being 
optimised, ne is the total number of electrodes, wnq of the qth residual at the nth titration point, 
yncalc is the calculated variable of the qth residual at the nth titration point and ynobs is the 
observed variable of the qth residual at the nth titration point. 
 
Using Gauss-Newton methods [10], Equation 3.38 can be expressed as a quadratic; 
 
         
   




Where a and b are Gauss-Newton quadratic parameter vectors, p is the optimization 
parameter vector and pt is the rear anged form of Equation 3.39 (Hessian method); 
 
    
      
      
 
(3.40) 
OBJE optimizes the titration parameters and calculates the standard deviations (δ) by; 
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(3.41) 
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(3.42) 
 
RH depends on random errors and the number of variables optimised.   If RH is less than RHlim 
then the model is accurate.   RHlim is expressed as; 
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)     
(3.43) 
Once the titration variables have been optimised and the program has converged, the 
speciation graph can be plotted from the initial concentrations of the analyte and the titrant.   
Accuracy, precision and reproducibility are achieved by having a large data population (np), 
and doing the same titration twice or more than two times (nT) and comparing the results with 
the literature if the titrations have been published before. 
 
 
3.4   RESULTS 
3.4.1 Protonation titrations 
 
3.4.1.1     Protonation of glycine 
Glycine protonation has been reported before [11-14].   This system is used to check the 
reliability of the method and that of the operator.   Glycine peptides (GLY-GLY, GLY-LEU, 
GLY-PHE and GLY-HIS) are compounds of interest and thus the study of glycine would 
provide a useful reference. 
 
Figure 3.1 shows ZH-bar as a function of pH for the protonation of glycine.   For clarity, a 
selected number of data points was plotted.   The blue markers represent the experimental 
plot and the solid line is the theoretical curve calculated using the model given in Table 3.1.   
The experimental and the theoretical plots are on top of each other.   This leads to confidence 
in the model.   At pH 11.0, ZH-bar is 0, therefore glycine exists as a free ligand and no 
protonation has occurred.   ZH-bar rises from pH 10.8 to pH 8.2, where it levels off at ZH-bar 
= 1.   In this pH range, glycine is being protonated from the L-form to the LH-form.   Log 












was fairly constant (ZH-bar ≈ 1) indicating that no further protonation was occurring.   From 
pH 3.5, ZH-bar rises from 1 to 1.5, as a result of the protonation of the second site.   This 
indicates that glycine has two dissociable protons. Complete protonation of LH to LH2 occurs 
at very low pH’s (pH < 2).   Titrations were not performed pH 2 because the electrode 




Figure 3.1: ZH-bar  as a function of pH for the protonation of glycine 
Even though the protonation constants could be estimated from ZH-bar graph, they were 
calculated and optimized using the OBJE function of ESTA.   Log KLH = 9.53 and log KLH2 = 
2.29 (Table 3.1).   These values agree well with the literature (KLH = 9.50 and log KLH2 = 
2.34) [11-14, 17].   The standard deviations σ p q r were small, RH was less than RHlim therefore 
the model was within the allowed maximum error. 
 
Table 3.1: Calculated protonation constants of glycine and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit [17] 
0 1 1 










Figure 3.2 shows the speciation of glycine in its three forms from pH 2 to pH 11.   At pH’s 
above pH 9.57, the most predominant species was L.   Between pH 9.57 and pH 2.35, the 




























Figure 3.2: Speciation for the protonation of glycine 
 
 
3.4.1.2     Protonation of sarcosine 
 
Studies on the protonation of sarcosine have also been done extensively [7-9].   Sarcosine 
was also used to test the reliability of the method and that of the operator.   Four sarcosine 
peptides (SAR-GLY, SAR-LEU, SAR-PHE and SAR-HIS) were also compounds of interest 
in this study thus sarcosine was used as a reference. 
 
Figure 3.3 shows ZH-bar as a function of pH for the protonation of sarcosine   Complete 
deprotonation of sarcosine occurs at very high pH’s (pH’s above 11).   Titrations could only 
be done between pH 2 and pH 11 because pH’s outside this pH range the electrode response 
is not linear.   ZH-bar rises from pH 11.0 to pH 8.5 where it levels off at ZH-bar = 1.   At this 
pH range the ligand was going from the L-form to the LH form.   The graph was extrapolated 
and the first protonation constant was estimated, log KLH = 10.0.   Between pH 8.5 and pH 
3.5 ZH-bar was not changing much (ZH-bar ≈ 1).   From pH 3.5 to pH 2, the graph rises to ZH-
bar = 1.4.   At this pH range, sarcosine was going from the LH form to the LH2 form.   
Complete protonation to LH to LH2 occurs at very low pH’s.  When the graph was 
































Figure 3.3: ZH-bar  as a function of pH for the protonation of sarcosine 
 
The pKa values are given in Table 3.2.   The standard deviations σ p q r are small, RH was less 
than RHlim therefore the model was within the allowed maximum error. 
 
Table 3.2: Calculated protonation constants of sarcosine and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 











Figure 3.2 shows the speciation of sarcosine from pH 2 to pH 11.   At pH’s above pH 9.57, 
the most predominant species was L.   Between pH 9.57 and pH 2.35, the most predominant 
species was LH.   LH2 was the most predominant species at pH’s below pH 2.35. 
 
 







































3.4.1.3     Protonation of glycyl-glycine 
 
Figure 3.5 shows ZH-bar  as a function of pH for the protonation of GLY-GLY.   GLY-GLY 
was completely deprotonated from pH 10.0.   ZH-bar  rises up from pH 9.9 to pH 7.0 
indicating protonation of GLY-GLY from L to LH.   The mid-point of this slope is equivalent 
to log KLH (log KLH = 8.2).   The graph levels off at ZH-bar  = 1 from pH 7.1 to pH 4.4.   
From pH 4.4 the graph rises up until it reaches ZH-bar  = 1.88.   Log KLH2 = 3.2. 
 
 
Figure 3.5: ZH-bar  as a function of pH for the protonation of GLY-GLY 
 
Optimised pKa’s are given in Table 3.3. 
 
Table 3.3: Calculated protonation constants of GLY-GLY and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 










Figure 3.6 shows the distribution of species from pH 2 to pH 11 for GLY-GLY protonation.   
At pH 8.68 there was already more L than LH in solution.   From pH 8.33 to pH 3.04, the 

























Figure 3.6: Speciation for the protonation of GLY-GLY 
 
3.4.1.4     Protonation of sarcosyl-glycine 
 
Figure 3.7 shows ZH-bar  as a function of pH for the protonation of SAR-GLY.   SAR-GLY 
was completely deprotonated from pH 10.0 (ZH-bar  is zero).   From pH 9.9 to pH 7.4 the 
graph rises then levels off at ZH-bar  = 1.   Mid-point of this slope is 8.4, therefore log KLH = 
8.4.   From pH 7.4 to pH 4.7 ZH-bar  does not change therefore the reactants and the products 
for this reaction were at equilibrium; LH + H LH2 
The second protonation constant was estimated by extrapolating the graph, log KLH2 = 3.  
 
 
Figure 3.7: ZH-bar  as a function of pH for the protonation of SAR-GLY 
 










































Table 3.4: Calculated protonation constants of SAR-GLY and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 










Figure 3.8 shows the distribution of species from pH 2.0 to pH 11.0 for SAR-GLY 
protonation.   From pH 11.0 to pH 8.6 L was the predominant species in solution.   From pH 
8.3 to pH 2.9, LH was the most predominant species in solution.   From pH 2.7 to pH 2.0, 
LH2 was predominant in solution. 
 
 
Figure 3.8: Speciation for the protonation of SAR-GLY 
 
3.4.1.5     Protonation of glycyl-L-leucine  
Figure 3.9 shows ZH-bar  as a function of pH for the protonation of GLY-LEU.   From pH 
11.0 to pH 10.0, Z is zero.   From pH 9.8 the graph rises until it gets to pH 7.1 where is levels 
off at ZH-bar  = 1.   The first protonation constant was estimated from the slope, log KLH = 
8.2.   From pH 7.2 to pH 4.6, the height of the graph does not change much.   From pH 4.2, 
the graph rises until ZH-bar  = 1.7 is achieved at pH 2.6.   The second protonation constant 































Figure 3.9: ZH-bar  as a function of pH for the protonation of GLY-LEU 
Table 3.5 shows calculated log K’s for the protonation of GLY-LEU.   The experimental 
values are in good agreement with the literature values. 
 
Table 3.5: Calculated protonation constants of GLY-LEU and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 










Figure 3.10 shows the distribution of GLY-LEU species from pH 2.0 to pH 11.0.   From pH 
11.0 to pH 8.3 the most predominant species is L.   From pH 8.0 to pH 3.2, the most 
predominant species is LH.   From pH 2.9 to pH 2.0 the most predominant species is LH2. 
 
 











































3.4.1.6     Protonation of sarcosyl-L-leucine 
 
Figure 3.11 shows ZH-bar as a function of pH for the protonation of SAR-LEU.   From pH 
11.0 to pH 10.5, the SAR-LEU was completely deprotonated (ZH-bar  is zero).   The graph 
rises up from pH 10.5 to pH 7.4.   Log KLH = 8.4.   From pH 7.4 to pH 5.1 the ZH-bar  ≈ 1 
was maintained.   The graph rises from pH 5.1 to pH 2.0 where ZH-bar  = 2 was reached.   




Figure 3.11: ZH-bar  as a function of pH for the protonation of SAR-LEU 
 
Table 3.6 shows calculated log K’s for the protonation of SAR-LEU.   The first protonation 
constant agrees well with the literature [15] and the second protonation is slightly higher than 
the literature [15].   The slight difference in log KLH2 could be due to the differences in the 
ionic strength. 
 
Table 3.6: Calculated protonation constants of SAR-LEU and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 












Figure 3.12 shows the speciation of SAR-LEU as a function of pH.   SAR-LEU exists in its L 
form from pH 11.0 to pH 8.5.   From pH 8.5 to pH 3.6, SAR-LEU exists in its LH form.   


























Figure 3.12: Speciation for the protonation of SAR-LEU 
 
3.4.1.7     Protonation of glycyl-L-phenylalanine 
 
ZH-bar for the protonation of GLY-PHE is given in Figure 3.13.   The graph levels off 
between pH 11.0 ant pH 9.8 where it rises until it reaches ZH-bar  = 1 (between pH 6.8 and 
pH 4.4).   The graph rises again from pH 4.4 to pH 2.2.   Protonation constants of GLY-PHE 




Figure 3.13: ZH-bar  as a function of pH for the protonation of GLY-PHE 
 
Optimized log K’s are given in Table 3.7.   Log K’s for the protonation of GLY-PHE agree 
well with literature [8, 9].   The standard deviations are small and the model is accurate since 








































Table 3.7: Calculated protonation constants of GLY-PHE and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
0 1  1 











Speciation for GLY-PHE protonation titrations is given in Figure 3.14.   From pH 11.0 to pH 
8.3 the most predominate species in solution is L.   From pH 8.0 to pH 3.1 the most 
predominate species in solution is LH and from pH 2.7 to pH 2.0 the most predominate 
species is LH2. 
 
 
Figure 3.14: Speciation for the protonation of GLY-PHE 
 
 
3.4.1.8     Protonation of sarcosyl-L-phenylalanine 
 
ZH-bar  for the protonation of SAR-PHE is given in Figure 3.15.    Equilibrium is observed 
between pH 11.0 and pH 9.6 for L + H   LH.   The equilibrium constant for this reaction 
from the graph, log KLH = 8.5.   The second equilibrium was observed between pH 7.4 and 
































Figure 3.15: ZH-bar  as a function of pH for the protonation of SAR-PHE 
Log KLH and log KLH2 were calculated and optimized.   These are given in Table 3.8.   
Protonation of SAR-PHE has not been reported before however the results obtained are 
comparable with the results obtained for GLY-PHE protonation.   The errors for log β’s are 
small and RH is less than RHlim.   This gives confidence in the results. 
Table 3.8: Calculated protonation constants of SAR-PHE and the standard deviations 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
0 1  1 









The speciation for the protonaion of SAR-PHE is given in Figure 3.16.   The L form of SAR-
PHE is most predominat from pH 11.0 to pH 8.7.   LH is most predominat from pH 8.3 to pH 





























Figure 3.16: Speciation for the protonation of SAR-PHE 
 
 
       3.4.1.9     Protonation of glycyl-L-histidine 
GLY-HIS titrations have been reported elsewhere [11].   The same media, titrations 
conditions and instrumentation were used, therefore these titrations were not repeated.   The 
first and the second protonation occur around the same pH region (log KLH = 8.34 and log 
KLH2 = 6.61).   Log KLH3 = 2.29.   The first protonation occurs on the amine terminal, the 
second protonation occurs on -atom of the imidazole ring and the third protonation occurs on 
the carboxylate terminal [11, 22-23]. 
 
       3.4.1.10   Protonation of sarcosyl-L-histidine 
Due to solubility problems, studies on SAR-HIS could not be done.   The order of protonation 










































   3.4.2    Complex formation titrations 
       3.4.2.1     Glycine complexes 
       3.4.2.1.1     GLY / Cu(II) 
ZM-BAR for Cu(II)/GLY is given in Figure 3.17.   The blue markers are the experimental 
data points, the solid line is the theoretical plot.   For clarity not all the data points have been 
plotted.   ZM-bar is zero from pL 9.4 to pL 8.6.   ZM-bar rises from pL 8.6 to pL 5.0.   From 
pH 5.0 to pH 2.0, ZM bar = 2.   This indicates the formation of the ML2, and that there are no 
hydroxo species forming in solution since the plot does not fan back at low pL’s. 
 
 
       
 
Figure 3.17: ZM-bar as a function of pL for the Cu(II)/GLY titrations 
 
Optimised log K’s are given in Table 3.9.   Log KML = 8.09 and log KML2 = 7.02.   These 
agree with the literature [13-14].   The standard deviations are small and RH is less than RHlim.    
This shows that the model is accurate. 
 
Table 3.9: Calculated equilibrium constants for Cu(II)/GLY complexes 
Metal p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 










The total number of dissociable protons on the ligand (n-bar) and the total number of lost 
protons upon complexation of Cu(II) with GLY (QM-bar) are shown in Figure 3.18.    The 
solid line is the experimental plot.   N-Bar (pink markers) rises from pH 11 to pH 9.1 where it 
levels off at QM-bar = 1.   The graph rises again from pH 3.3 to pH 2.0 where QM-bar = 1.7 is 
























ZM-bar  as a function of pH in protonation titrations).   The blue markers (QM-bar) shows the 
number of protons lost upon complexation of Cu(II) with GLY.    QM-bar rises from pH 11.0 
until it reaches a maximum value (QM-bar = 2 at pH 7.0), then drops until QM-bar is zero.   
This shows that all two dissociable protons are lost upon complexation of Cu(II) with GLY.   
The solid line is the experimental plot.   The theoretical plot and the experimental plot are 
superimposable; this gives confidence in the results. 
   
 
 
Figure 3.18: QM-bar as a function of pH for the Cu(II)/GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
Figure 3.19 shows the speciation for 1:2 Cu(II)/GLY from pH 2.0 to pH 11.0.   The ML 
species starts to form from pH 2.7 and the amount of this species increases until about 78 % 
(at pH 4.6) of it is formed, and the then starts decrease from pH 4.6 to pH 9.0 where it is 


























Figure 3.19: Speciation for complex formation titrations of Cu(II)/GLY, 1:2 ratio.   [GLY] = 0.006279 M. 
 
 
       3.4.2.2     Sarcosine complexes 
       3.4.2.2.1     SAR / Cu(II) 
ZM-bar for Cu(II)/SAR titrations is shown in Figure 3.20.   ZM-bar is zero from pL 10.0 to pL 
9.4.    From pL 9.4 the graph rises then levels off between pL 5.0 to pL 3.1 (ZM-bar = 2).   
This indicates the formation of ML2.   The graph then fans back at pL 3.1.   This indicates the 
formation of hydroxo species. 
 
 
Figure 3.20: ZM-bar as a function of pL for the Cu(II)/SAR titrations 
 
Equilibrium constants for species formed between Cu(II) and SAR from pH 2.0 to pH 11.0 







































shows that the model is accurate.   With the exception of log K2 the experimental equilibrium 
constants agree well with the literature [7, 8].   ML3 was not observed. 
 
Table 3.10: Calculated equilibrium constants for Cu(II)/SAR complexes 
Metal p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
Cu(II) 
1 1  0 
1 2  0 
1 1  1 
1 3  0 
























QM-bar as a function of pH for Cu(II)/SAR titrations is shown in Figure 3.21.   SAR has two 
dissociable protons and it loses two protons upon complexation with Cu(II).   QM-bar does 
not touch the baseline (X-axis) at pH 11.0.    This indicates the formation of hydroxo species 





Figure 3.21: QM-bar as a function of pH for the Cu(II)/SAR titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
 



























Figure 3.22: Speciation for complex formation titrations of Cu(II)/SAR, 1:2 ratio.   [SAR] = 0.002098 M. 
 
 
       3.4.2.3     Glycyl-glycine complexes 
       3.4.2.3.1     GLY-GLY / Cu(II) 
ZM-bar for Cu(II)/GLY-GLY is given in Figure 3.23.   ZM-bar levels off at 1.5.   At pH 4.5, 




Figure 3.23: ZM-bar as a function of pL for the Cu(II)/GLY-GLY titrations 
 
Species formed between Cu(II) and GLY-GLY and their equilibrium constants are given in 
Table 3.11.   The results are slightly higher than the literature [17, 24].   The slight difference 









































Table 3.11: Calculated equilibrium constants for Cu(II)/GLY-GLY complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 1 -1 
1 1 -2 
1 2 -1 
1 2 -2 
































GLY-GLY has two dissociable protons and about two protons were lost upon complexation 
of GLY-GLY with Cu(II) (Figure 3.24).   Between pH 7.1 and pH 8.9, QM-bar runs parallel 
to n-bar.    This indicates that complexation is complete.   The graph (QM-bar however rises 




Figure 3.24: QM-bar as a function of pH for the Cu(II)/GLY-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
Figure 3.25 shows the speciation graph for 1:2 Cu(II)/GLY-GLY between pH 2.0 and pH 
11.0.   ML species forms between pH 2.8 and pH 7.4.   ML2 forms between pH 4.2 and pH 






























Figure 3.25: Speciation for complex formation titrations of Cu(II)/GLY-GLY, 1:2 ratio.   [GLY-GLY] = 0.004345 M. 
 
       3.4.2.3.2     GLY-GLY / Ni(II) 
ZM-bar for Ni(II) GLY-GLY is given in Figure 3.26.   At pH 5.8 the graph rises and fans back 
at pH 3.3 indicating the formation of hydroxo species. 
 
 
Figure 3.26: ZM-bar as a function of pL for the Ni(II)/GLY-GLY titrations 
 
Species formed between Ni(II) and GLY-GLY and their stability constants are given in Table 











































Table 3.12: Calculated equilibrium constants for Ni(II)/GLY-GLY complexes. 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 3  0 
1 1  1 
1 2 -1 




























Figure 3.27 shows the QM-bar for Ni(II)/GLY-GLY titrations.   GLY-GLY has two 
dissociable protons and it loses one proton upon complexation with Ni(II).   The system 




Figure 3.27: QM-bar as a function of pH for the Ni(II)/GLY-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution graph for 1:2 Ni(II)/GLY-GLY titrations is shown in Figure 3.28.   




























Figure 3.28: Speciation for complex formation titrations of Ni(II)/GLY-GLY, 1:2 ratio.   [GLY-GLY] = 0.004258 M. 
 
       3.4.2.3.3     GLY-GLY / Zn(II) 
ZM-bar for Zn(II)/GLY-GLY is given in Figure 3.29.   The graph flags back at low pL’s 




Figure 3.29: ZM-bar as a function of pL for the Zn(II)/GLY-GLY titrations 
 
Log KML = 3.14, this agrees with the literature [17], log KMLH-1 = 8.18, this agrees well with 











































Table 3.13: Calculated equilibrium constants for Zn(II)/GLY-GLY complexes  
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 1  1 
1 1 -1 
























QM-bar for this titration is given in Figure 3.30.   QM-bar rises at pH 5.9.   The slope of this 
curve changes (but it does not level off) between pH 8.2 and pH 9.0.   The slope of the graph 
changes again from pH 9.0 to pH 11.0.    This shows that complexation starts at pH 5.9 and 
stops at pH 8.2.   However the production of the hydroxo species is rapid and the distribution 
curve for MLH-1 almost overlaps that of ML, therefore QM-bar does not level off as an 
indication that ML has finished forming, before rising again.as an indication that hydroxo 




Figure 3.30: QM-bar as a function of pH for the Zn(II)/GLY-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
Speciation for Zn(II)/GLY-GLY is given in Figure 3.31.   The gap between ML distribution 
curve and MLH-1 distribution curve is very small (0.70 pH units apart).   At pH 7.8 where 
ML stops forming, the amount of ML is equal to the amount of MLH-1 present in solution.   





























Figure 3.31: Speciation for complex formation titrations of Zn(II)/GLY-GLY, 1:2 ratio.   [GLY-GLY] = 0.004192 M. 
 
 
       3.4.2.4     Sarcosyl-glycine complexes 
       3.4.2.4.1     SAR-GLY / Cu(II) 




Figure 3.32: ZM-bar as a function of pL for the Cu(II)/SAR-GLY titrations 
 
Log KML = 6.15, this is slightly higher than the literature [17, 25].   Log K’s are affected by 
the ionic strength, the difference between the experimental and the literature is due to the 












































Table 3.14: Calculated equilibrium constants for Cu(II)/SAR-GLY complexes  
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 2 -1 






















SAR-GLY lost two protons upon complexation with Cu(II) (Figure 3.33).   Between pH 7.7 
and pH 8.7 complexation was complete.   Hydroxo species started to form from pH 8.7. 
 
 
Figure 3.33: QM-bar as a function of pH for the Cu(II)/SAR-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 































       3.4.2.4.2     SAR-GLY / Ni(II) 
ZM-bar for Ni(II)/SAR-GLY is given in Figure 3.35. 
 
 
Figure 3.35: ZM-bar as a function of pL for the Ni(II)/SAR-GLY titrations 
 
Log KML = 3.41, log KMLH-1 = 8.79 and log KMLH-2 = 10.5 (Table 3.15).   This titration has not 
been reported before, however the standard deviations are small and RH is less than RHlim.    












































Table 3.15: Calculated equilibrium constants for Ni(II)/SAR-GLY complexes  
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 1 -1 













SAR-GLY has two dissociable protons and it loses one proton upon complexation with Ni(II) 
(Figure 3.36).   Complexation was complete at pH 8.5 and hydroxo species formed between 
pH 8.5 and pH 11.0. 
 
 
Figure 3.36: QM-bar as a function of pH for the Ni(II)/SAR-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution graph for Ni(II)/SAR-GLY is given in Figure 3.37.  There was no chemical 
change from pH 2 to pH 5.1.   The base of ML distribution is 5.1 pH units long (from pH 5.1 
































       3.4.2.4.3     SAR-GLY / Zn(II) 
ZM-bar for Zn(II)/SAR-GLY is given in Figure 3.38. 
 
 
Figure 3.38: ZM-bar as a function of pL for the Zn(II)/SAR-GLY titrations 
 
ML species formed between Zn(II) and SAR-GLY are very unstable since log KML is very 
small (log KML = 2.08).   Only two species formed in this titration, ML and MLH-1.   The 
most predominant species is MLH-1 (log K = 7.53).   There is no published data on this 










































Table 3.16: Calculated equilibrium constants for Zn(II)/SAR-GLY complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 









SAR-GLY loses one proton upon complexation with Zn(II) (Figure 3.39).   QM-bar rises from 
pH 7.0 and levels off between pH 8.8 and pH 11.0.   There is a small depression between pH 
9.3 and pH 9.9.    This shows that ML forms between pH 7.0 and pH 9.3.    The depression is 
due to the formation of hydroxo (MLH-1) species. 
 
 
Figure 3.39: QM-bar as a function of pH for the Zn(II)/SAR-GLY titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution graph for Zn(II)/SAR-GLY is given in Figure 3.40.   A very small amount of 



























Figure 3.40: Speciation for complex formation titrations of Zn(II)/SAR-GLY, 1:2 ratio.   [SAR-GLY] = 0.004564 M. 
 
       3.4.2.5     Glycyl-L-leucine complexes 
       3.4.2.5.1     GLY-LEU / Cu(II) 
ZM-bar for Cu(II)/GLY-LEU t is given in Figure 3.41. 
 
 
Figure 3.41: ZM-bar as a function of pL for the Cu(II)/GLY-LEU titrations 
 
Log K’s for complexes formed between Cu(II) and GLY-LEU are given in Table 4.17.   














































Table 3.17: Calculated equilibrium constants for Cu(II)/GLY-LEU complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 1 -1 
1 1 -2 
1 2 -1 























QM-bar is given in Figure 3.42.   Complexation starts at very low pH’s (from pH 2.6) for 
Cu(II)/GLY-LEU titrations.   Complexation was complete between pH 7.0 and pH 9.4 where 




Figure 3.42: QM-bar as a function of pH for the Cu(II)/GLY-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The speciation for Cu(II)/GLY-LEU titrations is given in Figure 3.43.   Mixed species were 
observed at all pH’s except at pH’s below 2.6 where there was about 100 % Cu(II) in 


































       3.4.2.5.2     GLY-LEU / Ni(II) 




Figure 3.44: ZM-bar as a function of pL for the Ni(II)/GLY-LEU titrations 
 
Equilibrium constants for Ni(II)/GLY-LEU titrations are given in Table 3.18.   These agree 
with the literature [17].   Log KML (Cu(II)/GLY-LEU) is 1.61 log larger than log KML 
(Ni(II)/GLY-LEU).   ML species of Cu(II) and GLY-LEU are therefore more stable than ML 











































Table 3.18: Calculated equilibrium constants for Ni(II)/GLY-LEU complexes 
p q  r Log β σ p q r RH RHlim nT(nP) LogKexp Log Klit[17] 
1 1  0 
1 2  0 
1 3  0 




















One proton is lost when GLY-LEU forms complexes with Ni(II) (Figure 4.5).   Complexation 
stopped bewteen pH 7.4 and pH 9.1 where hydroxo species began to form. 
 
 
Figure 3.45: QM-bar as a function of pH for the Zn(II)/GLY-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution curve for this titration is given in Figure 3.46.   ML2H-1 species is the most 
predominant species in solution; however this forms at high pH’s (from pH 7.8).   ML3 is the 


































       3.4.2.5.3     GLY-LEU / Zn(II) 




Figure 3.47: ZM-bar as a function of pL for the Zn(II)/GLY-LEU titrations 
 
Four species were observed for this titration and the equilibrium constants are given in Table 
3.19.   These agree with the literature [17].   Log KML (Zn(II)/GLY-LEU) < Log KML 
(Ni(II)/GLY-LEU) < Log KML (Cu(II)/GLY-LEU).   GLY-LEU is therefore more selective of 












































Table 3.19: Calculated equilibrium constants for Zn(II)/GLY-LEU complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 1 -1 




















QM-bar for Cu(II)/GLY-LEU titrations is given in Figure 4.48.   Complexation begins at pH 
4.7 and stops between pH 7.7 and pH 8.2.   Hydroxo species form from pH 8.2.   GLY-LEU 




Figure 3.48: QM-bar as a function of pH for the Zn(II)/GLY-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution curve for Zn(II)/GLY-LEU is given in Figure 3.49.   From pH 2.0 to pH 6.2 
zinc mostly exists as free ions.   From pH 6.5 to pH 7.7, zinc exists as ML.   Between pH 7.9 
and pH 8.5 zinc mostly exists in its ML2 form and from pH 8.6 to pH 11.0, zinc exists mostly 






























Figure 3.49: Speciation for complex formation titrations of Zn(II)/GLY-LEU, 1:2 ratio.   [GLY-LEU] = 0.008003 M. 
 
 
       3.4.2.6     Sarcosyl-L-leucine complexes 
       3.4.2.6.1     SAR-LEU / Cu(II) 
ZM-bar for Cu(II)/SAR-LEU titrations is shown in Figure 3.50.   The graph flags back at low 




Figure 3.50: ZM-bar as a function of pL for the Cu(II)/SAR-LEU titrations 
Stability constants for complexes formed between Cu(II) and SAR-LEU are given in Table 
3.20.   Log KML is 1.00 log units larger than the literature [15].   The difference in these 
values is due to the fact that Datta and co-workers [15] used zero ionic strength and 0.15 M 











































Table 3.20: Calculated equilibrium constants for Cu(II)/SAR-LEU complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 1 -1 




















QM-bar for this titration is given in Figure 4.51.   SAR-LEU loses one protons upon 
complexation with Cu(II).   From pH 8.1 to pH 9.2 QM-bar runs parallel n-bar therefore 
complexation was complete at this pH range.   QM-bar rises from pH 9.2 indicating the 




Figure 3.51: QM-bar as a function of pH for the Cu(II)/SAR-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution curve for Cu(II)/SAR-LEU titrations is given in Figure 3.52.   Complexation 
































       3.4.2.6.2     SAR-LEU / Ni(II) 




Figure 3.53: ZM-bar as a function of pL for the Ni(II)/SAR-LEU titrations 
 
Stability constants for Ni(II)/SAR-LEU are given in Table 3.21.   There is no published data 
on this titration however the standard deviations are small and RH is less than RHlim.   The 













































Table 3.21: Calculated equilibrium constants for Ni(II)/SAR-LEU complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 2  0 
1 1 -1 

















QM-bar is given in Figure 3.54.   Complexation begins at pH 5.8 and stops between pH 8.1 














Figure 3.54: QM-bar as a function of pH for the Ni(II)/SAR-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The speciation graph for this titration is given in Figure 3.55.    From pH 2.0 to pH 7.8 the 


























Figure 3.55: Speciation for complex formation titrations of Ni(II)/SAR-LEU, 1:2 ratio.   [SAR-LEU] = 0.004306 M. 
 
 
       3.4.2.6.3     SAR-LEU / Zn(II) 




Figure 3.56: ZM-bar as a function of pL for the Zn(II)/SAR-LEU titrations 
 
Equilibrium constants for complexes formed between Zn(II) and SAR-LEU are given in 














































Table 3.22: Calculated equilibrium constants for Zn(II)/SAR-LEU complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 1 -1 













QM-bar (Figure 3.57) rises at pH 5.8 and levels off at QM-bar = 1.7 between pH 8.6 and pH 
9.8.   It does not drop before it rises again.    This indicates that SAR-LEU loses two protons 




Figure 3.57: QM-bar as a function of pH for the Zn(II)/SAR-LEU titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
Speciation graph for Zn(II)/SAR-LEU titrations is given in Figure 3.58.   ML is mostly 
predominant in solution between pH 6.7 and pH 7.4.   MLH-1 is mostly predominant in 



























Figure 3.58: Speciation for complex formation titrations of Zn(II)/SAR-LEU, 1:2 ratio.   [SAR-LEU] = 0.004191 M. 
 
 
       3.4.2.7     Glycyl-L-phenylalanine complexes 
       3.4.2.7.1     GLY-PHE / Cu(II) 




Figure 3.59: ZM-bar as a function of pL for the Cu(II)/GLY-PHE titrations 
 
Equilibrium constants for these titrations are given in Table 3.23.   Only four species were 
observed (ML, ML2, MLH-1 and MLH-2).   The equilibrium constants for these species are 
comparable with the literature [16, 17, 19], except for ML2 which was not observed in the 











































Table 3.23: Calculated equilibrium constants for Cu(II)/GLY-PHE complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit[17] 
1 1  0 
1 2  0 
1 1 -1 
1 1 -2 
1 2 -1 
1 2 -2 
































Two protons were lost upon complexation of GLY-PHE with Cu(II) (Figure 3.60).   
Complexation was complete between pH 7.1 and pH 8.6.   Hydroxo formed from pH 8.6. 
 
 
Figure 3.60: QM-bar as a function of pH for the Cu(II)/GLY-PHE titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The speciation graph for Cu(II)/GLY-PHE is given in Figure 3.61.   Complexation begins at 
pH 2.2 and ML species exist for quite a wide range (from H 2.2 to pH 11.0).   ML is most 
predominant in solution between pH’s 4.7 and 6.1.   ML2 is most predominant in solution 
from pH 6.5 to pH 8.8.   MLH-1 is mostly predominant in solution between pH’s 9.1 and 10.5.   




























Figure 3.61: Speciation for complex formation titrations of Cu(II)/GLY-PHE, 1:2 ratio.   [GLY-PHE] = 0.004542 M. 
 
       3.4.2.7.2     GLY-PHE / Ni(II) 
ZM-bar for Ni(II)/GLY-PHE titrations is given in Figure 3.62.    
 
 
Figure 3.62: ZM-bar as a function of pL for the Ni(II)/GLY-PHE titrations 
 
Species formed between Ni(II) and GLY-PHE and their stability constants are given in Table 















































Table 3.24: Calculated equilibrium constants for Ni(II)/GLY-PHE complexes 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp Log Klit 
1 1  0 
1 2  0 
1 3  0 
1 1 -1 
1 1 -2 






























QM-bar is given in Figure 3.63.   QM-bar rises from pH 5.4, levels off at QM-bar = 0.6 
(between pH 7.2 and pH 8.0).   This indicates that GLY-PHE lost one proton upon 
complexation with Ni(II).   QM-bar drops from pH 8.0 to pH 8.4, and rises again at pH 8.4 




Figure 3.63: QM-bar as a function of pH for the Ni(II)/GLY-PHE titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution graph (Figure 3.64) shows that there was free Ni(II) in solution from pH 2.0 
to pH 10.3.   ML species exist between pH 5.4 and pH 10.3, MLH-1 occurs between pH 7.2 





























Figure 3.64: Speciation for complex formation titrations of Ni(II)/GLY-PHE, 1:2 ratio.   [GLY-PHE] = 0.004529 M. 
 
 
       3.4.2.7.3     GLY-PHE / Zn(II) 





Figure 3.65: ZM-bar as a function of pL for the Zn(II)/GLY-PHE titrations 
 
 
Zn(II) and GLY-PHE form three species in solution (ML, MLH-1 and MLH-2).   Equilibrium 












































Table 3.25: Calculated equilibrium constants for Zn(II)/GLY-PHE complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 1 -1 












QM-bar for this titration is given in Figure 3.66.   QM-bar rises at pH 6.2 and levels off 
between pH 8.1 and pH 8.6.   The graph does not drop, it rises instead.   This shows that ML 
and MLH-1 begin form around the same pH. 
 
 
Figure 3.66: QM-bar as a function of pH for the Zn(II)/GLY-PHE titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 















































       3.4.2.8     Sarcosyl-L-phenylalanine complexes 
       3.4.2.8.1     SAR-PHE / Cu(II) 




Figure 3.68: ZM-bar as a function of pL for the Cu(II)/SAR-PHE titrations 
 
 
There are three species formed between Cu(II) and SAR-PHE.   The species and their 
equilibrium constants are given in Table 3.26.   There is no published data on these titrations 
to compare with, however the errors a small and RH is less than RHlim.   This gives confidence 
in the model. 
 
 
Table 3.26: Calculated equilibrium constants for Cu(II)/SAR-PHE complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 1 -1 







































Figure 3.69: QM-bar as a function of pH for the Cu(II)/SAR-PHE titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 
The distribution curve for this titration is given in Figure 3.70.   ML occurs between pH 2.5 
and pH 7.4.   MLH-1 occurs between pH 4.0 and pH 11.0.   MLH-2 occurs from pH 7.8. 
 
 
       


















































       3.4.2.8.2     SAR-PHE / Ni(II)  





Figure 3.71: ZM-bar as a function of pL for the Ni(II)/SAR-PHE titrations 
 
 
Equilibrium constants for Ni(II)/SAR-PHE are given in Table 3.27.   Four species were 
observed; ML, ML2, MLH-1 and MLH-2 (KML = 4.12, KML2 = 2.46, KMLH-1 = 8.97 and KMLH-2 
= 10.2). 
Table 3.27: Calculated equilibrium constants for Ni(II)/SAR-PHE complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 2  0 
1 1 -1 















SAR-PHE loses one proton upon complexation with Ni(II) (Figure 3.72).   Compleation 


























Figure 3.72: QM-bar as a function of pH for the Ni(II)/SAR-PHE titrations.   Pink curve is n-bar, blue curve is 
experimental Q-bar and the solid line is the theoretical plot. 
 




Figure 3.73: Speciation for complex formation titrations of Ni(II)/SAR-PHE, 1:2 ratio.   [SAR-PHE] = 0.004287 M. 
 
 
       3.4.2.8.3     SAR-PHE / Zn(II) 















































Figure 3.74: ZM-bar as a function of pL for the Zn(II)/SAR-PHE titrations 
 
Stability constants for species formed between Zn(II) and SAR-PHE are given in Table 3.28.   
Three species formed in solution.   ML for Zn(II) is less stable than ML for Ni(II) and Cu(II) 
of the same ligand. 
Table 3.28: Calculated equilibrium constants for Zn(II)/SAR-PHE complexes 
 
p q  r Log β σ p q r RH RHlim nT(nP) Log Kexp 
1 1  0 
1 1 -1 












QM-bar is shown in Figure 3.75.   SAR-PHE has two dissociable protons and it losses both 
protons upon complexation with Zn(II).   ML and MLH-1 for start forming around the same 













         
 
Figure 3.75: QM-bar as a function of pH for the Zn(II)/SAR-PHE titrations.   Pink curve is n-bar, blue curve is 









































Figure 3.76: Speciation for complex formation titrations of Zn(II)/SAR-PHE, 1:2 ratio.   [SAR-PHE] = 0.004513 M. 
 
 
3.5    DISCUSSIONS 
A summary table for the protonation constants is given in Table 3.29.   The presence of the 
methyl group could have an inductive and steric effect.   Comparing the amine protonation 
(log KLH; GLY = 9.53; SAR = 10.0) it was bserved that indeed the methyl group does have 
an inductive effect making the SAR amine 0.47 log units more basic.   A similar effect is seen 
with the dipeptides, thus SAR-GLY is 0.27 log units more basic than GLY-GLY; SAR-LEU 
is 0.49 more basic than GLY-LEU; and SAR-PHE is 0.28 log units more basic than GLY-
PHE. 
 
The N-methyl substituent increases log KLH by 0.47 log units and it decreases log KLH2 by 
0.18 log units (pKa1 SAR minus pKa1 GLY; and pKa2 SAR minus pKa2 GLY).   The peptide 
bond decreases log KLH by 1.37 log units for GLY-GLY and decreased by 1.33 log units for 
GLY-LEU and GLY-PHE.   The peptide bond therefore decreases log KLH in glycine 
peptides by 1.37 log units, and the 2-methyl propyl of GLY-LEU and the methyl benzyl 
substituents increases log KLH by 0.04 log units.    Similarly, log KLH2 increased (from 2.29) 
by 0.84 (GLY-GLY), 0.85 (GLY-LEU) and 0.62 (GLY-PHE).   The peptide bond increases 
log KLH2 by 0.84 log units, the 2-methyl propyl on the α-carbon of the C-terminal decreases 
log KLH2 by 0.01 and the benzyl methyl increases log KLH by 0.22 log units.    In sarcosine 






























log KLH2 by 0.06 and the benzyl methyl increases log KLH2 by 0.15 log units.   The peptide 
bond increases log KLH2 by 0.84 log units; 2-methyl propyl decreases log KLH2 by 0.53 log 
units and the benzyl methyl increases log KLH by 0.48 log units.   The effect of the second 
amino acid on the log values is not the same in sarcosine peptides as in glycine peptides due 
to the inductive effect possessed by the methyl substituent. 
 
Table 3.29: A summary table for protonation constants 
Ligand p q  r Log Kexp 
GLY 0 1 1 0 1 2 
9.53 
2.29 
SAR 0 1 1 0 1 2 
10.0 
2.11 
GLY-GLY 0 1 1 0 1 2 
8.16 
3.18 
SAR-GLY 0 1 1 0 1 2 
8.43 
2.95 
GLY-LEU 0 1 1 0 1 2 
8.20 
3.14 
SAR-LEU 0 1 1 0 1 2 
8.69 
3.48 
GLY-PHE 0 1 1 0 1 2 
8.20 
2.91 




SAR and GLY differ only by a methyl substituent on the amine, thus their metal complexes 
are likely to be very similar.   The inductive effect of the methyl group is expected to increase 
the stability of the SAR complex.   In fact the Cu-GLY complexes are slightly more stable 
than the Cu-SAR complex (0.16 log units) which means that the methyl group must have 
some steric effect as well.   It may be possible to clarify this point using enthalpy and entropy 
measurements (see Chapter 4). 
 
Since a major fraction of copper in plasma is bound to serum albumin it is important to study 
the effect peptide formation has on the stability of amino acid complexes.   To this end a 
series of dipeptides were studied.   With dipeptides, in addition to the two terminal groups, 
there is also the possibility of coordination to the central amide, either through the carbonyl 
group or the deprotonated amide nitrogen.   A summary table for the equilibrium constants of 













Table 3.30: A summary table of equilibrium constants  
Ligand p q  r Log Kexp 




1 1  0 
1 2  0 
1 1  1 






1 1  0 
1 2  0 
1 1 -1 






1 1  0 
1 2  0 
1 2 -1 






1 1  0 
1 1 -1 
1 2 -1 






1 1  0 
1 2  0 
1 1 -1 






1 1 0 
1 2  0 
1 2 -1 






1 1  0 
1 1 -1 





Although thermodynamics does not give information about species structure it is possible to 
infer something about the structure of the different species formed by comparing results from 
different ligands.   The crystal structure of Cu-GLY shows that the metal ion is coordinated to 
both the amine and carboxyl group [33, 35].   While solution and solid state structures are not 
always the same it is generally accepted that this is the mode of coordination of GLY.  Log 
KML (GLY) is 1.44 log units less than log KLH (GLY).   Previous studies [35] show that 
Cu(II) coordinates to the amine N and the carboxylate O when the ML forms.   From this 
information the structure of the ML species that form between Cu(II) and the ligands can be 
predicted.   Log KML (GLY-GLY) is 1.83 log units less than log KLH (GLY-GLY); log KML 
(GLY-LEU) is 2.41 log units less than log KLH (GLY); and log KML (GLY-PHE) is 1.83 units 












0.39 log units more less than log KLH (GLY).   It is possible than Cu(II) could be coordinating 
on the same sites as Cu-GLY.   Cu(II) could be coordinating to the Carbonyl O and the 
carboxylate O when ML-GLY-LEU forms.   A small decrease in log KLH (GLY-LEU) may 
mean that the amine terminal is still protonated. 
 
Similarly, log KLH(SAR) decreased by 2.11 log units when ML forms, log KLH(SAR-GLY) 
decreased by 2.28 log units, log KLH(SAR-LEU) decreased by 2.37 long units and log 
KLH(SAR-PHE) decreased by 1.94.   ML(SAR), ML(SAR-GLY), ML(SAR-LEU) and 
ML(SAR-PHE) all have the same structure.   Cu(II) binds to the amine N and the carboxylate 
O when this species forms. 
 
All ligands are more selective for Cu(II) than they are for Ni(II) and Zn(II).   All ligands are 
more selective for Ni(II) than they are for Zn(II).   This trend obeys Irving-Williams stability 
series [30]. 
 
3.6    CONCLUSIONS 
The aim of this study was to develop lipophilic copper complexes, which could possibly be 
used to increase the in vivo bioavailable pool of copper.  The idea is that methyl group on the 
amine terminal may would increase the lipophilicity of the ligands without compromising the 
stability of Cu(II) complexes.   The results shown here confirm that the complexation of SAR 
dipeptides and GLY dipeptides are comparable and so the metal complex stability has not 
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4.   ISOTHERMAL TITRATION CALORIMETRY 
4.1   INTRODUCTION 
Isothermal titration calorimetry (ITC) is used to determine the thermodynamic properties of 
substances in solution [6].   A typical isothermal titration calorimeter has a reference cell and 
a sample cell [1, 6, 7].   The sample cell is filled with the analyte solution and the reference 
cell is filled with solvent, water if the analyte is in water or a buffer solution if the analyte is 
in a buffer solution or a mixture of solvents if the analyte is in a mixture of solvents [1, 6, 7].   
The titrations are run at a fixed temperature and the amount of heat transfer between the 
sample cell and the surroundings upon injection of titrant solutions into the sample cell is 
monitored by temperature sensors [6, 7].   The same volume should be used from the 
beginning of the titration to the end.   The signals are reported as heat units per mole of 
injection [1], therefore the amount of heat evolved/absorbed depends on the concentration of 
the titrant and as well as the volume of the titrant: a 2 µm injection gives twice the heat per 
injection as the heat produced by 1 µm of the same concentration. 
 
The sensors of the calorimeter measure the amount of power used to maintain the temperature 
between the reference cell and the sample cell after every injection.   The power is measured 
in µcal.sec-1.   This power has to be within the dynamic range of 0-12.25 µcal.sec-1.   If the 
power used to maintain the temperature of the sample cell the same as that of the reference 
cell does not fall within this range, the sensors overreact and give incorrect results.  The 
amount to power depends mostly on the concentrations of the titrant solutions and injection 
volume.   Since the heats measured between injections are given in heat units per mol of 
injection, it is wise to use dilute titrant solutions.   It is also wise to control the injection 
volumes.    
 
Using the mass balance equations, ITC data is then reported in heat units per mol of injection 
as a function of molar ratio of the amount of the titrant to the amount of analyte [6, 7].   
Thermodynamic parameters can then be generated from this data by model fitting.   These 
parameters are basically N the equivalence point, K the binding constant, ΔH the enthalpy 
change and ΔS the entropy change.   There are different programs used to fit the ITC data, the 
most common one being Origin (by OriginLab).   This program has five fitting modes;  













ii. Two set of sets of sites model, 
iii. Sequential binding model, 
iv. Competitive binding model, and 
v. Dissociation fitting mode. 
All five model fitting modes have been described fully in the user manual [1]. 
 
To make sure that the results are accurate, prior to fitting data the background heats of 
dilution for both the analyte and the titrant solutions have to be determined [6].   The easiest 
way is by running control experiments for both the analyte and the titrant.   A control 
experiment for the analyte is done by injecting a solvent (water if the analyte is in water, a 
buffer solution if the analyte is in a buffer solution or a mixture of solvents if the analyte is in 
a mixture of solvents) into the analyte solution and measure the heat transfer between the 
sample cell and the reference cell.   It is possible to get non-zero background heats if the 
analyte hydrolyses in solution, there is heat accompanying that process, and if the analyte 
forms aggregates, or foam.   There is heat accompanying all those processes.   If the 
backgrounds heats are non-zero heats then the ITC data have to be corrected by subtracting 
data obtained from the control [1, 6, 13, 14]. 
 
A control experiment for the titrant is done by injecting the titrant into a sample cell filled 
with the solvent.   In this control experiment, the sample cell and the reference cell are filled 
with the same substance.   There should not be any heat transfer between the sample cell and 
the reference cell if the titrate does not hydrolyse, or form aggregates, or forms lather.   If 
non-zero heats are obtained in this control the control data has to be corrected from the actual 
titration [1, 6, 14].   Once data has been corrected then all four thermodynamic parameters 
(N, K, ΔH and ΔH) can be calculated from a single titration. 
 
Kasimova [18] has discussed how to diagnose errors on ITC data.   Some of the things they 
discussed are the drifting baseline, overlapping power signals, oscillating signals, square 
signals and unevenly distributed data points.   It is important that cells and the syringe are 
clean and that the ionic strength of analyte and that of the titrant should match to avoid the 
baseline from drifting.   The titrant solutions should also be at the same temperature as the 
analyte solution.   If the titrant is at lower (or higher) temperatures than the analyte, upon 













temperature.   This will cause the baseline to drift and the results will be affected [18].   To 
avoid the power signals from overlapping, enough retention time should be set to allow all 
the analyte that has been injected into the sample cell to react [1, 7, 18].   Enough reference 
power should be set to avoid the power signals from oscillating [1, 8].   If square power 
signals are observed, then the titrant solutions are too concentrated and have to be diluted, 
and if the data points are not evenly distributed then the injection volume may not be properly 
edited.   The same injection volume should be used throughout the titration; if 1.0 µL are 
used, 1.0 µL should be used from the first point of the titration to the last point of the titration 
[18]. 
 
4.2   THEORY 
The sample cell of the ITC instrument has a fixed volume V0.   This cell is shaped like a 
lollipop.   When an analyte solution of concentration M0t is titrated with a ligand of 
concentration X0t and the injection volume of the ligand is ΔVi per injection, some of the 
solution in the sample cell will be pushed out of the cell into the overflow tubing.   The total 
volume of the solution that has been pushed into the dead volume at nth titration point is ΔV.   
Since some of the analyte will be pushed into the dead volume, its concentration in the 
sample cell will not be the same from titration point to titration point. 
 
If the concentration of the analyte at the nth titration point is Mt, mass balance equation 
requires that;  
            
 
 
       
 
       
(4.0) 
The concentration of the analyte solution at the nth titration point Mt can be calculated by re-
arranging Equation 4.0; 
     
 
  
          
          
 
(4.1) 
The total amount of the titrant after the nth titration point differs from titration point to 
titration point.   If the total concentration of the titrant in the sample cell after the nth titration 














             
 
 
     
(4.3) 
 
Re-arranging Equation 4.3 gives; 
     
 
  (  
  
   
) 
(4.4) 
Origin calculate Mt and Xt from titration point to titration point, and measures the amount of 
heat transfer between the sample cell and the reference cell from point to point.   Origin 
calculates four thermodynamic parameters from a single titration by model fitting.   These 
parameters are n the number of binding sites, K the binding constant, ΔH the enthalpy change 
and ΔS the entropy change. 
 
The value of n depends mostly on the shape of the titration curve.   A single S-curve is 
observed for substances that have one biding site.   However, a single S-curve can be 
observed for a substance that has identical multiple sites.   The model used to fit the data 
depends on the type of distribution curve obtained during the titration.   Origin provides with 
five model fitting modes.   Only three of these modes were used in this study.   These being; 
i. One set of sites fitting mode, 
ii. Two set sites model, and 
iii. Competitive binding mode. 
For a single set of identical sites, the binding constant K can be expressed as; 
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) 
(4.5) 
Where [X] is the concentration of the free titrant solution and Θ is the fraction of sites 
occupied by the titrant X. 
 
The concentration of the titrant solution Xt at the nth titration point can be expressed in terms 
of [X] the concentration of the free titrant, Θ the fraction of sites occupied by titrant X, the 
number of binding sites n, and Mt the concentration of the analyte at the nth titration point as; 














Adding Equations 4.5 and 4.6 yields; 
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(4.7) 
Q total heat per in the sample cell of volume V0 at fractional saturation Θ is expressed as; 
 
           
(4.8) 
 
Where ΔH is the heat in heat unit per mole of injection of the titrant.   Substituting Θ in 
equation 4.8 with Equation 4.7 yields; 
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Calculations for Q are done at any point of the titration for any value of n, K and ΔH.   The 
parameter of interest however is the change in heat (ΔQ) between injections.   Since after 
every injection some of the sample cell contents are being pushed into the dead volume and 
the amount that goes into the dead volume outflows with some heat quantity, about 50 % of 
the heat is lost when the solution is pushed into the dead volume and about 50 % of the heat 
remains in the sample cell.   Origin takes into account the amount of heat lost and the change 
in heat between injections (Qi) at the nth titration point can be expressed as; 
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]       
(4.10) 
 
When the titration is done, the output is the concentration of the analyte at every titration 
point, the concentration of the titrant at every titration point, the volume of the titrant injected 
at every titration point, the ratio of the concentrations of titrant/concentrations of the analyte 













all four thermodynamic parameters (n, K, ΔH and ΔS) are optimised by Levenberg-
Marquandt methods for nonlinear least squares [19, 20]. 
 
For a two sets of sites model, the first binding constant K1 can be expressed as; 
    (
   
          
) 
(4.11) 
The second binding constant can be expressed as;  
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) 
(4.12) 
And the concentration of the titrant at the nth titration point (Xt) can be expressed as;  
                         
(4.13) 
The definition of terms is the same for all fitting models.   Solving for Θ1 and Θ2 in Equations 
4.11 and 4.12 and substituting them in Equation 4.12 yields; 
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(4.15) 
Equation 4.14 can be expressed in terms of p, q and r; 
 
















Q can therefore be expressed as; 
 
                            
(4.17) 
 
Corrections for displaced heat can be expressed as; 
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]       
(4.18) 
The thermodynamic parameters n1, n2, K1, K2, ΔH1, ΔH2, ΔS1, ΔS2 can then be optimised by 
Levenberg-Marquandt methods for nonlinear least squares [19, 20]. 
 
Complex formation titrations are mostly competitive.   For two ligands A and B that compete 
for the third molecule P by; 
 
           ΔHA 
P + A   PA 
KA can be expressed as; 
     
    
      
 
(4.19) 
And for the reaction; 
           ΔHA 
P + B   PB 
KB can be expressed as; 
     
    
      
 
(4.20) 
Where [A] is the concentration of the compound A, [B] is the concentration of the compound 















Sigurskjold [21] has described fully how the concentrations of each compound (A, B, P, PA, 
PB) can be calculated from titration point to titration point.   From Sigurskjold’s work [21] 
the corrected heat can be expressed as;1 
 
                          
(4.21) 
4.3   EXPERIMENTAL 
 
   4.3.1    Sample preparation and calorimetric measurements  
 
NaCl granules, NaOH and HCl ampoules were purchased from Merck.    They were of 
analytical grade and were used without further purification.   GLY, GLY-GLY, GLY-LEU, 
GLY-PHE, GLY-HIS and SAR were purchased from SIGMA-ALDRICH.    SAR-GLY, 
SAR-LEU, SAR-PHE and SAR-HIS were purchased from GL Biochem (Shanghai).   
Microcal iTC200 calorimeter was used to measure the heats evolved/absorbed.   The titration 
parameters were set as described in the iTC200 and Origin 7 user manual [1, 7]: the jacket 
temperature was set to 250C for all titrations, the cell temperature was also set to 250C, the 
number of injections ranged between 18 to 76 injections, the reference was set between 9 
µcal.mol-1 and 12 µcal.mol-1, the initial delay ranged between 60 sec and 120 sec, the cell 
concentration ranged between 0.3 mM to 1 mM and the syringe concentration ranged 
between 5 mM and 10 mM, the stirring speed was set to 1000 RPM for all titrations. 
 
Solutions of different concentrations of HCl were prepared and standardised as described  
[14-16].   For acid/base titrations, 0.5 mM NaOH solutions were prepared.   All solutions 
were prepared in degassed/deionised water and were of 0.15 M ionic strength with NaCl.   
The reference cell was rinsed and filled with 0.15 M NaCl solution.    The sample cell was 
rinsed and filled with 0.5 mM NaOH solution.   The syringe was rinsed and filled with known 
concentrations of HCl.   The syringe was purged twice to remove any air bubbles that could 
have been trapped into the solutions.   The tip of the pipette was inserted into the sample cell 
and the titration was started.   A control experiment was also run to measure background 
heats of dilution of NaOH. 
 
                                                          
1














For ligand protonation titrations, 1 mM ligand solutions were prepared in dilute NaOH.   The 
pH of the ligand solutions was adjusted such that it is very close to the pH that gives the first 
protonation/deprotonation constant.   This was to avoid having excess OH- in solution.    All 
solutions were prepared in degassed/deionised water and were of 0.15 M ionic strength with 
NaCl.   The reference cell was rinsed and filled with 0.15 M NaCl solution.   The sample cell 
was rinsed and filled with the ligand solutions.   The syringe was rinsed and filled with 
known concentrations of HCl.   The syringe was purged twice to remove trapped air bubbles.   
The tip of the pipette was inserted into the sample cell and the titration was started.  A control 
experiment was also run to measure heats of dilution of the ligand solutions. 
 
For complex-formation titrations, 1:1 and 1:2 metal/ ligand solutions were prepared in 
degassed/deionised water.   All solutions were of 0.15 M ionic strength with NaCl.   The 
analyte solutions for complex formation titrations were adjusted to pH’s below pH 7 with 
NaOH/NaCl.   The sample cell was filled with metal/ligand solutions of known proportions 
and titrated against HCl.   A control experiment for complex-formation titrations was also run 
to measure heats of dilution of the metal/ligand solutions. 
 
   4.3.2    Data handling 
 
Data were analysed with Origin 7.   Origin has five model fitting modes.   The fitting mode 
that best describes the titration data was used.   Data for the acid/base titrations was fit with 
one set of site model.   One proton goes on OH- to form water; 
OH-(aq) + H+(aq)   H2O (l) 
 
Data for ligand protonation titrations were fitted to a two site model.   All ligands have two 
dissociable protons except for GLY-HIS that has three; 
   L + H   LH 
 LH + H   LH2 
LH2 + H   LH3 
For complex formation titration, known ratios of metal/ligand were set to pH’s below pH 7 
and titrated with acid until metal/ligand solutions were completely saturated with acid.  
Control experiments were done for all protonation titrations and all complex formation to 













4.4   RESULTS 
               4.4.1 Method validation 
Water/water titrations and acid/base titrations were done to test whether the method is 
reliable or not.   Water/water titrations were done basically to test the stability of the 
instrument.   The sample cell was filled with distilled/deionised water, and the syringe was 
filled with distilled/deionised water.   The titration parameters were set and the titration was 
started.   As water in the syringe was being injected into the sample cell, power was 
measured.   This power is the power that was used to maintain the temperature between the 
sample cell contents and the reference cell constant, T = 25 0C.   Since the sample cell and the 
reference were both filled with distilled/deionised water, very little power was expected to 
maintain the temperature constant.     
 
Acid/base titrations were done for two reasons.   It is a well known system so it was used to 
test the reliability of the method and that of the operator.   It was also used as a reference 
most importantly as a caution whenever there is excess OH- since the titrations were started 
from high pH’s to low pH’s. 
 
       4.4.1.1     Water/water titrations 
 
Figure 4.1: Isotherm for water titrated against water 
 
Figure 4.1 shows an isotherm obtained when water was titrated against water at 25 0C at zero 
ionic strength.  The upper panel shows the raw power signals in µcal.sec-1 plotted against 







































time in minutes.   No signals were observed.   This shows that the instrument is very stable.   
The lower panel shows the integrated heats.   The black markers are the experimental points 
and the solid line is the optimal fit.   The data were fit with a one set of site model.   The heats 
ranged between -0.2 and 0.2 kcal.mol-1.   These heats are very small indicating the instrument 
is very stable.    
 
 
       4.4.1.2     Acid/base titrations 
 
Figures 4.2A-D show the isotherms for different [H+]/[OH-] titrations at 25 0C and 0.15 M 
ionic strength.   The black signals are the power signals in µcal.sec-1 and the red solid lines 
are baselines.   When a more concentrated acid solution was used, the power signals were 
bigger.   The height of the power signals depends on the injection volumes and the 
concentration of the titrant.   Injection volume = 1 µL per injection for all four titrations 
therefore the concentrations of the titrant are the ones that control the height of the power 
signals in this section.   Power signals in Figure 4.2 D ([H+] = 20 mM) were the longest 
followed by power signal in Figure 4.2B ([H+] = 10 mM).   The height of the power signals 
when 5 mM H+ was used are more or less the same height, see Figure 4.2B and Figure 4.2C. 
 
Figure 4.2 E shows integrated heats as a function of molar ratio [H+]/[OH-].   The one site  
model was used to fit the data.   Integrated heats for 0.5 mM NaOH vs 10 mM HCl; 0.5 mM 
NaOH vs 5 mM HCl and 0.25 mM NaOH vs 5 mM HCl all have the same height.   The 
height of the integrated heats is equivalent to ΔH of the reaction.   The titration of 2 mM 
NaOH with 20 mM HCl however has a bigger height.   This is because Microcal200 has a 
dynamic range of 0-12.25 µcal.sec-1.   The heights of the power signals for the first three 
titrations were within 0-12.25   µcal.sec-1 range (Figures 4.2 A-C).   The data that was 
obtained when 2 mM NaOH was titrated with 20 mM HCl is was outside the range of the 
instrument.   Olive green markers in Figure 4.2 show the heats of dilution of NaOH.   These 


















Figure 4.2: Isotherms for acid/base titrations.   A: Raw isotherm for 0.5 mM NaOH vs 10 mM HCl;     B: Raw 
isotherm for 0.5 mM NaOH vs 5 mM HCl;        C: Raw isotherm for 0.25 mM NaOH vs 5 mM       D: Raw isotherm 
for 2 mM NaOH vs 20 mM    E: All four trials plus the control experiment 
 
Thermodynamic parameters ΔH and ΔS were calculated by fitting data using Origin 7.   
These are given in Table 4.1. 























































































0.5 mM NaOH vs 10 mM HCl
0.5 mM NaOH vs 5 mM HCl
0.25 mM NaOH vs 5 mM HCl


















Table 4.1: Thermodynamic parameters NaOH vs HCl titrations 












0.5 mM NaOH   vs 10 mM HCl 5.32 -12.6 (±0.2) -17.9 
0.5 mM NaOH   vs  5 mM HCl 6.06 -12.7 (±0.1) -18.2 
0.25 mM NaOH vs 5  mM HCl 5.37 -12.5 (±0.1) -16.5 
2 mM NaOH     vs  20 mM HCl 5.11 -22.9 (±0.2) -53.9 
 
 
The equilibrium constant, log K, is different for all four titrations.   All of them do not agree 
with the literature value of log K = 13.78 [2, 3, 4].  The equilibrium constants determined by 
ITC depend on the concentrations of the analyte [5, 6, 7].   Baranauskienė and co-workers [5] 
have described fully how the equilibrium constants for several titrations, including the 
acid/base titration determined by ITC differ from the literature values.   Log K obtained by 
ITC defines the curvature of the isotherms [7], with an isotherm with the steepest slope 
(Figure 4.2E, plot for 0.5 mM NaOH vs 5 mM HCl) being the one with the highest log K 
value (Table 4.1).    
 
ΔH for titrations 0.5 mM NaOH vs 10 mM HCl; 0.5 mM NaOH vs 5 mM HCl and 0.25 mM 
NaOH vs 5 mM HCl were reproducible.   The power signals for all three titrations fall within 
the range 0-12.25 µcal.sec-1, which is the range at which the instrument works.   When all 
three plots were fit with Origin, an average of -12.6 kcal.mol-1 was calculated.   This value 
agrees well with the literature value ΔH = -13.3 kcal.mol-1 [5, 8, 9, 10,].   ΔH for the titration 
2 mM NaOH vs 20 mM HCl does not agree with the other three because the solutions were 
too concentrated and the power signals for this titration were not within 0-12.25 µcal.sec-1 
and hence this titration has to be discarded. 
 
The ΔS for the first three titrations are given in Table 4.1.   They are reproducible but wrong 
because they are based on an incorrect logK as determined by the Origin software.   For this 
reason these ΔS should be discarded and calculated from the know log K values determined 
independently by potentiometry.   Gibbs’s free energy, ΔG, was calculated from;  
 














Where R is the universal gas constant (R = 8.314 J. K-1.mol-1), T is the temperature and K is 
the protonation constant determined with glass electrode potentiometry. ΔS was calculated 
from the Gibb’s free energy change ΔG, enthalpy change ΔH and temperature T.  
ΔG = ΔH   TΔS 
(4.23) 






ΔH was converted from kcal.mol-1 to kJ.mol-1.   ΔG and ΔS were calculated.   These are 
given in Table 4.2.  
 
Table 4.2: Calculated enthalpy changes and entropy changes for the formation of water 









LH 13.7 -78.2 -52.6 (±0.05) 85.6 (±20) -55.8 80.7 
 
ΔG is a large negative number therefore the reaction was spontaneous.   ΔH is a large 
negative number and ΔS is a large negative value therefore the reaction driven by both the 
enthalpy change and the entropy change.   ΔH and ΔS compare well with the literature values 
[5, 6] and the errors are relatively small which gives us confidence in the results. 
 
 
   4.4.2    Protonation titrations 
 
       4.4.2.1     Protonation of glycine 
 
Glycine was titrated with acid from pH 9.13 until the height of the power signals reached 
zero, the baseline (pH ≈ 2).   The results are shown in Figure 4.3.   Figure 4.3A is the raw 
isotherm.    The black signals are the power signals and the red solid line is the reference 
power.   The reference power was set to 10  µcal.sec-1 and it is very stable therefore the 
sample cell was clean and the ionic strength of the ligand solutions matched that of the acid 
solutions.    The power signals are below the baseline therefore the heats were exothermic.   
















Figure 4.3: Isotherms for acid/base titrations.   A: Raw isotherm for GLY Protonation B: Final isotherm for GLY 
protonation          C: Molar ratio per mol of injection for the protonation of GLY ([H+]/[L]) as a function of dH  
 
Figure 4.3B shows the final isotherm for glycine protonation.   Data were fit with a two site 
model.   The upper panel is the raw data (same as Figure 4.3A) except the baseline has been 
set to zero.   The lower panel is the integrated data.   The integrated data is the one that shows 
the actual heats evolved/absorbed.   The black markers are the experimental data points and 
the solid line is the optimal fit.   The isotherms are interpreted from left to right (small molar 
ratio to bigger molar ratio).   The molar ratio describes the degree of saturation of the cell 
contents with the syringe contents.   In this case the molar ratio = [H]/ [L].   The isotherm 
levels off at    -9.94 Kcal.mol-1 of injection from molar ratio 0 to 0.25.   In this range the 
reactants and the products were in thermal equilibrium;   L + H   LH 
 

























































The heat of formation of LH is therefore -9.94 kcal.mol-1.   The negative sign shows that the 
reaction was exothermic.   The isotherm rises from molar ratio 0.25 to molar ratio 0.36.   This 
indicates the formation of a new species.   From molar ratio 0.36 to molar ratio 0.39 the 
isotherm levels off at -2.4 Kcal.mol-1 of injection.   In this range LH2 was at thermal 
equilibrium with LH and H;   LH + H   LH2 
 
The heat accompanying this reaction was -2.35 kcal.mol-1.   The negative sign shows that the 
reaction was exothermic.   From molar ratio 0.39 the graph rises until it reaches zero (the 
baseline).   This indicates that LH2 had finished forming and the acid that was being injected 
into the sample cell at this stage was just diluting the cell contents.   To check if the results 
were reproducible, the same experiment was done twice.   The results were put on the one 
graph (Figure 4.3 C).   The solid line is the optimal fit of the two experimental plots.   The 
olive green markers represent the heats of dilution of glycine.   These were very small and 
thus negligible.   The heats of protonation were converted to kJ.mol-1.   The values are shown 
in Table 4.3. 
 
Table 4.3: Calculated enthalpy changes and entropy changes for protonation of glycine  

























ΔG for the protonation of the amine terminal is negative therefore the reaction was 
spontaneous.   The heat accompanying the formation of LH was calculated to be -41.6 
kcal.mol-1.   This value agrees well with the literature value [8, 11, 12].   ∆S for the formation 
of LH is a large positive value therefore the production of LH was favoured 
thermodynamically.   Formation of LH2 is also favored thermodynamically since ΔG is 
negative, ΔH is negative and ΔS is positive.   The heat accompanying the formation of LH2 is 


















       4.4.2.2     Protonation of sarcosine 
Sarcosine was titrated with acid from pH 9.28 until the height of the power signals reached 




Figure 4.4: A: Raw isotherm for SAR Protonation B: Final isotherm for SAR protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of SAR 
 
The heats of protonation were converted to   kJ.mol-1.   The values are shown in Table 4.4. 
 
Table 4.4: Calculated heats of protonation of sarcosine and the standard deviations 
























The heats accompanying the formation of LH were -28.9kJ.mol-1.   This value is significantly 
less than the literature value of -40.0 kJ.mol-1.   The results were reproducible and the 
























































standard deviations are small which leads to confidence in the results.   ΔG is a large negative 
value therefore the formation of LH was spontaneous.   Formation of LH was 
thermodynamically favoured since ΔS is a large positive value.   Formation of LH2 was also 
spontaneous.   Heats of formation of LH2 were slightly larger than the literature value [8].   
Protonation of sarcosine for both the acidic and the basic sites is driven by both entropy and 
enthalpy (Table 4.4). 
 
  
       4.4.2.3     Protonation of glycyl-glycine 
 
The results for GLY-GLY protonation titrations are given in Figure 4.5.   Two plateaus are 
observed for this titration.   The height of the first plateau is equivalent to the heat of 
protonation of the basic end of the ligand, ΔH1 = -10.6 kCal.mol-1.   The height of the second 
plateau is equivalent to the heat evolved when the acidic end of the ligand was being 
protonated, ΔH2 = -3.05 kCal.mol-1. 
 
To test the reproducibility of the results, the same titration was done twice.   The graphs are 
put together and shown in Figure 4.5C.   The solid line is the optimal fit.   The olive green 
markers are the heats of dilution.   The heats of dilution are very small and thus negligible.   
The two experimental data sets run on top of each other and the optimal fit runs on top of the 


















Figure 4.5: A: Raw isotherm for GLY-GLY Protonation B: Final isotherm for GLY-GLY protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of GLY-GLY 
 
The thermodynamic parameters for the protonation of GLY-GLY are shown in Table 4.5.   
ΔG and ΔS for the protonation of the carboxylate end of GLY-GLY do not compare well 
with the literature [8]. 
 
Table 4.5: Calculated heats of protonation of glycyl-glycine and the standard deviations 
















































































       4.4.2.4     Protonation of sarcosyl-glycine 
 
The results for SAR-GLY protonation are given in Figure 4.6.    ΔH1 = -10.6 kCal.mol-1 and 
ΔH2 = 2.51 kCal.mol-1.   The background heats of dilution are small and thus negligible.   The 
graphs in Figure 4.6C are superimposable therefore the results were reproducible.   This gives 




Figure 4.6: A: Raw isotherm for SAR-GLY Protonation B: Final isotherm for SAR-GLY protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of SAR-GLY 
 
Table 4.6 shows the thermodynamic parameters for the protonation of SAR-GLY.    The 
experimental results for SAR-GLY are comparable with the experimental results for GLY-
GLY. 























































Table 4.6: Calculated heats of protonation of sarcosyl-glycine and the standard deviations 

















       4.4.2.5     Protonation of glycyl-L-leucine 
The results for the protonation of GLY-LEU are given in Figure 4.7.   The heat at the end of 
the titration should be zero.   At the end of the titration the ligand solution should be 
completely saturated with the acid solution therefore the heat observed at the end of the 
titration is the background heat of dilution [7, 17, 18].   The background heat for GLY-LEU 
is slightly higher than zero.   Observation of the solution showed that slight foam had been 
generated by the stirring of this solution and this accounted for the small endothermic 
reaction.   Kasimova [18] however, has suggests that the heat at the end of a titration may go 
above the baseline because the concentration of the solutions in the sample cell will have 
degassed significantly at the end of the titration.    
 
For this titration ΔH1 = - 10.7 kCal.mol-1and ΔH2 = -2.20 kCal.mol-1.   The graphs in Figure 
4.7C are superimposable therefore the results were reproducible.   The background heats of 
dilution cannot be ignored because they are non-zero.   Data were corrected as described 



















Figure 4.7: A: Raw isotherm for GLY-LEU Protonation B: Final isotherm for GLY-LEU protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of GLY-LEU 
 
The corrected heats are shown in Table 4.7.   ΔH for the formation of LH is comparable with 
the literature value [8].   ΔH for the formation of LH2 is higher than the literature value [8], 
however all measures used to validate the method have been met.    
 
Table 4.7: Calculated heats of protonation of glycyl-L-leucine and the standard deviations 



















































































       4.4.2.6     Protonation of sarcosyl-L-leucine 
Results for the protonation of SAR-LEU are given in Figure 4.8.   The heat accompanying the 
first protonation of SAR-LEU is -9.19 kCal.mol-1 and the heat accompanying the second 
protonation of this ligand is -2.21 kCal.mol-1.   The graphs in Figure 4.8C are on top of each 
other.   The results were therefore repeatable.   This gives confidence in the results.   Non-
zero background heats were also observed with this ligand.   These were corrected as 




Figure 4.8: A: Raw isotherm for SAR-LEU Protonation B: Final isotherm for SAR-LEU protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of SAR-LEU 
Formation of LH is therefore favoured thermodynamically and it does not depend on 
temperature.   There is not published work on heats of protonation of SAR-LEU.   The errors 
are small and the ΔH’s compare well with GLY-LEU which is expected to have more or less 
the same chemical properties as SAR-LEU. 






















































Table 4.8: Calculated heats of protonation of sarcosyl-L-leucine and the standard deviations      
















4.4.2.7     Protonation of glycyl-L-phenylalanine  
The results for the protonation of GLY-PHE are given in Figure 4.9.   The heat 
accompanying the first protonation of GLY-PHE is -10.7 kCal.mol-1 and the heat 
accompanying the second protonation is -1.91 kCal.mol-1.   The results were reproducible 
since the graphs on Figure 4.9C are on top of each other.   The background heats of dilution 
were very small and thus negligible. 
 
   
 
Figure 4.9: A: Raw isotherm for GLY-PHE Protonation B: Final isotherm for GLY-PHE protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of GLY-PHE 






















































Table 4.9 shows thermodynamic parameters for the protonation of GLY-PHE.   Formation of 
LH is favoured thermodynamically.  ΔH and ΔS for the formation of LH agree well with the 
literature [8].    The spontaneity is mostly driven by enthalpy since ΔH = -44.6 kJ.mol-1 >         
-TΔS = -2.18 kJ.mol-1.   ΔH and ΔS for the formation of LH2 is also favoured 
thermodynamically.   The contribution of entropy and enthalpy is almost the ΔH = -8.00 
kJ.mol-1 > -TΔS = -8.60 kJ.mol-1. 
 
 
Table 4.9: Calculated heats of protonation of glycyl-L-phenylalanine and the standard deviations      



























       4.4.2.8     Protonation of sarcosyl-L-phenylalanine 
 
The results for the protonation of SAR-PHE are given in Figure 4.10.  ΔH1 = -9.77 kCal.mol-1 
and ΔH2 = -2.53 kCal.mol-1.   The graphs in Figure 4.10C are superimposable.   The results 




















Figure 4.10: A: Raw isotherm for SAR-PHE Protonation B: Final isotherm for SAR-PHE protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of SAR-PHE. 
Protonation heats of SAR-PHE are shown in Table 4.10.   There is no literature for the 
protonation heats of SAR-PHE but the errors are small and the heats are comparable with the 
heats of protonation of GLY-PHE which is expected to have more or less the same chemical 
properties as SAR-PHE. 
 
Table 4.10: Calculated heats of protonation of sarcosy-L-phenylalanine and the standard deviations      














































































       4.4.2.9     Protonation of glycyl-L-histidine 
ITC data for the protonation of GLY-HIS is given in Figure 4.11.   The heat accompanying 
the protonation of the amine terminal is -12.2 kCal.mol-1.  The heat accompanying the 
protonation of the imidazole N is -4.41 kCal.mol-1.   The heat accompanying the protonation 
of the carboxylate terminal is zero.   The results are reproducible (Figure 4.11C) since the 
graphs are on top of each other.   The background heats of dilution are very small and thus 
negligible 
 
GLY-HIS has three dissociable protons [14, 18-20].   A total of three plateaus were expected.   
At the beginning to the titration (molar ratio = 0.05) the isotherms were expected to levels off 
indicating thermal equilibrium of L, H and LH for; L + H   LH 
 
The second plateau was expected to be observed around pH 6 where the imidazole nitrogen is 
protonated.    The third plateau was expected around pH 2 where the carboxylate terminal is 
protonated.   Once the carboxylate was protonated, the graph was expected to rise until it 
reaches the baseline.   However this was not observed because the amine terminal and the 
nitrogen of the imidazole are protonated at the same time (log KLH = 8.14 and log KLH2 = 






















Figure 4.11: A: Raw isotherm for GLY-HIS Protonation B: Final isotherm for GLY-HIS protonation                                               
C: Molar ratio ([H+]/[L]) as a function of dH per mol of injection for the protonation of GLY-HIS 
The data were analysed with a sequential 3 site model and the thermodynamic parameters for 
the protonation of GLY-HIS are given in Table 4.11.   The spontaneity for the formation of 
LH is driven by enthalpy, the spontaneity for the formation of LH2 is driven by both enthalpy 
and entropy, and the spontaneity for the formation of LH3 is driven by entropy.   There is no 
published work on the protonation heats of GLY-HIS but the results obtained here are 
comparable with all the other three glycine dipeptides (GLY-GLY, GLY-LEU and GLY-
PHE). 
Table 4.11: Calculated heats of protonation of glycyl-L-histidine and the standard deviations      
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   4.4.3    Complex formation titrations 
All complex formation titrations were started from pH 7 or below.   This was to avoid access 
OH- ions which may mask the results by; OH- + H+   H2O 
The heats accompanying this reaction are huge and if the amount of OH- present in solution 
is not controlled the heat of formation of water may mask the results. 
 
For all complex formation titrations, species form at different pH’s and the complexes 
complete for Cu(II), the ligand and free H+.   This makes complex formation titrations more 
of a competitive reactions than the protonation titrations which are basically sequential.   To 
check that the competitive model fitting mode of Origin is suitable for complex formation, 
solutions of two ligands that have different affinity for H+ were put together in one sample 
cell and titrated with acid from pH 10.21 (the first protonation of these ligands occurs around 
this pH).   1:1 solutions of SAR (log KLH = 10.0; log KLH2 = 2.11) and SAR-LEU (log KLH = 
8.69; log KLH2 = 3.48) were put in the sample cell and titrated with acid until the solutions 
were completely saturated with acid.   Both the sample cell solutions and the pipette solutions 
were of 0.15 M ionic strength with NaCl.   The results are shown in Figure 4.12. 
 
From molar ratio 0.05 the graph levels off until it reached molar ratio 2.26 where it rises.   
The heat of this plateau is -7.08 kcal.mol-1.   This heat is comparable with the heat of 
protonation of the amine terminal of SAR (Section 4.4.2.2).   From molar ratio 2.26 the graph 
rises until it reaches molar ratio 2.43 where is levels off.   The height of this plateau is             
-2.3kcal.mol-1.   This value agrees well with the value obtained for the heat of protonation of 
the carboxylate terminal of SAR (Section 4.4.2.2).   The graph rises again from molar ratio 
3.51 until it touches the baseline at molar ratio between molar ratios 3.74 and 4.09.    
 
Thermodynamic parameters for only one ligand could be calculated, not the average of the 
two or parameters for each ligand as anticipated.   This shows that the competitive models 















Figure 4.12: A: Raw isotherm for competitive protonation titrations of SAR and SAR-LEU B: Final isotherm for 
competitive protonation titrations of SAR and SAR-LEU                                            
       4.4.3.1     GLY / Cu(II) 
1:1 Cu(II)/GLY at pH 7.02 was titrated with acid until the system was completely saturated 
with acid.   The results are shown in Figure 4.13.   Data were fit with a one site model.   The 
isotherms are interpreted from lower molar ratio to higher molar ratio.   The graph levels off 
from molar ratio 0.05 to molar ratio 0.45 where it rises until it touches the baseline.   ΔH for 
only one species was observed, ΔH = -4.2 kcal.mol-1. 
 
1:2 Cu(II)/GLY was titrated with acid from pH 6.15.   The results are put together with the 
results for 1:1 Cu(II)/GLY.   These are shown in Figure 4.13C.   The height of the graphs ΔH 
for the two graphs is the same.   The equivalence point N however is not the same.   This is 
because the amount of complexes formed depends on the amount of OH- present and the 
metal/ligand ratio.   ΔH for only one species was observed.   The olive green markers are the 
background heats of dilution.   These were very small and thus negligible.      
 
Cu(II) and GLY form only two species in solution [14-16].   These are ML and ML2.   The 
stability constant for ML is 1.07 log units greater than the stability constant of ML2 (Chapter 
3 Section 3.4.1.2).   The height of the isotherms is -4.2 kcal.mol-1.   This is the heat 
accompanying the formation of ML since ML is more stable than ML2 and Origin calculates 




























thermodynamic parameters of species that are the most stable in solution (Section 4.4.3), for 





Figure 4.13: A: Raw isotherm for complexation of Cu(II) with GLY B: Final isotherm for the complexation of Cu(II) 
with GLY  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of Cu(II) with 
GLY 
The heats were converted to kJ.mol-1 and are giving in Table 4.12.   The formation of ML is 
favoured thermodynamically. 
Table 4.12: Calculated heats for complexation of Cu(II) with GLY and the standard deviations      

















































































Complex formation titrations for Cu(II)/GLY have been done before [14].   A different 
experimental approach was used.   Cu(II) and GLY solutions were prepared in buffer 
solutions.   Ammonium acetate/acetic acid buffer was used for pH 5; 2-[N-morpholino] 
ethanesulfonic acid buffer was used for pH 6; 3-[N-morpholinino] propanesulfonic acid 
buffer was used for pH 7; and 3-[4,(2-hydroxyethyl)-1-piperazinyl] propanesulfonic acid 
buffer was used for pH 8.   Cu(II) solutions were prepared in buffers and GLY solutions were 
also prepared in a matching buffer solution [14].   The sample cell was filled with Cu(II) 
solutions and titrated with GLY solutions [14].   The results differ significantly from pH to 
pH.   At pH 5, the observed ΔH = 18.5 kJ.mol-1; at pH6 ΔH = 3.36 kJ.mol-1; at pH 7, ΔH = -
13.2kJ.mol-1; and at pH 8 ΔH = -11.8 kJ.mol-1 [14].   All these values do not agree with ΔHML 
= -25.0 kJ.mol-1 and ΔHML2 = -54.8 kJ.mol-1.   This experimental design does not measure 
the true thermodynamic parameters but the conditional parameters (dependent on pH) for the 
completion between the ligand and the buffer for the metal ion.    Hence one must be careful 
in comparing literature data which may be recorded using a different experimental approach. 
 
       4.4.3.2     SAR / Cu(II) 
1:1 Cu(II)/SAR solutions were titrated with acid from pH 7.01 until the system was 
completely saturated with acid.   The results are shown in Figure 4.14.   The graph levels off 
from molar ratio 0.07 to molar ratio 0.23.   The height of the plateau is -4.7kcal.mol-1.    
 
1:2 Cu(II)/SAR solutions were titrated with acid until the system was completely saturated 
with acid.   The results are put together on one graph with the results for 1:1 Cu(II)/SAR 
titrations.   These are given in Figure 4.14C.   The height of the isotherms is reproducible 
regardless of the metal/ligand ratio used.   N the equivalence point is however not 
reproducible since there is more free ligand in a 1:2 system than it is in a 1:1 system.  N value 
for 1:2 Cu(II)/SAR titrations (N = 0.627) is twice the N value for 1:1Cu(II)/SAR titrations   
(N = 1.22 ).   The olive green markers are the background heats of dilution.   These are very 



























Figure 4.14: A: Raw isotherm for complexation of Cu(II) with SAR B: Final isotherm for the complexation of Cu(II) 
with SAR  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of Cu(II) with 
SAR 
Thermodynamic parameters of the complexation of Cu(II) with SAR are given in Table 4.13.   
Production of ML is spontaneous at all temperatures.   The value of ΔH and ΔS for the 
formation of ML compares well with literature (ΔH = -19.0 kJ.mol-1) [8].   Potentiometry 
revealed that several copper species are possible in this system, however, only one ΔH (ML) 
could be determined. 
 
Table 4.13: Calculated heats for complexation of Cu(II) with SAR and the standard deviations      






























































































       4.4.3.3     GLY-GLY / Cu(II) 
The results for the complex formation titrations of Cu(II) with GLY-GLY are given in Figure 
4.15.   ΔHML = -6.10 kCal.mol-1.   The height of the graph for 1:1 Cu(II)/GLY-GLY is the 
same as the height of the graph for 1:2 Cu(II)/GLY-GLY.   The background heats of dilution 




Figure 4.15: A: Raw isotherm for complexation of Cu(II) with GLY-GLY B: Final isotherm for the complexation of 
Cu(II) with GLY-GLY  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with GLY-GLY 
Thermodynamic parameters for the complexation of Cu(II) with GLY-GLY are given in 
Table 4.14.   ΔH compares well with the literature value (ΔH = -27.0 kJ.mol-1).   ΔH and ΔS 
could not be determined and there is no available data on ΔH and ΔS for the formation of 
ML2 in the literature. 





















































Table 4.14: Calculated heats for complexation of Cu(II) with GLY-GLY and the standard deviations      






































       4.4.3.4     SAR-GLY / Cu(II)  
Complex formation titrations of Cu(II) with SAR-GLY are given in Figure 4.16.   ΔHML =     
-6.00 kCal.mol-1.   The olive green markers are the background heats of dilution.   These are 





Figure 4.16: A: Raw isotherm for complexation of Cu(II) with SAR-GLY B: Final isotherm for the complexation of 
Cu(II) with SAR-GLY  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with SAR-GLY 






















































Thermodynamic parameters for the complex formation titrations are shown in Table 4.15.   
ΔH observed in Figure 4.16 is the ΔH for the formation of ML.   Even though ML2H-1 (log K 
= 8.35) and ML2H-2 (log K = 11.5) have higher log K values than ML (lig K = 6.15), these 
two species form at very high pH’s (above pH 7).   Since the titration were started below pH 
7 to about pH 2 there were mainly two species in solution, ML and ML2.   ML (log K = 6.15) 
is more stable than ML2 (log K = 4.19) and since only ΔH for the most stable species in 
solution is observed for competitive titrations, the -6.00 kcal.mol-1 observed in Figure 4.16 is 
the heat accompanying the formation of ML. 
 
ΔH and ΔS for the complexation titrations of Cu(II) with SAR-GLY are not available in 
literature, however ΔH and ΔS for the formation of ML is comparable with ΔH and ΔS for 
the formation of ML for Cu(II)/GLY-GLY titrations.    
 
 
Table 4.15: Calculated heats for complexation of Cu(II) with SAR-GLY and the standard deviations      




























       4.4.3.5     GLY-LEU / Cu(II) 
Figure 4.17 shows the results for complex formation titrations of Cu(II)/GLY-LEU.   The 
heat accompanying the formation of ML for this titration is -6.61 kCal.mol-1.   The heights 
for 1:1 Cu(II)/GLY-LEU titration curve and that of a 1:2 Cu(II)/GLY-LEU titration are the 

























Figure 4.17: A: Raw isotherm for complexation of Cu(II) with GLY-LEU B: Final isotherm for the complexation of 
Cu(II) with GLY-LEU  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with GLY-LEU 
Thermodynamic properties for the complexation of Cu(II) with GLY-LEU are given in Table 
4.16.   ΔH and ΔS for the formation of ML is not available in the literature therefore the 
results could not be compared with the values reported there. 
 
Table 4.16: Calculated heats for complexation of Cu(II) with GLY-LEU and the standard deviations      


















































































       4.4.3.6     SAR-LEU / Cu(II) 
Results for Cu(II)/SAR-LEU are given in Figure 4.18.   ΔHML = -5.23 kCal.mol-1.   ΔHML for 
1:1 Cu(II)/SAR-LEU is the same as ΔHML for 1:2 Cu(II)/SAR-LEU.   The background heats 




Figure 4.18: A: Raw isotherm for complexation of Cu(II) with SAR-LEU B: Final isotherm for the complexation of 
Cu(II) with SAR-LEU  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with SAR-LEU 
 
 
ΔH for the formation of ML for Cu(II)/SAR-LEU titrations were converted to kJ.mol-1.   
These are given in Table 4.17.   There is no published work on calorimetry for Cu(II)/SAR-
LEU however the errors were very small. 
 



























































       4.4.3.7     GLY-PHE / Cu(II) 
 
ΔHML for this titration is -4.96 kCal.mol-1.   The isotherms are given in Figure 4.19.   The 
results were reproducible since the graph for 1:1 Cu(II)/GLY-PHE titrations have the same 



































































Figure 4.19: A: Raw isotherm for complexation of Cu(II) with GLY-PHE B: Final isotherm for the complexation of 
Cu(II) with GLY-PHE  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with GLY-PHE 
Thermodynamic parameters for titrations of Cu(II)/GLY-PHE with acid were calculated and 
are given in Table 4.18.   ΔH for the formation of ML slightly less than the literature value 











































Table 4.18: Calculated heats for complexation of Cu(II) with GLY-PHE and the standard deviations      
 
       4.4.3.8     SAR-PHE / Cu(II) 
 
ΔHML = -6.13 kCal.mol-1.   The isotherms are given in Figure 4.20.   The results were 
reproducible.  Olive green markers are the background heats of dilution.   These are very 





Figure 4.20: A: Raw isotherm for complexation of Cu(II) with SAR-PHE B: Final isotherm for the complexation of 
Cu(II) with SAR-PHE  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with SAR-PHE 






























































































Thermodynamic parameters for Cu(II)/SAR-PHE titrations are given in Table 4.19.   There is 
not published data to compare with.   ΔH for the formation of MLH-1 and for the formation of 
MLH-2 could not be determined.  ΔS’s for these species could not be calculated either. 
 
 








       4.4.3.9     GLY-HIS / Cu(II)  
Isotherms for Cu(II)/GLY-HIS complex formation titrations are given in Figure 4.21.   The 
heat accompanying the formation of ML is -3.60 kCal.mol-1.   The height of isotherms for 1:1 
Cu(II)/GLY-HIS is the same as the height for isotherms for 1:2 Cu(II)/GLY-HIS.   ΔHML for 
this titration was therefore reproducible.   The background heats of dilution are very small 










































Figure 4.21: A: Raw isotherm for complexation of Cu(II) with GLY-HIS B: Final isotherm for the complexation of 
Cu(II) with GLY-HIS  C: Molar ratio ([H+]tot/[L]tot) as a function of dH per mol of injection for the complexation of 
Cu(II) with GLY-HIS 
 
Thermodynamic parameters for these titrations are given in Table 4.20.   Complex formation 
titrations for Cu(II)/GLY-HIS have been done before but Cu(II) solutions and GLY-HIS 
solutions were prepared in buffers [14].   At pH 5, ΔH was 37.6 kJ.mol-1; at pH 6, ΔH was -
53.0 kJ.mol-1; at pH 7, ΔH was -28.6 kJ.mol-1 and at pH 8, ΔH = -12.4 kJ.mol-1.   None of 
these four values agree with the -15.1 kJ.mol-1 (Table 4.20).   Complex formation titrations 
depend on the amount of free acid as well as the amount of free metal/free ligand in solution.  
Titrations done at a fixed pH may restrict the amount of species formed as well as the 
distribution of species formed. 





















































 Table 4.20: Calculated heats for complexation of Cu(II) with GLY-HIS and the standard deviations 





































4.5    DISCUSSIONS  
All protonation equilibria are favoured thermodynamically even though the spontaneity of the 
formation of some species is more driven by entropy while some are driven by both entropy 
and enthalpy.   A summary for thermodynamic parameters of the ligand protonation is given 
in Table 4.21.   From potentiometric titrations, the first pKa of GLY (log KLH = 9.53) was 
found to be less than the first pKa of SAR (log KLH = 10.0).   At this point the question was 
raised as to whether this was due to the inductive effect of the N-methyl group.   From the 
calorimetry results, it is observed that ΔHLH (GLY) is 12.7 kJ.mol-1 more than ΔHLH (SAR).   
TΔSLH (GLY) is however 15.4 kJ,mol-1 less than TΔSLH (SAR).    Thus the increased basicity 
of SAR is entropy driven rather than enthalpy driven.   A similar effect is seen in the pKa of 
substituted amines, where the inductive effect of the methyl group results in a gas phase 
basicity order of (CH3)3N > (CH3)2NH > (CH3)NH2  > NH3.   However, in water the order is 
(CH3)2NH > NH3 > (CH3)NH2  > (CH3)3N.    This is the result of two competing effect, the 
inductive effect of the methyl group and the effect of H-bonding in solution [23].   
 
As expected, the thermodynamic parameters for protonation of the carboxylic acid of GLY 
and SA  are very similar.   ΔHLH2 (GLY) is 0.34 kJ.mol-1 greater than ΔHLH2 (SAR), and 
TΔSLH2 (GLY) is 0.69 kJ.mol-1 greater than TΔSLH2 (SAR).      The substantial decrease in 
ΔHLH2 compared to ΔHLH is expected as the strength of the OH bond is much less than the 
NH bond.  However, one might have expected ΔS to be large and positive because of 
decreased solvation of the neutral  COOH as opposed to the charged  COO-.   The LH form 
of both ligands is nonpolar and therefore the spontaneity of protonation of LH to LH2 is 
mostly driven by enthalpy.   Indeed, Li et al [24] obtained a value of 30.9 J.K-1.mol-1 for 
protonation of the carboxyl group of glycine. 
 
The effect of the peptide bond upon pKa can be seen by comparing GLY and GLY-GLY.   
The pKa1 of GLY is 9.53 and that of GLY-GLY is 8.16, a decrease of 1.37 log units.   The 
peptide bond decreases pKa2 by 0.84 log units.   Looking at the thermodynamic parameters 
for these two ligands, it is observed that the enthalpy values are very similar but that the 
entropy values are very different.   Again one might have expected the electron withdrawing 













With the exception of GLY-HIS, the pKa’s and enthalpies of protonation of the dipeptides 
are all very similar.  However, the entropies for the peptides (GLY-GLY, SAR-GLY, GLY-
LEU, SAR-LEU, GLY-PHE and SAR-PHE) vary from 7 to 37 J.K-1mol-1.  This is most likely 
due the error in the entropy measurement. 
Table 4.21: Gibbs’s free energy, enthalpy change and entropy change for the protonation of GLY ligands and SAR 
ligands.      
































































































A summary of ITC results for complex formation titrations is given in Table 4.22.   ΔHML 
(GLY) is 2.2 kJ.mol-1 greater than ΔHML (SAR); ΔHML (GLY-GLY) is 1.0 kJ.mol-1 greater 
than ΔHML (SAR-GLY); ΔHML (GLY-LEU) 5.8 kJ.mol-1 greater than ΔHML (SAR-LEU); 
ΔHML (GLY-PHE) is 4.8 kJ.mol-1 less than ΔHML (SAR-PHE) and ΔHML (GLY-HIS) is the 
least of all.   The literature [16, 25, 36] shows that Cu(II) coordinates to the amine N-donor 
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From Hancock’s work [36], the heat accompanying the first reaction is -52.7 kJ,mol-1, and the 
heat accompanying the second reaction is -47.7 kJ.mol-1.   The heat accompanying a single 
Cu-N bond (5-memebered chelate ring) is therefore -26.4 kJ.mol-1, and the heat 
accompanying a single Cu-N bond (6-memebered chelate ring) is   23.9 kJ.mol-1.   Soli and 
co-workers [27], and other publishers [28, 29] have determined ΔH accompanying the 
formation of CuCO3 = -10.4 kJ.mol-1.   From Mohan, Bancroft and Abbort’s work [37], the 
heat accompanying the first reaction is -59.9  kJ.mol-1 (ΔH single (Cu-N) = -30.0 kJ.mol-1), 
the heat accompanying the third reaction is +4.60 kJ.mol-1(ΔH single (Cu-O)  =  +2.30 
kJ.mol-1), the heat accompanying the 4th reaction is -21.8 kJ.mol-1 (heat for a single Cu-O = -













on the ligand’s affinity to bind with the metal ion (log KML).   The heat accompanying a 
single Cu-N bond is almost the same for the first two reactions because the log KML’s for the 
first two ligands are similar; log KML (Cu-ethylene diamine) = 10.5 and   log KML (Cu- 
propylene-1, 3-diamine) = 9.68 [36, 37].   Log KML (Cu-malonate) = 5.22, log KML (Cu-
pyrocachol) = 13.8.   The size of the chelate ring also affects ΔH’s, with a single Cu-N 
(propylene-1, 3-diamine) being less than that of ethylene diamine.   From this information the 
structure of Cu-peptides can be predicted.   The peptides have four active binding sites; the 
terminal amine N, amide N, amide O and the carboxylate O.   GLY-HIS has two additional 
N-donors on the imidazole side ring.   All ΔHML (Cu-peptide) suggest that Cu(II) coordinates 
to one N donor atom and on one O donor atom since the experimental values are between      
-20.8 kJ.mol-1 and  -27.7 kJ.mol-1.   These values are close to -31.1 kJ.mol-1 which is the sum 
of the average ΔH (Cu-N) and ΔH (Cu-O).    ΔHML (Cu-GLY-HIS) is significantly less than   
-31.1 kJ.mol-1 therefore Cu(II) does not coordinate to the same electron donor groups as the 
other dipeptides when ML forms. 
-TΔSML (GLY) and -TΔSML (SAR) are almost three times more than -TΔSML (GLY-GLY),            
-TΔSML (SAR-GLY) and -TΔSML (SAR-PHE).   This could mean that when Cu(II) coordinates 
to GLY-GLY, SAR-GLY and SAR-PHE very few water molecules were lost (almost a third 
of molecules that GLY and SAR) upon complexation with Cu(II).   Some of the electron 
donor groups are still engaged in H-bonding with the water molecules.   -TΔSML (SAR-LEU) 
and -TΔSML (GLY-PHE) are almost half -TΔSML (GLY) and -TΔSML (SAR).   Very few water 
molecules were lost upon complexation of GLY-LEU with Cu(II).   This could mean that 





















Table 4.22: Gibbs’s free energy, enthalpy change and entropy change for the complex formation titrations of Cu(II) 
with GLY ligands and SAR ligands 









GLY ML 8.09 -46.2 -17.5 (±0.05) 96.2  -28.7 
SAR ML 7.89 -45.0 -19.7 (±0.02) 84.9  -25.3 
GLY-GLY ML 6.33 -36.1 -25.5 (±0.03) 35.5  -10.6 
SAR-GLY ML 6.15 -35.1 -25.1 (±0.01) 33.6  -10.0 
GLY-LEU ML 5.79 -33.0 -27.7 (±0.06) 18.0  -5.37 
SAR-LEU ML 6.32 -36.1 -21.9 (±0.2) 47.5  -14.2 
GLY-PHE ML 6.37 -36.3 -20.8 (±0.08) 52.3  -15.6 
SAR-PHE ML 6.54 -37.3 -25.6 (±0.03) 39.1  -11.7 
GLY-HIS ML 9.16 [12] -52.3 -15.1 (±0.02) 125  -37.2 
 
4.6    CONCLUSIONS 
The methyl substituent of sarcosine ligands does not affect the stability of ligands and 
subsequently does not affect the stability of complexes of these ligands with Cu(II) 
thermodynamically.   Many authors [27-35] have used ITC to study thermodynamic 
properties of Cu(II) complexes but all of them have used buffers, which makes our 
experimental design the first of its kind and thus more studies have to be made to gather 
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5.   STRUCTURAL STUDIES 
5.1   1H NMR SPECTROSCOPY 
5.1.1   INTRODUCTION 
Proton magnetic resonance spectroscopy (1H NMR) is a technique used to determine the 
structure of molecules.   In the magnetic field, different protons resonate at different 
frequencies [15].     A spectrum for 1H NMR is a plot of signal intensity against chemical 
shift.   The choice a solvent used is critical when doing NMR experiments [4, 13].   
Deuterated water is commonly used in 1H NMR titrations and NaOD/DCl solutions are used 
to adjust the pD of the solutions [1-4]. 
 
The chemical shift depends on electron density which changes as the ligands changes from 
LH2 to LH to L [5].    Thus a plot of chemical shift vs pD can be used to determine the site of 
protonation of a ligand [4, 5].   Many authors have used 1H NMR to determine the sequence 
of protonation of the ligands, to estimate the protonation constants and to predict the 
structures of metal/ligand complexes [1-3, 8-12].    
 
Due to its paramagnetic property, Cu(II) broadens spectra when it coordinates to the ligand.   
This broadening can be a “through bond effect” (Fermi contact interaction) or a “through 
space effect” which is dependent on the distance between the paramagnetic center and the 
observed nucleus.  The differential effect of the metal ion on the ligand can then be used to 
determine the structure of the complex. 
 
5.1.2   EXPERIMENTAL 
All solutions were prepared in D2O.   Tertiary butyl alcohol was used as an internal reference.   
The pD of the solutions was adjusted with NaOD/DCl as described [1-3].   A CRISONmicro 
pH meter equipped with Ω Metrohm glass electrode was used to measure the pH.   The 
spectra were recorded from pD 2 to pD 11 with a Bruker Avance 400 NMR spectrometer.   
Complex formation titrations were run as described [1].   Into the ligand solution, small 
aliquots of dilute Cu(II) solution were added.   The pD of the ligands solutions was fixed at 
about pH 6 for the first six/seven titrations, and the pD was varied for the last three/four 
titrations.   Since a pH electrode was used to measure pD, corrections are made as described 












pD = pH meter reading + 0.44                                                   (5.1) 
 
5.1.3   RESULTS 
   5.1.3.1    Protonation titrations 
1H NMR can be used as a probe to the site of protonation during a pH titration.   In the case 
of the dipeptides studied, the site of protonation is known but the effect of protonation in 
terms of chemical shift change is not known.  This information is needed when looking at the 
effect of metal ions upon the NMR spectrum.   In water, the amine protons are in rapid 
chemical exchange and so are not seen in the NMR spectrum.   At low pH it is possible to see 
the amide protons but they too are exchange broadened above pH ~6.   For this reason the 
spectra were all run in D2O, which is technically much easier and does not require solvent 
suppression. 
 
       5.1.3.1.1     Protonation of glycyl-leucine 
1H NMR results for the titration of GLY-LEU are given in Figure 5.1.   Figure 5.1A is the 
raw spectra from pD 2.75 to pD 9.30.   The signal labeled ‘a’ shifted significantly from pD 
2.75 to pD 4.26.   This signal is assigned to the proton of the α-carbon of the C-terminal 
(labeled ‘a’ on Figure 5.1C).   This indicates that the protonation of the carboxylate terminal 
occurs at low pD’s.  A small change in chemical shift for the proton of the α-carbon ‘a’ was 
observed from pD 5.70 to pD 9.30.   Form pD 2.75 to pD 7.95, signal ‘b’ did not shift 
significantly.   A significant shift was observed between pD 7.95 and pD 9.30.   This signal is 
assigned to the protons of the α-carbon of the N-terminal (carbon labeled ‘b’ on Figure 5.1B).   
This indicates that protonation of the amine terminal occurs at high pD’s.   Signals ‘c’ and ‘d’ 
did not shift significantly.   Figure 5.1B shows the chemical shift as a function of pD.   The 
protonation constants of GLY-LEU can be estimated from this graph.   Log KLH = 8.2.   This 
is the mid-point of the steepest slope of ‘a’ on Figure 5.1B.   Log KLH2 = 3.1.   This is the 
mid-point of the steepest slope of ‘b’ on Figure 5.1B.   These agree with the potentiometric 



























Figure 5.1: A: Raw 1H NMR titration data from pD 2 to pD 10 for the protonation of GLY-LEU:      B: Change in chemical 
shift for the protonation of GLY-LEU       C: Assigned chemical shifts for GLY-LEU 
 
       5.1.3.1.2     Protonation of sarcosyl-leucine 
Results for SAR-LEU protonation are given in Figure 5.2.  Raw data is shown in Figure 
5.2A, change in chemical shifts as a function of pD is given in Figure 5.2B and the 
assignments are given in Figure 5.2C.   Protonation of the amine terminal occurs from pD 
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the potentiometric results (Table 3.6).   Protonation of the carboxylate terminal occurs at low 
pD’s and it could not be estimated.   Signals ‘a’ and ‘e’ however shifted at low pD’s (pD 2.23 
















Figure 5.2: A: Raw 1H NMR titration data from pD 2 to pD 10 for the protonation of SAR-LEU.       B: Change in chemical 
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       5.1.3.1.3     Protonation of glycyl-L-phenylalanine 
Results for GLY-PHE protonation are given in Figure 5.3.   Signal ‘a’ did not shift 
significantly throughout the titration, signal ‘b’ shifted from pD 7.44 to pD 11.17, signals ‘c’ 
and ‘d’ shifted between pD 2.22 and pD 4.07 and signal ‘e’ did not shift significantly and the 
change in this signal was not plotted against pD (Figure 5.3C).   The first protonation occurs 
on the amine terminal and the second protonation occurs on the carboxylate terminal.   Log 



















Figure 5.3: A: Raw 1H NMR titration data from pD 2 to pD 11 for the protonation of GLY-PHE.       B: Change in chemical 
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       5.1.3.1.4     Protonation of sarcosyl-L-phenylalanine 
The results for the protonation of SAR-PHE are given in Figure 5.4.   The signals that shift 
the most are signals ‘b’ and ‘e’ assigned to the protons of the α-carbon of the N-terminal and 
the protons of the methyl substituent respectively.   These signals shift mostly from pD 6.91 
to pD 11.17.   Log KLH = 8.5.   This agrees with the potentiometric results (Table 3.8).   This 
indicates the protonation of the amine terminal.   Signal ‘f’ shifted the most between pD 2.22 



















Figure 5.4: A: Raw 1H NMR titration data from pD 2 to pD 10 for the protonation of SAR-PHE.       B: Change in chemical 
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   5.1.3.2    Complex formation titrations 
       5.1.3.2.1     GLY-LEU / Cu(II) 
1H NMR results for complex formation titrations of GLY-LEU with Cu(II) are given in 
Figure 5.5.   At pH 6.01, MLH-1 is the most predominant species.   The ‘a’ and ‘b’ protons 
broaden significantly indicating that the metal is bound to sites near these protons.    This 
must be the terminal amine and either the deprotonated amide nitrogen or the amide carbonyl.   
Since the stoichiometry of this complex is MLH-1,  binding to the amide nitrogen is indicated.   
When the pD was changed from pD 6.01 to pD 7.01 signal ‘b’ disappeared completely while 
‘a’was still visible.   At this pH, ML2H-1 is the predominant species and these NMR results 
are consistent with  both amine nitrogens being coordinated but only one of the amide 
nitrogens.   
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       5.1.3.2.2     SAR-LEU / Cu(II) 
1H NMR results for Cu(II)/SAR-LEU are given on Figure 5.6.   ML species is the most 
predominant species at pH 5.65.   Signals ‘a’, ‘b’, ‘d’ and ‘e’ were already broadened at the 
beginning of the Cu(II)/ligand titration.   Signal ‘c’ broadened upon further titration with 
Cu(II).   The broadening of signals ‘a’ and ‘c’ indicate coordination to the terminal N.   The 
broadening of ‘b’, ‘d’ and ‘e’ indicate coordination to the amide N or the amide O.   The 
stoichiometry supports coordination to the amine N and the amide O for this species.   The 
second ligand molecule will arrange itself in the same manner when ML2 forms (Cu(II) binds 
to the amine N and the amide O of both ligands).   When the pH was increased from 5.65 to 
higher, signals ‘a’, ‘b’ and ‘c’ disappeared.   The stoichiometry supports coordination to the 
amine N and the amide N when MLH-1 forms, and further coordination to the carboxylate O 
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       5.1.3.2.3     GLY-PHE / Cu(II) 
1H NMR results for the complexation of GLY-PHE with Cu(II) are given on Figure 5.7.   At 
pD 6.32, ML is the most predominant species in solution.   Signals ‘b’, ‘c’, ‘d’ and ‘e’ 
broadened when the concentration of Cu(II) was increased and the pH kept constant at pH 
6.32.   The broadening of signal ‘b’ indicates coordination of Cu(II) to the terminal amine. 
The broadening of ‘c’, ‘d’ and ‘e’ indicates coordination to the amide N or the amide O.   
Cu(II) binds to the amine N and the amide O when ML forms.   When the pH was increased 
from 6.32 to 11.05, ‘b’, ‘c’, ‘d’ and ‘e’ disappeared completely.   This indicates further 
coordination to the neighboring donors atoms; amine N, amide O and amide N.   Cu(II) binds 
to the amine N and the amide O of both ligands when ML2 forms.   The stoichiometry 
supports coordination of Cu(II) to the amine N of both ligand molecules, coordination to the 
amide N of the first ligand molecule and coordination to the amide O of the second ligand 
molecule when ML2H-1 forms, and coordination to amine N and amide N of both ligands 
















Figure 5.7: A: Raw 1H NMR titration for the complexation of GLY-PHE: with Cu(II).     B: Assigned chemical shifts for 
GLY-PHE 
e a c, d b 
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       5.1.3.2.4     SAR-PHE / Cu(II) 
Results for 1H NMR titrations of SAR-PHE with Cu(II) are given in Figure 5.8.   At pH 5.81, 
the most predominant species is the ML.   When the Cu: ligand ratio was varied (from 1:290 
to 1:80), signals ‘b’, ‘c’. ‘d’ and ‘f’ broadened.   The broadening of signal ‘b’ indicates 
coordination on the amine N.   Broadening of signals ‘b’, ‘c’ and ‘f’ indicate coordination of 
the amide N or the amide O.   Signal ‘e’ broadened from 1:110 Cu/ligand, at pH 5.81.   The 
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   5.1.3.3    Discussions 
The ligands have two dissociable protons, one on the terminal carboxylate and the other on 
the amine terminus.   The first protonation occurs on the amine terminal and the second 
occurs on the carboxylate terminal.   While this observation is trivial it does serve to illustrate 



















LH2 LH L  
 
Where R = -H, and -CH3 
And R1 = -H, and  
 
From 1H NMR results it can be concluded that coordination occurs on the amine N and amide 
N or the amide O when ML forms.   The stoichiometry however suggests that Cu(II) 
coordinates to the amine N and the amide O when ML forms, since coordination on the 
amide N will occur only if the amide proton is displaced.    The latter represents the structure 
of species MLH-1.  For the same reasons, Cu(II) coordinates to the amine N and the amide O 
of both ligands when ML2 forms.   Cu(II) coordinates to the amine N of both ligands, on the 
amide O of the first ligand and on the amide N of the second ligand when ML2H-1 forms.   
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(5, 5 chelate sequence) and a
         5-membered chelate  
Where R = -H, and -CH3 
And R1 = -H, and            
 
 
The charges on the electron donor groups that are engaged in coordination are omitted for 
simplicity.   In each case the terminal carboxyl group could be coordinated.  In some cases it 
would coordinate in an equatorial position but in others an axial position. 
 
Electron paramagnetic resonance (EPR) measurements can be used to determine the number 




















5.2   UV-VIS SPECTROPHOTOMETRY 
5.2.1   INTRODUCTION 
Ultraviolet-visible absorption spectrophotometry (UV-Vis) is a spectroscopic technique 
which is used to gain insight into the structure of different metal species in solution [15-16].   
When a beam of light is passed through an analyte solution, its intensity is reduced.  This is 
because some of the light will have been absorbed by the analyte solution; some will have 
been reflected/ scattered [15-16].   The fraction of light absorbed by a species at a certain 
wavelength is its absorptivity (Ɛ) at that wavelength.   UV-Vis is used for quantitative 
analysis (Beer-Lambert’s law); 
  Ɛ   
(5.2) 
 
Where A is the absorbance, Ɛ is the molar extinction coefficient, b is the path length of the 
sample cell and C is the molar concentration of the absorbing species.   If the analyte solution 
is a mixture of different species, the total absorbance at a specific wavelength (Aλ) can be 
expressed as; 
     Ɛ 
    Ɛ 
    Ɛ 
     Ɛ 
     
(5.3) 
 
Where the superscript λ is a parameter at a certain wavelength, subscripts 1, 2, 3…n are 
absorbing species.   Equation 5.3 can be simplified; 
    ∑Ɛ 
    
(5.4) 
 
If A, b and C are defined, then Ɛ can be calculated.    Different species absorb light at 
difference wavelengths and the maximum wavelengths of absorption can be correlated with 
the type of structure of a species.    λmax’s can therefore  be used to predict structures of 
complexes.    Billo’s method [14] is one of the most popular methods of structure 
determination using λmax’s.    Calculated λmax is expressed as; 
      
   














Where ni is the number of equatorial donor groups and νi is the ligand field of the complex. 
Ligands used in this study have four main electron donor atoms; N-donor of the amide,        
N-donor of the amine, O-donor of the carboxylate and O-donor of water.   The electron donor 
groups and their corresponding ligand fields are given in Table 5.0. 
 
Table 5.0: Electron donor groups and corresponding ligand field. 



















Many authors [18-22] have used UV-Vis to predict the structures of Cu(II) complexes. 
 
5.2.2   EXPERIMENTAL 
1:2 Cu(II)/ligands solutions were prepared in distilled-deionised water.   The pH of these 
solutions was adjusted with NaOH/HCl from pH 2 to pH 11.   CRISONmicro pH meter 
equipped with Ω Metrohm glass electrode was used to measure the pH.   The exact amount of 
NaOH/HCl added was noted.   The concentrations of the absorbing species were calculated at 
every pH.   The absorbances of these solutions were measured with a Hewlette Parkard 
8452A Diode Array spectrophotometer from 350 nm to 820 nm.   A blank was used to correct 
the absorbance.   Mixed species are formed at every pH and thus precise measurements of 
absorbance for individual species cannot be achieved and thus the molar extinction 
coefficients for individual species cannot be calculated directly form the spectra.   A home-
written computer program UV_spectra was used deconvolute the sectra and calculate the 
spectrum of individual species.   This program uses essential Newton’s method to solve 












wavelength.   The equilibrium model determined from potentiometry is used to calculate each 
species concentration at the different pH’s.   Since each the data, at each wavelength, are 
analysed independently there is no pre-condition that a smooth spectrum is obtained when the 
results are combined.   Hence if the data can be deconvoluted (the set of simultaneous 
equations are non-singular) and smooth curves are obtained it lends confidence to the 
potentiometric model. 
 
5.2.3   RESULTS 
 
Table 5.1: Proposed electron donor groups and corresponding calculated λmax’s for Cu(II)/dipeptide complexes. 
Structure Species 
Involved electron-donor atoms/ groups 
Calculated 













































































































































Hypothetical structures for the copper dipeptides complexes are given below and the 
calculated maximum wavelengths for each structure given in Table 5.1.  Koltun and co-
workers [36], Gigel and Martin [37], Brookes and Pettit [38] suggest Structure A for ML, 























































































































































































K                                                           L                                                              M  
Where R = -H, and -CH3 
And R1 = -H, and            
 
       5.2.3.1     GLY-GLY / Cu(II) 
UV-Vis results for Cu(II)/GLY-GLY are given in Figure 5.9.   The smooth graphs indicate 
that the model is reasonable.   A single absorption band was observed for each species.   All 
the species absorb UV-Vis light between 450 nm and 800 nm.  λmax (ML) = 645 nm, (Ɛmax = 
81.7 dm3.mol-1.cm-1);  λmax (ML2) = 635 nm, (Ɛmax = 15.5 dm3.mol-1.cm-1);   λmax (MLH-1) = 
630 nm,   (Ɛmax = 71.4 dm3.mol-1.cm-1);    and λmax (MLH-2) = 630 nm,    (Ɛmax = 56.9 
dm3.mol-1.cm-1).   The extinction coefficients are characteristic of LaPorte forbidden, spin 
allowed d-d transitions of a tetragonally distorted octahedral complex.   GLY-GLY has four 
potential electron donor atoms; N-amine, N-amide, O-amide, O-carboxylate. 
 
λmax (ML) suggests that Cu(II) coordinates to the amine N-donor, on the amide O-donor, on 
the carboxylate O-donor and on one water molecule resulting in an 5,7 chelate sequence.   
When ML2 forms, Cu(II) binds to the second ligand molecule through the amine N and the 
amide O, as a result, the band shifts to a shorter λmax.    λmax shifts to a shorter wavelength 
when MLH-1 forms.   This is a result of a Cu-Oamide to Cu-Namide rearrangement.   There is no 
observable change in λmax when MLH-1 goes to MLH-2, however the intensity of the band 













Figure 5.9: Molar extinction coefficients as a function of wavelength for Cu(II)/GLY-GLY complexes.   The total 
ligand concentration = 0.005099 M and the total Cu(II) concentration = 0.005103 M. 
 
Table 5.2 shows observed λmax’s and calculated λmax’s for Cu(II)/GLY-GLY system.   
Observed λmax (ML) is 47 nm less than the calculated maximum wavelength.   A difference of 
47 nm between the calculated and the observed λmax may be due the fact that coordination to 
the carboxylate O is axial while coordination to amide O, amine N and water O is equatorial.   
Billo’s method [14] assumes no axial coordination.   Coordination of Cu(II) to N-amine and   
O-amide when ML2 forms is equatorial.   The observed and calculated maximum wavelengths 
agree a slight difference of 7 nm falls within the experimental error and the accuracy of 
Billo’s method.   Some of the complex species form in very low concentrations which makes 
data analysis not as precise.    Deprotonation of ML yields MLH-1.   The Cu-Oamide bond 
breaks and the Cu-Namide bonds forms.   There is a good agreement between the observed and 
the calculated λmax’s for this species.   Deprotonation of MLH-1 yields MLH-2.      The second 
proton is lost from a coordinated water molecule.   A red shift was observed; calculated λmax 
is 36 nm less than the observed λmax.   Axial Cu-Ohydroxide has been reported to result in a red 
shift [39]. 
 
λmax (ML) does not agree with the literature  λmax (ML) = 735 nm [36],   however,  λmax 
(MLH-1) and λmax (MLH-2) agree with the literature (λmax (MLH-1) = 635 nm and   λmax   
(MLH-2)  = 625 nm) [36].   The literature [36] suggests Cu(II) coordinates to the amine N, the 
amide O and two water molecules when ML forms.   Proposed structures are given in    















































coordinated and the water molecules are not shown.   The resonance structures are also not 
shown. 
Table 5.2: Observed and calculated λmax’s for Cu(II)/GLY-GLY complexes.   Observed is abbreviated as obs and 




Obs. Ɛ max  
(dm3.mol-1.cm-1) 
Cal. λ max 
(nm) 
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       5.2.3.2     SAR-GLY / Cu(II) 
The results for Cu(II)/SAR-GLY are given in Figure 5.11.   λmax (ML) = 640 nm.   This 
suggests that Cu(II) coordinates to the amine N, amide O, carboxylate O and a water 
molecule yielding a 5, 7 chelate sequence.   Cu-Namine, Cu-Oamide and Cu-Owater are equatorial, 
Cu-Ocarboxylate is axial.   The band shifts to a lower wavelength when ML2 forms; λmax (ML2) = 
635 nm.   Equatorial Cu-Owater and axial Cu-Ocarboxylate break when ML2 forms from ML, and 
Cu(II) coordinates to Namine and Oamide of the second ligand molecule.   There is no 
observable change when ML2H-1 and ML2H-2 form.    The stoichiometry suggests ML2H-1 
forms when ML2 is deprotonated.   Cu(II) will therefore coordinate to amine N and the amide 
N of the first ligand, and to the amine N and the amide O of the second ligand when ML2H-1.   
The deprotonation of ML2H-1 yields ML2H-2.   The stoichiometry suggests Cu(II) coordinates 




Figure 5.11: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR-GLY complexes.   The total 
ligand concentration = 0.005399 M and the total Cu(II) concentration = 0.005321 M. 
 
Observed and calculated λmax’s for Cu(II)/SAR-GLY titrations are given in Table 5.3.   
Predicted structures are given in Figure 5.12.   Axial coordination of Ocarboxylate results in a 
blue shift (52 nm difference between the calculated maximum wavelength and the observed 
maximum wavelength).   A slight red shift is observed with a neutral species ML2.  
Gustiananda and co-workers [41] suspect an increase in H-bonding within peptides may 















































and ML2H-2.   Induced deprotonation of the amide nitrogen when a Cu-Namide bond forms has 
been reported to be accompanied by a red shift of between 76 nm and 80 nm for some ligands 
[40]. 
Table 5.3: Observed and calculated λmax’s for Cu(II)/SAR-GLY complexes.   Observed is abbreviated as obs and 




Obs. Ɛ max  
(dm3.mol-1.cm-1) 
Cal. λ max 
(nm) 
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Figure 5.12: Structures of complexes formed between Cu(II) and SAR-GLY.   The total ligand 












       5.2.3.3     GLY-LEU / Cu(II) 
Results for Cu(II)/GLY-LEU titrations are given in Figure 5.13.   λmax (ML) = 790 nm.   This 
indicates that Cu(II) coordinates to the amine N and the amide O as suggested [36-38].   The 
band shifts to a lower wavelength when MLH-1 forms.  This is a result of bond re-
arrangements; Cu-Oamide bond breaks and Cu(II) coordinates to the Namide and Ocarboxylate when 
MLH-1 forms.   The band shifts to a much lower maximum wavelength when ML2H-1 forms.   
λmax (ML2H-1) = 605 nm.   This suggest that Cu(II) coordinates to Ocarboxylate of the first and 
the second ligand molecule, to Namide of the first ligand molecule and Namine of the second 
ligand molecule.   λmax (MLH-1) = λmax (M2L2H-3).   This suggest that Cu(II) coordinates to 




Figure 5.13: Molar extinction coefficients as a function of wavelength for Cu(II)/GLY-LEU complexes.   The total 
ligand concentration = 0.005108 M and the total Cu(II) concentration = 0.004983 M. 
 
Observed and calculated λmax’s for the complex species are given in Table 5.4.   The 
proposed structures are given in Figure 5.14.   A red shift is observed for ML species.   This 
might be a result of H-bonding between the non-coordinated COO- and the solvent [41].   
There is a good agreement between calculated and observed λmax’s for other species.   
M2L2H-3 has two λmax’s.   These are very close and thus overlapped, resulting in a broad band 




















































Table 5.4: Observed and calculated λmax’s for Cu(II)/GLY-LEU complexes.   Observed is abbreviated as obs and 




Obs. Ɛ max  
(dm3.mol-1.cm-1) 
Cal. λ max 
(nm) 
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       5.2.3.4     SAR-LEU / Cu(II) 
Results for Cu(II)/SAR-LEU are given in Figure 5.15. 
 
 
Figure 5.15: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR-LEU complexes.   The total 
ligand concentration = 0.005123 M and the total Cu(II) concentration = 0.004998 M. 
 
Calculated and observed λmax’s are given in Table 5.5.   Predicted structures are given in 
Figure 5.16.   Note that all the species had the same observed λmax which was unexpected.  
However, the raw data for this ligand was different in that there was no shifting of the single 
absorption band during the titration. 
 
Table 5.5: Observed and calculated λmax’s for Cu(II)/SAR-LEU complexes.   Observed is abbreviated as obs and 
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       5.2.3.5     GLY-PHE / Cu(II) 
Results for Cu(II)/GLY-PHE titrations are given in Figure 5.17 
 
 
Figure 5.17: Molar extinction coefficients as a function of wavelength for Cu(II)/GLY-PHE complexes.   The total 
ligand concentration = 0.005059 M and the total Cu(II) concentration = 0.005001 M. 
 
Calculated λmax’s, observed λmax’s and corresponding electron donor groups and molar 
extinction coefficients are given in Table 5.6.   The proposed structures are given in Figure 
5.18. 
 
Table 5.6: Observed and calculated λmax’s for Cu(II)/GLY-PHE complexes.   Observed is abbreviated as obs and 




Obs. Ɛ max  
(dm3.mol-1.cm-1) 
Cal. λ max 
(nm) 
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       5.2.3.6     SAR-PHE / Cu(II) 
Results for Cu(II)/SAR-PHE titrations are given in Figure 5.19. 
 
 
Figure 5.19: Molar extinction coefficients as a function of wavelength for Cu(II)/SAR-PHE complexes.   The total 
ligand concentration = 0.004866 M and the total Cu(II) concentration = 0.004785 M. 
 




Table 5.7: Observed and calculated λmax’s for Cu(II)/SAR-PHE complexes.  Observed is abbreviated as obs and 
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Figure 5.20: Structures of complexes formed between Cu(II) and SAR-PHE. 
 
5.2.4    Discussions 
At low pH’s, where ML forms, Cu(II) coordinates to the Namine, Oamide, Ocarboxylate and one 
water molecule for all the dipeptides except GLY-LEU.   Cu-Namine, Cu-Oamide and Cu-Owater 
are equatorial and Cu-Ocarboxylate is axial.   Axial coordination results in a blue shift since 
Billo’s method assumes the coordination is equatorial for all species.    The deprotonation of 
ML yields MLH-1.   Cu(II) displaces the amide H when MLH-1 forms.   Cu-Oamide to Cu-
Namide bond re-arrangement shifts the band to a lower wavelength.   The second deprotonation 
occurs on the coordinated water molecule when MLH-2 forms. 
 
The second route of complexation is from ML to ML2 to ML2H-1 to ML2H-2.   The axial Cu-
Ocarboxylate bond breaks when ML2 forms and the second ligand molecule coordinates through 
the Namine and Oamide.   The deprotonation of ML2 yields ML2H-1.   Hamide is displaced by 
Cu(II) when ML2H-1 forms.   The second Hamide is also displaced when ML2H-2 forms.   The 
sequence of complexation of Cu-GLY-LEU differs significantly from that of other ligands 
(GLY-GLY, SAR-GLY, SAR-LEU, GLY-PHE and SAR-PHE): ML to ML2 to  MLH-1 to 
MLH-2 or ML to ML2 to ML2H-1 to ML2H-2.   The sequence of complexation for Cu-GLY-
LEU is ML to MLH-1 to ML2H-1 to M2L2H-3.   Cu(II) coordinates to Namine, Oamide and two 
water molecules when ML (Cu-GLY-LEU) forms.   Log KML (Cu-GLY-LEU) is less than 6 
log units (Chapter 3).   Log KML for the other peptides is greater than 6 log units.   The 
proposed structure for MLH-1 is the same as the other Cu-peptides.    The structure of ML2H-1 
(Cu-GLY-LEU) differs significantly from the other Cu-peptides; Cu(II) coordinates to 
Ocarboxylate of the first and the second ligand molecules, to Namine of the first ligand molecule 












5.3   MOLECULAR MECHANICS 
5.3.1   INTRODUCTION 
Molecular mechanics is a method used to calculate the motion of atoms in a molecule using 
Newton’s laws of motion [25].   The main task is to determine the most stable conformation 
of molecules at equilibrium using mathematical functions that best describe the total strain 
energy of a molecule [17, 23].   The structures are built using molecular orbital and valance 
bond theories, their conformation is optimised using force fields and the strain energy (U) of 
these structures is calculated.   The geometry is optimised such that the total bond 
deformation strain (Ub), the total steric strain/van der Waals strain (Us), the angle strain (Ua), 
and the torsional strain (Ut) are minimised.    The total strain energy (Utot) can therefore be 
expressed as; 
 
                 
(5.6) 
 
Bond deformation strain is energy the exerted on a bond between atoms, either by stretching 
the bond or compressing it.   Due to a bond’s ability to stretch/compress, the total bond 
deformation strain can be estimated using Hooke’s law. 
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Where k1 is the force constant for a particular length, l is the bond length when the structure 
is deformed and l0 is the length of the bond when the structure is at equilibrium.   Ub can also 
be expressed in terms of Morse function; 
 
   ∑   
     
               
(5.8) 
 
The steric/van der Waals strain is the strain experienced by a molecule that has non-bonded 












these substituents is less than van der Waals radii [24].   Rappé and co-workers [24] have 
derived equations for calculating total steric strain; 
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Where DIJ is the finite energy for breaking bonds, xIJ is the van der Waals bond length, x is 
the atomic van der Waals distance, and ζ is the shape factor. 
 
The angle deformations can also be estimated using Hooke’s law. 
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Where kb is the force constant for a particular angle, b is the bond angle when the structure is 
deformed and b0 is the bond angle when the structure is at equilibrium. 
 
Torsional strain is experienced when a molecule undergoes a complete rotation around one 
bond. 
   
  
 
           
  
 
            
  
 
            
(5.11) 
 
V1 is a term assigned to van der Waals interactions/residual dipole-dipole interactions, V2 is a 
term assigned to conjugation/hyper-conjugation and the term V3 is assigned to steric or 
bonding/anti-bonding interactions. 
 
Different force fields are used to optimise the geometry, the most common ones being the 
universal force filed (UFF).   The mathematical expressions used when optimizing the 
structures differ from force field to force field.   Many authors have stated which expressions 













5.3.2   EXPERIMENTAL 
Structures of the most probable complex species were built and minimization was carried out 
on a Windows Vista machine with Avogadro software [29-32].   The conformation of the 
structures was optimised with the universal force field (UFF) [24, 29, 33].   The results were 
verified with the steepest descent algorithm (gradient convergence). 
 
5.3.3   RESULTS 
  
        (a) ML                           (b) ML                     (c) ML                           (d) ML-funny 
  
         (e)   MLH-1             (f) MLH-2                     (g) cis ML2                     (h) trans ML2 
 













                 (k)  cis  ML2H-1                                     (l)  trans  ML2H-1                (m)  cis  ML2H-1   
       
 
             (n)  trans  ML2H-1            (o)  trans   ML2H-2                                       (p)    ML2H-2 
 
 
(q)    M2L2H-3 
 
Cu(II) forms 6-coordinate complexes in an octahedral geometry.   Structures (a) to (q) are 
different isomers of Cu(II) complexes.   The calculated minimum energies are given in Table 
5.7.   In comparing these energies one must be careful to note that these are strain energies 












with the same bonding.   All Cu-glycine peptide complexes are more stable than Cu-sarcosine 
peptide complexes.   The methyl substituent on the amine terminal adds more strain (steric 
strain) to the complexes.   There are four possible conformations of ML: Structures (a) – (d).   
Structure (c) is the most stable of all, however uv-vis results show this conformation was only 
observed with Cu-GLY-LEU.   Structures (a) and (b) were not observed with neither 1H 
NMR nor uv-vis.   It is not easy for Cu(II) to coordinate to both the terminal amine and the 
terminal carboxylate at the same time, nor is it easy for Cu(II) to coordinate to Oamide and 
Ocarboxylate without coordinating to Namine.   Cu-N bonds are stronger than Cu-O bonds.   
Conformation (d) was observed with all the peptides except for GLY-LEU.   Of all the four 
probable ML conformations, this conformation is not favoured thermodynamically.   
Complexes that have equatorial Cu-ligand bonds and two axial Cu-water bonds are more 
stable than complexes that have one of the Cu-ligand bonds axial.   The latter experience 
more angle and torsional strain. 
 
MLH-2 is more stable than MLH-1.   The isomers (i) and (j) are more stable than isomers (g) 
and (h).   Isomers (g) and (h) were not observed with 1H NMR and uv-vis.   The most stable 
conformation of ML2H-1 is Structure (k).   The trans form of ML2H-2 is more stable than the 
cis form, except for Cu-SAR-GLY. 
 
Table 5.7:  Total minimum strain energies for structures (a) to (q) 
Ligand 












































































































































5.4   GENERAL CONCLUSIONS 
The first protonation occurs on amine terminal and the second one occurs on the carboxylate 
terminal.   All cis isomers have lower total strain energies than their trans isomers except for 
ML2H-2 whose trans forms are more stable than the cis forms.   The cis form of ML2H-2 (Cu-























































Molecular mechanics calculations suggest that a 5-memebered chelate (Cu-Namine, Cu-Oamide 
and two Cu-Owater chelate system) is the most probable ML conformation.   The complexation 
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Where R = -H, and -CH3 
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6. TISSUE PERMEABILITY AND BIO-
DISTRIBUTION STUDIES 
6.1 OCTANOL / WATER DISTRIBUTION COEFFICIENTS 
6.1.1   INTRODUCTION 
Octanol/water distribution coefficient is a technique used to measure the difference in 
solubility of compounds in two immiscible solvents.   The degree of solubility in aqueous 
phase or in organic phase describes the hydrophilicity or lipophilicity of compounds.  This is 
a powerful tool in estimating the tissue permeability of drugs.   By definition, distribution 
coefficient (log Dow) is described as; 
 
          (
      
                 
) 
(6.1) 
Where [X]oct is the concentration of a solute X in octanol, [X]aq(i) is the concentration of a 
solute X that ionized in water, and [X]aq(n) is the concentration of a neutral (un-ionised) 
species of X in water. 
 
 Log Dow is normally confused with log Pow (partition coefficient).   Log Pow is defined as the 
ratio of un-ionised species between an organic phase and an aqueous phase.   Log Pow is 
expressed as; 
                 (
         




The most common method is the shake-flask method [1-4].   A solution of a known 
concentration of an analyte is made in water.   The analyte is then extracted into a known 
volume of an organic solvent (1-octanol for example).   The amount of analyte left in the 
aqueous phase and the amount that went into the organic phase is measured.   Depending on 
the nature of the analyte, some researchers use ultraviolet-visible spectrophotometry (UV-
Vis) to measure the amount of the analyte [5, 6], some use atomic absorption spectroscopy 
(AAS) [7-9] and some use  inductively coupled plasma mass spectrometry (ICP-MS) or 














Scherrer and Howard [12] have derived equations that correlate distribution coefficients of 
acids (log Dow(acids)), partition coefficients (log Pow(acids)), pKa’s and pH. 
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Where Pow is defined as the ratio of un-ionised species between an organic phase and an 
aqueous phase.   Log Pow is expressed as; 
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) 
(6.4) 
Similarly, log Dow(bases) is expressed as; 
 
                               (
 




                 (
            
         
) 
(6.6) 
If (pH – pKa) >> 1 then Equation 6.5 can be written as; 
 
                                   
(6.7) 
And if (pKa-pH) >> 1 then, 
 
                                   
(6.8) 
If the analyte is largely un-ionised in solution then; 
 















For metal complexes the above definition of distribution or partition coefficient is not a really 
suitable measure of the lipophilicity/hydrophilicity of metal complexes and so  log Dow (or 
log Pow) is defined as [7-9, 13]; 
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Where [Cu(II)]oct is the amount of Cu(II) extracted into the organic phase and [Cu(II)] is the 
amount of Cu(II) left in the aqueous phase. 
 
6.1.2   EXPERIMENTAL 
Standard solutions of Cu(II) were prepared as described [7-9] and calibration curves were 
constructed.   1:1 Cu(II)/ligand solutions were prepared in distilled/deionised water.   Into ten 
different glass vials, 10 mL aliquots of 1:1 Cu(II)/ligand solutions were dispersed.   Each 
glass vial contained 1:1 Cu(II)/ligands solutions at different pH’s (from pH 2 to pH 11).   Into 
the aliquots, 10 mL of 1-octanol (99 %) was added.   The octanol had previously been 
saturated with water.   The mixture was shaken for 2 min and left for 5 min for the two 
phases to separate.   From each phase, 8 mL aliquots were withdrawn.   Cu(II) in the organic 
phase was extracted back into an aqueous phase with 8 mL of 5 % HNO3.   7 mL aliquots 
were withdrawn from this new aqueous phase (5 % HNO3).   The concentration of copper in 
each solution was determined using AAS (Varian SpectrAA Model 220FS).   The 
octanol/water distribution coefficients were calculated using Equation 6.9. 
 
6.1.3   RESULTS 
       6.1.3.1     GLY-GLY / Cu(II) 
The results for Cu-GLY-GLY are given in Figure 6.1.   Figure 6.1A is the log Dow results and 
Figure 6.1B is the speciation graph for Cu(II)/GLY-GLY.   Complexes of Cu(II) and GLY-
GLY are more soluble in water than in 1-octanol since the log Dow’s are negative (Figure 
6.1A).   The distribution coefficients do not change with pH (from pH 2 to pH 11).   The 
distribution curves (Figure 6.1B) show that mixed species are observed at some pH’s; log 
Dow’s obtained here are therefore not for a single species.    All four species (ML, ML2, 
MLH-1 and MLH-2) have about the same log Dow value.   ML2 was formed in very small 
















Figure 6.1:   A;   Log (Dow) as a function of pH for Cu(II)/GLY-GLY titrations    B:   Speciation graph for 1:1 
Cu(II)/GLY-GLY.   GLY-GLY total concentration = 0.01004 M. 
 
6.1.3.2    SAR-GLY / Cu(II) 
Distribution coefficient curve for Cu(II)/SAR-GLY is given in Figure 6.2A.   The solubility 
in 1-octanol increases with increase in pH (from pH 5 to pH 11).   In the pH range 2 – 5, the 
copper is predominantly present as the free ion or the ML species.   Since log Dow is constant 
in this pH range we conclude that both Cu(II) and ML have a distribution coefficient of -1.5.   
Log Dow = -1.3 at pH 8.5 where 97 % f the Cu(II) is present as ML2H-1 and so the 





Figure 6.2: A:   Log (Dow) as a function of pH for Cu(II)/SAR-GLY titrations B:   Speciation graph for 1:1 

















































































6.1.3.3      GLY-LEU / Cu(II) 
Results for Cu(II)/GLY-LEU are given in Figure 6.3.   The solubility in 1-octanol increases 
from low pH’s to high pH’s.   Log Dow (ML2H-1) = -0.96.   Log Dow = -0.96 at pH 9.1 where 
95 % of the Cu(II) is present as ML2H-1 and so the distribution coefficient is assigned to this 
value.   This is the most predominant species at pH 7.4.    
 
 
Figure 6.3: A:     Log (Dow) as a function of pH for Cu(II)/GLY-LEU titrations     B:   Speciation graph for 1:1 
Cu(II)/GLY-LEU.   GLY-LEU total concentration = 0.01021 M. 
6.1.3.4 SAR-LEU / Cu(II) 
The distribution curves of complexes of Cu(II) and SAR-LEU in water and 1-octanol are 
given in Figure 6.4A.   MLH-1 is the most predominant species at pH 7.4.      Dow (MLH-1) = 
-0.80.   The log Dow curve drops at pH’s above pH 9.3.  Cu(II) most likely precipitates out as 




Figure 6.4: A:     Log (Dow) as a function of pH for Cu(II)/SAR-LEU titrations     B:   Speciation graph for 1:1 

















































































6.1.3.5 GLY-PHE / Cu(II) 
The results for Cu(II)/GLY-PHE are given in Figure 6.5.   Log Dow (pH 7.4) = -1.1.   ML2H-1 
is most predominant at pH 7.4.   At this pH there is a mixture of ML, ML2 and ML2H-1.   Log 
Dow at pH 8.4 = -1.0 where about 97.8 % of ML2H-1 forms.   Log Dow increases to -0.82 at pH 




Figure 6.5: A:      Log (Dow)  as a function of pH for Cu(II)/GLY-PHE titrations     B:   Speciation graph for 1:1 
Cu(II)/GLY-PHE.   GLY-PHE total concentration = 0.01082 M. 
 
6.1.3.6 SAR-PHE / Cu(II) 
The results for Cu(II)/SAR-PHE are given in Figure 6.6.   Log Dow (pH 7.4) = -1.4.   At this  
pH the most predominant species is the MLH-1.   Log Dow increases significantly from pH 
9.3 to pH 10.9 where a neutral species (net charge = zero)  MLH-2 forms. 
 
 
Figure 6.6: A:     Log (Dow) as a function of pH for Cu(II)/SAR-PHE titrations     B:   Speciation graph for 1:1 


















































































6.1.3.7 GLY-HIS / Cu(II) 
The results for Cu(II)/GLY-HIS are given in Figure 6.7.   At pH 2.8, where the most 
predominant species is Cu(II), log Dow = -1.4;  at pH 7.4 where the most predominant species 
is the ML, log Dow  = -1.3; at pH 10.6 where the most predominant species is the MLH-1, log 
Dow = -1.3 and at pH’s above pH 11, where  MLH-3 is the most predominant species in 




Figure 6.7: A:     Log (Dow) as a function of pH for Cu(II)/GLY-HIS titrations     B:   Speciation graph for 1:1 
Cu(II)/GLY-HIS.   GLY-HIS total concentration = 0.01128 M. 
 
6.1.5      DISCUSSIONS 
The lipophilicity of complex species improves with an increase in pH, except in systems 
where Cu(II) precipitated out when excess amounts of NaOH were added.   Complex species 
with a net charge of zero are the most lipophilic.  The results are consistent with Zhu’s work,  
[14], Jackson and co-workers [15-22, 25], ; complex species with a net charge of zero are 
more lipophilic than charged complex species.   A summary table for log Dow’s for 






















































Table 6.1: Log Dow’s for Cu(II) complexes with different ligands at pH 7.4 
Ligand Species 
Log Dow 
(at pH 7.4) 
GLY-GLY MLH-1 -1.4 
SAR-GLY ML2H-1 -1.3 
GLY-LEU ML2H-1 -0.96 
SAR-LEU MLH-1 -0.80 
GLY-PHE ML2H-1 -1.0 
SAR-PHE MLH-1 -1.4 
GLY-HIS ML -1.3 
 
The N-methyl substituent on the terminal amine enhances the lipophilicity of the copper 
complexes at pH 7.4 as anticipated.   The lipophilicity of Cu-GLY-GLY and Cu-GLY-LEU is 
slightly increased but the lipophilicity of Cu-GLY-PHE decreases.   However methylated 
terminal amine of SAR-PHE does increase the lipophilicity at higher pH, with a log Dow (Cu-
SAR-PHE) of -0.63 observed at pH 11. 
 
All the complex species showed log Dow’s below zero.   Log Dow < 2.5 is considered “low 
lipophilicity”, log Dow > 5 is considered “high lipophilicity” and log Dow between 2.5 and 5 is 
considered “intermediate lipophilicity” [24].   Log Dow (complexes) that fall within the range 
2.5 < log Dow < 5 were aimed for.   Zvimba and Jackson [25], however, suggest log Dow of 
0.60 is sufficient enough to allow trans-dermal transportation of drugs. 
 
Not much work has been reported in the literature on the lipophilicity of Cu(II)-dipeptide 
complexes to compare with.   However, novel Cu(II)-based anti-inflammatory drugs with log 
Dow’s above zero at a physiological pH of 7.4 have been reported [18].   This ligand has two 





















6.2   BLOOD PLASMA MODEL 
      6.2.1   INTRODUCTION 
The chemical analysis of all the metal species present in a complex solution like blood 
plasma is not really possible.   However, assuming the system is at equilibrium a computer 
model can be used to calculate this [18].   A typical model has a list of ligands and metals that 
are found at high concentrations in blood plasma.   It also has a list of complex species that 
form between these ligands and metals together with their stability constants.   This system 
can then be solved for the concentration of the individual species.   Using this model it is 
possible to calculate the effect of an exogenous drug as long as its stability constants with the 
major metal ions, present in the model, are known [19-22].   This process is termed speciation 
modeling. 
 
      6.2.2   DATA HANDLING 
Evaluation of Constituent Concentrations in Large Equilibrium Systems (ECCLES) was used 
to calculate the concentration of test drugs.   The ECCLES has a list of species that are found 
in blood plasma and their cumulative stability constants [19-22].   The cumulative stability 
constants of species of interest are put into ECCLES and it simulates the speciation of species 
of interest at physiological pH of 7.4.   Competition with other species is taken into account.   
This includes 7 metal ions and 40 ligands that generate 5000 complexes that are present in 
blood plasma [18-19].   ECCLES also calculates the plasma mobilizing index (p.m.i) [8-8, 
18-19].   By definition; 
 
      
                                                                                        

























      6.2.3   RESULTS 
    6.2.3.1     GLY-GLY 
The blood plasma index of as a function of concentration is given in Figure 6.8.   Despite the 
high in vivo concentration of Zn(II), GLY-GLY is able to mobilize Cu(II).   However, at low 




Figure 6.8: p.m.i as a function of log10 [L] for complexes of GLY-GLY and Cu(II), Ni(II) and Zn(II). 
 
    6.2.3.2     SAR-GLY 
P.m.i curves for SAR-GLY are given in Figure 6.9.   SAR-GLY mobilises Cu(II) more than 
Ni(II) and Zn(II). 
 
 













































    6.2.3.3     GLY-LEU 




Figure 6.10: p.m.i as a function of log10 [L]  for complexes of GLY-LEU and Cu(II), Ni(II) and Zn(II). 
 
 
   6.2.3.4     SAR-LEU 
P.m.i curves for SAR-LEU are given in Figure 6.11.   SAR-LEU mobilises Cu(II) than Ni(II) 
and Zn(II) at ligand concentrations above 0.1 M. 
 
 


















































    6.2.3.5     GLY-PHE  




Figure 6.12: p.m.i as a function of log10 [L]  for complexes of GLY-PHE and Cu(II), Ni(II) and Zn(II). 
 
    6.2.3.6     SAR-PHE 
P.m.i curve for SAR-PHE is given in Figure 6.13.   Cu(II) is mobilized at [SAR-PHE] above 
0.01 M, Ni(II) is mobilized from lower ligand concentrations ([SAR-PHE] = 0.001 M).   
Zn(II) is mobilised at ligand concentrations about 1 M. 
 
 














































    6.2.3.7     GLY-HIS 
P.m.i’s for complexes of GLY-HIS with Cu(II), Ni(II) and Zn(II) have been reported before 
[22].   GLY-HIS mobilized Ni(II) than it mobilizing Cu(II) in blood plasma.  
 
      6.2.4    DISCUSSIONS  
Table 6.2 shows p.m.i values of different peptides with copper as a function -log10 peptide 
concentration.   A graphic representation is given in Figure 6.2.   GLY-LEU and GLY-PHE 
have the highest ability to mobilise copper in vivo from concentrations as low as 0.001M.   
Novel Cu(II)-based anti-inflammatory drugs with better copper mobilizing capacity have 
been reported [7, 20, 23, 25].  
 


























































Figure 6.14: p.m.i as a function of log10 [L] for complexes of Cu(II) and GLY-GLY, SAR-GLY, GLY-LEU, SAR-


































6.2   CONCLUSIONS 
GLY-LEU and GLY-PHE are better Cu(II) chelaters in vivo than other dipeptides covered in 
this study.   GLY-GLY and SAR-GLY have a better Cu(II) mobilizing capacity than SAR-
LEU, SAR-PHE and GLY-HIS, however, their efficiency is only observed when the ligand 
concentration is about 0.01 M which is unrealistically high.   GLY-LEU and GLY-PHE also 
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7. GENERAL DISCUSSIONS, CONCLUSIONS 
AND RECOMMENDATIONS 
7.1   DISCUSSIONS 
The main aim of this study was to develop drugs that will alleviate the inflammation 
associated with rheumatoid arthritis.   These drugs should be dermally absorbable, copper 
complex that will elevate the bioavailable pool of copper in vivo without changing the 
composition of Ca(II), Ni(II) and Zn(II) in vivo.   Four glycine dipeptides (GLY-GLY. GLY-
LEU. GLY-PHE and GLY-HIS) and four sarcosine dipeptides (SAR-GLY, SAR-LEU, SAR-
PHE and SAR-HIS) were developed.   N-methylated compounds have been reported to be 
more lipophilic than their non-methylated analogues [1-3].   The N-methyl substituent 
however should not change the thermodynamic stability of complexes.    Due to solubility 
problems studies on SAR-HIS could not be done. 
 
Glass electrode potentiometry and isothermal titration calorimetry were used to study the 
thermodynamics of Cu-peptide complexes at 25 0C and 0.15 M ionic strength (NaCl).   The 
methyl group does not compromise the thermodynamic stability of complexes.   The stability 
of complexes however depends on the second amino acid residue of the peptide.   ML (Cu-
GLY-HIS) has the highest log K value.   The side ring of GLY-HIS has two N-donor atoms 
(pKa = 6.6) [4-10].   Cu(II) coordinates to the Namine, the Oamide, Nimidazole and Owater when ML 
(Cu-GLY-HIS) forms [4, 7-10].   Cu-N bond is stronger than Cu-O bond, therefore ML (Cu-
GLY-HIS) is more stable than ML (Cu-peptide covered in this study).   Cu(II) coordinates to 
Namine, the Oamide, Ocarboxylate and Owater when ML (Cu-peptide) forms (Chapter 5). 
 
The lipophilicity of complexes was determined using octanol/water distribution coefficients.    
The N-methyl substituent does enhance the lipophilicity of peptide complexes.   The second 
amino acid residue also affects the lipophilicity of the complexes.   Of interest is the 
lipophilicity of the complex species that forms at physiological pH 7.4.   The complexes of 
GLY-LEU and SAR-LEU with copper have the highest log Dow values at this pH (-0.96 log 
units for Cu-GLY-LEU and -0.80 for Cu-SAR-LEU).   ML2H-1 is the most predominant 
species at pH 7.4 in a Cu-GLY-LEU system, and MLH-1 is the most predominant species at 































Figure 7.1: Structures of complex species of the highest log Dow values. 
 
Evaluation of Constituent Concentrations in Large Equilibrium Systems (ECCLES) was used 
determine the Cu(II)-mobilising capacity of peptides in vivo in the presence of other metal-
ligand species that are found in high concentrations in blood plasma.   Of interest are the 
three metal ions Ca(II), Ni(II) and Zn(II) which are competitors with Cu(II) in blood plasma.  
SAR-GLY and GLY-PHE mobilise Cu(II) more than Ca(II), Ni(II) and Zn(II) from very low 
concentrations.   GLY-LEU and GLY-GLY also have a high mobilizing capacity but they 
mobilise Ni(II) and Zn(II) more at low ligand concentrations.   A summary graph is given in 
Figure 7.2. 
 
Figure 7.2: p.m.i as a function of log10 [L] for complexes of Cu (II) and GLY-GLY, SAR-GLY, GLY-LEU, SAR-LEU, 






























7.2   CONCLUSIONS AND RECOMMENDATIONS 
The methylated terminal amines increase the lipophilicity of copper complexes without 
compromising their thermodynamic stability.   However, log Dow’s (Cu-peptides) are all 
negative and thus they are all very hydrophilic.    Log Dow < 2.5 is considered “low 
lipophilicity”, log Dow > 5 is considered “high lipophilicity” and log Dow between 2.5 and 5 is 
considered “intermediate lipophilicity” [18].   Log Dow (complexes) that fall within the range 
2.5 < log Dow < 5 were aimed for.   Since GLY-LEU and GLY-PHE have the highest 
mobilising capacity than all the other peptides.   It will be interesting to see if a series of 
tripeptides that have a glycine residue, a leucine and a phenylalanine residue will compare 
with a series of tripeptides that have a sarcosine residue, a leucine and a phenylalanine 
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